0001628280-21-009294.txt : 20210506 0001628280-21-009294.hdr.sgml : 20210506 20210506160703 ACCESSION NUMBER: 0001628280-21-009294 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 68 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210506 DATE AS OF CHANGE: 20210506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CareTrust REIT, Inc. CENTRAL INDEX KEY: 0001590717 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 463999490 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36181 FILM NUMBER: 21897739 BUSINESS ADDRESS: STREET 1: 905 CALLE AMANECER, SUITE 300 CITY: SAN CLEMENTE STATE: CA ZIP: 92673 BUSINESS PHONE: (949) 542-3140 MAIL ADDRESS: STREET 1: 905 CALLE AMANECER, SUITE 300 CITY: SAN CLEMENTE STATE: CA ZIP: 92673 10-Q 1 ctre-20210331.htm 10-Q ctre-20210331
0001590717--12-312021Q1falseus-gaap:HealthCareResidentServiceMemberus-gaap:HealthCareResidentServiceMemberus-gaap:HealthCareResidentServiceMemberus-gaap:HealthCareResidentServiceMemberP5DP1Y00015907172021-01-012021-03-31xbrli:shares00015907172021-05-05iso4217:USD00015907172021-03-3100015907172020-12-31iso4217:USDxbrli:shares00015907172020-01-012020-03-310001590717us-gaap:CommonStockMember2020-12-310001590717us-gaap:AdditionalPaidInCapitalMember2020-12-310001590717us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2020-12-310001590717us-gaap:CommonStockMember2021-01-012021-03-310001590717us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001590717us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2021-01-012021-03-310001590717us-gaap:CommonStockMember2021-03-310001590717us-gaap:AdditionalPaidInCapitalMember2021-03-310001590717us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2021-03-310001590717us-gaap:CommonStockMember2019-12-310001590717us-gaap:AdditionalPaidInCapitalMember2019-12-310001590717us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2019-12-3100015907172019-12-310001590717us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001590717us-gaap:CommonStockMember2020-01-012020-03-310001590717us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2020-01-012020-03-310001590717us-gaap:CommonStockMember2020-03-310001590717us-gaap:AdditionalPaidInCapitalMember2020-03-310001590717us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2020-03-3100015907172020-03-31ctre:facility0001590717ctre:SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMember2021-03-31ctre:bed0001590717ctre:SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMember2021-01-012021-03-31ctre:statectre:property0001590717ctre:PropertiesWithPurchaseOptionLeaseExpirationOctober2034FirstOption2021Memberctre:AssistedLivingFacilityMember2021-03-310001590717ctre:SkilledNursingFacilityMemberctre:PropertiesWithPurchaseOptionLeaseExpirationNovember2030FirstOption2022Member2021-03-310001590717ctre:PropertiesWithPurchaseOptionLeaseExpirationMarch2029FirstOption2022Memberctre:SkilledNursingFacilityMember2021-03-310001590717ctre:PropertiesWithPurchaseOptionLeaseExpirationOctober2032FirstOption2023Memberctre:SkilledNursingAndCampusFacilitiesMember2021-03-310001590717ctre:SkilledNursingFacilityMemberctre:PropertiesWithPurchaseOptionLeaseExpirationNovember2034FirstOption2024Member2021-03-310001590717ctre:PropertiesWithPurchaseOptionLeaseExpirationOctober2034FirstOption2026Memberctre:AssistedLivingFacilityMember2021-03-310001590717ctre:MetronIntegratedHealthSystemsAffiliatesMember2021-01-012021-03-310001590717ctre:SkilledNursingPropertiesMember2021-01-012021-03-31ctre:unit0001590717ctre:MultiServiceCampusPropertiesMember2021-01-012021-03-310001590717ctre:MultiServiceCampusPropertiesMembersrt:ScenarioForecastMember2022-01-012022-12-310001590717us-gaap:DiscontinuedOperationsHeldforsaleMemberctre:FiveOaksHealthcareLLCMember2020-12-310001590717us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberctre:FiveOaksHealthcareLLCMember2021-02-012021-02-010001590717us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberctre:FiveOaksHealthcareLLCMember2021-02-010001590717us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberctre:OwnedAndOperatedLivingFacilitiesMember2020-11-010001590717us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberctre:OwnedAndOperatedLivingFacilitiesMember2020-11-012020-11-010001590717us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberctre:OwnedAndOperatedLivingFacilitiesMember2020-10-012020-12-310001590717us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberctre:MetronSkilledNursingFacilitiesMember2020-02-140001590717us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberctre:MetronSkilledNursingFacilitiesMember2020-02-142020-02-140001590717us-gaap:MortgageReceivablesMemberctre:CascadeCapitalGroupLLCMember2020-02-14xbrli:pure0001590717us-gaap:MortgageReceivablesMemberctre:CascadeCapitalGroupLLCMember2020-04-012020-04-300001590717us-gaap:MortgageReceivablesMemberctre:CascadeCapitalGroupLLCMember2020-04-300001590717us-gaap:MortgageReceivablesMemberctre:CascadeCapitalGroupLLCMember2020-07-012020-07-310001590717ctre:NobleVAHoldingsLLCMemberctre:AssistedLivingFacilityMember2020-12-010001590717ctre:NobleTripleNetMasterLeaseMember2020-12-01ctre:extension_option0001590717ctre:NobleVAHoldingsLLCMember2020-12-012020-12-010001590717ctre:MezzanineLoanMemberctre:NextVAStarRealtyHoldingsLLCMember2020-11-300001590717ctre:MezzanineLoanMemberctre:NextVAStarRealtyHoldingsLLCMembersrt:MinimumMember2020-11-300001590717srt:MaximumMemberctre:MezzanineLoanMemberctre:NextVAStarRealtyHoldingsLLCMember2020-11-300001590717ctre:MezzanineLoanMemberctre:NextVAStarRealtyHoldingsLLCMember2020-11-012020-11-300001590717ctre:MezzanineLoanMember2021-01-012021-03-310001590717ctre:MantecaValleyPostAcuteMemberus-gaap:MortgageReceivablesMember2019-07-012019-07-310001590717ctre:MantecaValleyPostAcuteMemberus-gaap:MortgageReceivablesMember2019-07-310001590717ctre:MantecaValleyPostAcuteMember2019-07-012019-07-310001590717ctre:CommuniCareMemberus-gaap:MortgageReceivablesMember2019-09-300001590717us-gaap:MortgageReceivablesMemberctre:CascadeCapitalGroupLLCMember2020-02-290001590717us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberctre:MetronSkilledNursingFacilitiesMember2020-02-290001590717ctre:CascadeCapitalGroupLLCMember2020-04-300001590717us-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:MortgageReceivablesMemberctre:CascadeCapitalGroupLLCMember2020-04-300001590717us-gaap:MortgageReceivablesMember2021-03-310001590717us-gaap:MortgageReceivablesMember2021-01-012021-03-310001590717us-gaap:MortgageReceivablesMember2020-01-012020-03-310001590717us-gaap:LoansReceivableMember2021-01-012021-03-310001590717ctre:PreferredEquityInvestmentCascadiaDevelopmentBoiseIDMember2016-09-300001590717ctre:PreferredEquityInvestmentCascadiaDevelopmentBoiseIDMemberus-gaap:PrimeRateMember2016-09-012016-09-300001590717ctre:PreferredEquityInvestmentCascadiaDevelopmentBoiseIDMember2016-09-012016-09-300001590717ctre:SkilledNursingPropertiesMember2020-01-012020-01-310001590717ctre:PreferredEquityInvestmentCascadiaDevelopmentBoiseIDMember2020-01-012020-01-310001590717ctre:PreferredEquityInvestmentCascadiaDevelopmentBoiseIDMember2020-01-012020-03-310001590717ctre:MezzanineLoanMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001590717ctre:MezzanineLoanMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001590717ctre:MezzanineLoanMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001590717ctre:MezzanineLoanMemberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001590717ctre:MezzanineLoanMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001590717ctre:MezzanineLoanMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001590717ctre:MezzanineLoanMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001590717ctre:MezzanineLoanMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001590717us-gaap:FinancingReceivablesEqualToGreaterThan90DaysPastDueMember2021-03-310001590717ctre:SeniorUnsecuredNotesMember2021-03-310001590717us-gaap:FairValueInputsLevel2Memberctre:SeniorUnsecuredNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-03-310001590717us-gaap:FairValueInputsLevel2Memberctre:SeniorUnsecuredNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-03-310001590717ctre:SeniorUnsecuredNotesMember2020-12-310001590717us-gaap:FairValueInputsLevel2Memberctre:SeniorUnsecuredNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2020-12-310001590717us-gaap:FairValueInputsLevel2Memberctre:SeniorUnsecuredNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2020-12-310001590717us-gaap:SeniorNotesMember2021-03-310001590717us-gaap:SeniorNotesMember2020-12-310001590717ctre:SeniorUnsecuredTermLoanMember2021-03-310001590717ctre:SeniorUnsecuredTermLoanMember2020-12-310001590717us-gaap:LineOfCreditMember2021-03-310001590717us-gaap:LineOfCreditMember2020-12-310001590717ctre:SeniorUnsecuredNotesMemberctre:FivePointTwoFiveSeniorNotesDue2025Member2017-05-100001590717ctre:SeniorUnsecuredNotesMemberctre:FivePointTwoFiveSeniorNotesDue2025Member2017-05-102017-05-100001590717ctre:SeniorUnsecuredNotesMemberctre:FivePointTwoFiveSeniorNotesDue2025Member2020-06-012020-06-010001590717us-gaap:RevolvingCreditFacilityMemberctre:NewRevolvingFacilityMember2019-02-080001590717us-gaap:LetterOfCreditMember2019-02-080001590717ctre:SwinglineLoanMember2019-02-080001590717ctre:SeniorUnsecuredTermLoanMemberctre:NewTermLoanFeb2019Member2019-02-080001590717us-gaap:RevolvingCreditFacilityMemberctre:NewRevolvingFacilityMembersrt:MinimumMemberus-gaap:BaseRateMember2019-02-082019-02-080001590717srt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberctre:NewRevolvingFacilityMemberus-gaap:BaseRateMember2019-02-082019-02-080001590717us-gaap:RevolvingCreditFacilityMemberctre:NewRevolvingFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMembersrt:MinimumMember2019-02-082019-02-080001590717srt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberctre:NewRevolvingFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMember2019-02-082019-02-080001590717ctre:SeniorUnsecuredTermLoanMemberctre:NewTermLoanFeb2019Membersrt:MinimumMemberus-gaap:BaseRateMember2019-02-082019-02-080001590717ctre:SeniorUnsecuredTermLoanMembersrt:MaximumMemberctre:NewTermLoanFeb2019Memberus-gaap:BaseRateMember2019-02-082019-02-080001590717ctre:SeniorUnsecuredTermLoanMemberctre:NewTermLoanFeb2019Memberus-gaap:LondonInterbankOfferedRateLIBORMembersrt:MinimumMember2019-02-082019-02-080001590717ctre:SeniorUnsecuredTermLoanMembersrt:MaximumMemberctre:NewTermLoanFeb2019Memberus-gaap:LondonInterbankOfferedRateLIBORMember2019-02-082019-02-080001590717us-gaap:RevolvingCreditFacilityMemberctre:NewRevolvingFacilityMembersrt:MinimumMember2019-02-082019-02-080001590717srt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberctre:NewRevolvingFacilityMember2019-02-082019-02-080001590717us-gaap:RevolvingCreditFacilityMemberctre:NewRevolvingFacilityMember2019-02-082019-02-080001590717srt:MaximumMemberctre:AtTheMarketOfferingProgramMember2020-03-100001590717ctre:AtTheMarketOfferingProgramMember2020-01-012020-03-310001590717ctre:AtTheMarketOfferingProgramMember2021-01-012021-03-310001590717ctre:AtTheMarketOfferingProgramMember2021-03-3100015907172020-03-200001590717us-gaap:RestrictedStockMemberctre:EnsignEmployeesMember2014-06-012014-06-010001590717us-gaap:RestrictedStockMemberctre:EnsignEmployeesMember2020-01-012020-12-310001590717us-gaap:RestrictedStockMemberctre:EnsignEmployeesMember2021-03-310001590717us-gaap:RestrictedStockMemberctre:OfficerAndEmployeeMember2021-01-012021-01-310001590717us-gaap:RestrictedStockMemberctre:OfficerAndEmployeeMember2021-02-012021-02-28ctre:installment0001590717us-gaap:RestrictedStockMemberctre:OfficerAndEmployeeMember2021-02-280001590717us-gaap:RestrictedStockMemberctre:OfficerAndEmployeeMember2021-01-310001590717us-gaap:PerformanceSharesMembersrt:OfficerMember2021-01-012021-01-310001590717srt:MinimumMemberus-gaap:PerformanceSharesMembersrt:OfficerMember2021-01-012021-01-310001590717srt:MaximumMemberus-gaap:PerformanceSharesMembersrt:OfficerMember2021-01-012021-01-310001590717us-gaap:PerformanceSharesMembersrt:OfficerMember2021-02-012021-02-28ctre:company0001590717srt:MinimumMemberus-gaap:PerformanceSharesMembersrt:OfficerMember2021-02-012021-02-280001590717srt:MaximumMemberus-gaap:PerformanceSharesMembersrt:OfficerMember2021-02-012021-02-280001590717us-gaap:PerformanceSharesMember2021-01-012021-03-310001590717ctre:EnsignAndPennantMember2021-03-310001590717ctre:CapitalImprovementsAtTripleNetLeasedFacilitiesMember2021-03-310001590717ctre:EnsignMemberctre:SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMember2021-03-31ctre:unit_bed0001590717ctre:EnsignMember2021-01-012021-03-310001590717us-gaap:SalesRevenueNetMemberctre:EnsignMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001590717us-gaap:SalesRevenueNetMemberctre:EnsignMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-03-310001590717ctre:PriorityManagementGroupLLCMemberctre:SkilledNursingAndCampusFacilitiesMember2021-03-310001590717us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberctre:PriorityManagementGroupLLCMember2020-01-012020-03-310001590717us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberctre:PriorityManagementGroupLLCMember2021-01-012021-03-310001590717ctre:SkilledNursingPropertiesMemberus-gaap:SubsequentEventMember2021-04-012021-04-300001590717ctre:BayshireLLCMemberus-gaap:SubsequentEventMember2021-04-300001590717ctre:BayshireLLCMemberctre:SkilledNursingPropertiesMemberus-gaap:SubsequentEventMember2021-04-012021-04-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2021
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     

Commission File Number: 001-36181

CareTrust REIT, Inc.
(Exact name of registrant as specified in its charter)

Maryland46-3999490
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
905 Calle Amanecer, Suite 300, San Clemente, CA
92673
(Address of principal executive offices)(Zip Code)

(949) 542-3130
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareCTREThe Nasdaq Stock Market LLC
(Nasdaq Global Select Market)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.      Yes      No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).      Yes      No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).      Yes      No
As of May 5, 2021, there were 96,785,096 shares of common stock outstanding.





INDEX
 






PART I—FINANCIAL INFORMATION
Item 1. Financial Statements.

CARETRUST REIT, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts)
(Unaudited)
 
March 31, 2021December 31, 2020
Assets:
Real estate investments, net$1,577,450 $1,448,099 
Other real estate investments, net15,155 15,000 
Assets held for sale, net 7,226 
Cash and cash equivalents30,469 18,919 
Accounts and other receivables, net1,780 1,823 
Prepaid expenses and other assets, net7,448 10,450 
Deferred financing costs, net1,797 2,042 
Total assets$1,634,099 $1,503,559 
Liabilities and Equity:
Senior unsecured notes payable, net$296,858 $296,669 
Senior unsecured term loan, net198,978 198,925 
Unsecured revolving credit facility170,000 50,000 
Accounts payable and accrued liabilities16,898 19,572 
Dividends payable25,924 24,251 
Total liabilities708,658 589,417 
Commitments and contingencies (Note 10)
Equity:
Preferred stock, $0.01 par value; 100,000,000 shares authorized, no shares issued and outstanding as of March 31, 2021 and December 31, 2020
  
Common stock, $0.01 par value; 500,000,000 shares authorized, 95,981,062 and 95,215,797 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively
960 952 
Additional paid-in capital1,180,840 1,164,402 
Cumulative distributions in excess of earnings(256,359)(251,212)
Total equity925,441 914,142 
Total liabilities and equity$1,634,099 $1,503,559 











See accompanying notes to condensed consolidated financial statements.

1

CARETRUST REIT, INC.
CONDENSED CONSOLIDATED INCOME STATEMENTS
(in thousands, except per share amounts)
(Unaudited)
 
 For the Three Months Ended March 31,
 20212020
Revenues:
Rental income$45,246 $42,464 
Independent living facilities 625 
Interest and other income505 1,251 
Total revenues45,751 44,340 
Expenses:
Depreciation and amortization13,473 13,160 
Interest expense5,762 6,714 
Property taxes696 485 
Independent living facilities  546 
General and administrative5,142 4,054 
Total expenses25,073 24,959 
Other loss:
Loss on sale of real estate(192)(56)
Net income$20,486 $19,325 
Earnings per common share:
Basic$0.21 $0.20 
Diluted$0.21 $0.20 
Weighted-average number of common shares:
Basic95,378 95,161 
Diluted95,385 95,161 













See accompanying notes to condensed consolidated financial statements.
2

CARETRUST REIT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(in thousands, except share and per share amounts)
(Unaudited)



Common StockAdditional
Paid-in
Capital
Cumulative
Distributions in Excess of Earnings
Total
Equity
SharesAmount
Balance at January 1, 202195,215,797 $952 $1,164,402 $(251,212)$914,142 
Issuance of common stock, net702,000 7 16,184 — 16,191 
Vesting of restricted common stock, net of shares withheld for employee taxes63,265 1 (1,331)— (1,330)
Amortization of stock-based compensation— — 1,585 — 1,585 
Common dividends ($0.265 per share)
— — — (25,633)(25,633)
Net income— — — 20,486 20,486 
Balance at March 31, 202195,981,062 $960 $1,180,840 $(256,359)$925,441 









































See accompanying notes to condensed consolidated financial statements.

3

CARETRUST REIT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(in thousands, except share and per share amounts)
(Unaudited)

 Common StockAdditional
Paid-in
Capital
Cumulative
Distributions in Excess of Earnings
Total
Equity
SharesAmount
Balance at January 1, 202095,103,270 $951 $1,162,990 $(236,350)$927,591 
Issuance of common stock, net— — (90)— (90)
Vesting of restricted common stock, net of shares withheld for employee taxes93,061 1 (1,987)— (1,986)
Amortization of stock-based compensation— — 884 — 884 
Common dividends ($0.25 per share)
— — — (23,931)(23,931)
Net income— — — 19,325 19,325 
Balance at March 31, 202095,196,331 $952 $1,161,797 $(240,956)$921,793 























See accompanying notes to condensed consolidated financial statements.
4

CARETRUST REIT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(Unaudited)
 For the Three Months Ended March 31,
 20212020
Cash flows from operating activities:
Net income$20,486 $19,325 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization (including below-market ground leases)13,486 13,175 
Amortization of deferred financing costs487 487 
Amortization of stock-based compensation1,585 884 
Straight-line rental income(12)(26)
Loss on sale of real estate192 56 
Interest income distribution from other real estate investment 1,346 
Change in operating assets and liabilities:
Accounts and other receivables, net(100)335 
Prepaid expenses and other assets, net278 454 
Accounts payable and accrued liabilities(2,453)482 
Net cash provided by operating activities33,949 36,518 
Cash flows from investing activities:
Acquisitions of real estate, net of deposits applied(138,151)(25,905)
Purchases of equipment, furniture and fixtures and improvements to real estate(1,319)(2,418)
Investment in real estate mortgage and other loans receivable(700)(100)
Principal payments received on real estate mortgage and other loans receivable 56 662 
Repayment of other real estate investment 2,327 
Escrow deposits for potential acquisitions of real estate (1,000)
Net proceeds from sales of real estate6,814 2,134 
Net cash used in investing activities(133,300)(24,300)
Cash flows from financing activities:
Proceeds from (costs paid for) the issuance of common stock, net16,191 (90)
Borrowings under unsecured revolving credit facility120,000 15,000 
Net-settle adjustment on restricted stock(1,330)(1,986)
Dividends paid on common stock(23,960)(21,532)
Net cash provided by (used in) financing activities110,901 (8,608)
Net increase in cash and cash equivalents11,550 3,610 
Cash and cash equivalents, beginning of period18,919 20,327 
Cash and cash equivalents, end of period$30,469 $23,937 
Supplemental disclosures of cash flow information:
Interest paid$1,325 $2,289 
Supplemental schedule of noncash investing and financing activities:
Increase in dividends payable$1,673 $2,399 
Transfer of pre-acquisition costs to acquired assets$358 $167 
Sale of real estate settled with note receivable$ $32,400 






See accompanying notes to condensed consolidated financial statements.
5

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)



1. ORGANIZATION
Description of Business—CareTrust REIT, Inc.’s (“CareTrust REIT” or the “Company”) primary business consists of acquiring, financing, developing and owning real property to be leased to third-party tenants in the healthcare sector. As of March 31, 2021, the Company owned and leased to independent operators, 222 skilled nursing, multi-service campuses, assisted living and independent living facilities consisting of 23,222 operational beds and units located in 28 states with the highest concentration of properties by rental revenues located in California, Texas, Louisiana, Idaho and Arizona. As of March 31, 2021, we also had other real estate investments consisting of one mezzanine loan receivable with a carrying value of $15.2 million.
The COVID-19 pandemic has led governments and other authorities around the world, including federal, state and local authorities in the United States, to impose measures intended to reduce its spread, including restrictions on freedom of movement and business operations such as travel bans, border closings, business limitations and closures (subject to exceptions for essential operations and businesses), quarantines and shelter-in-place orders. Although most of these governmental restrictions have since been lifted or scaled back, resurgences of COVID-19 and the emergence of new variants thereof have resulted in the reimposition of certain restrictions and may lead to other restrictions being reimplemented in response to efforts to reduce the spread of COVID-19. Given the dynamic nature of these circumstances and the related adverse impact these restrictions have had, and may continue to have, on the economy generally, the Company’s business, results of operations and financial condition may be adversely impacted by the COVID-19 pandemic.
The duration and extent of the COVID-19 pandemic’s effect on the Company’s operational and financial performance, and the operational and financial performance of the Company’s tenants, will depend on future developments, which are highly uncertain and cannot be predicted at this time, including new information which may emerge concerning the timing of vaccine rollouts, public acceptance and usage of vaccines and the effectiveness of vaccines in limiting the spread of COVID-19 and its variants that may continue to occur, and how quickly and to what extent normal economic and operating conditions can resume. The adverse impact of the COVID-19 pandemic on the Company’s business, results of operations and financial condition could be material.
 
2. BASIS OF PRESENTATION
Basis of Presentation—The accompanying condensed consolidated financial statements of the Company were prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and Article 10 of Regulation S-X. Accordingly, the condensed consolidated financial statements do not include all of the disclosures required by GAAP for a complete set of annual audited financial statements. The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020. In the opinion of management, all adjustments which are of a normal and recurring nature and considered necessary for a fair presentation of the results of the interim periods presented have been included. The results of operations for the interim periods are not necessarily indicative of results for the full year. All intercompany transactions and account balances within the Company have been eliminated.
 Recent Accounting Pronouncements— In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-04, Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”), that provides optional relief to applying reference rate reform to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”), which will be discontinued by the end of 2021. The amendments in this update are effective immediately and may be applied through December 31, 2022. The Company is still evaluating the impact of ASU 2020-04 and expects to take full advantage of the offered optional expedients and exceptions, but does not expect the adoption of the standard to have a material impact on the Company’s consolidated financial statements.

6

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


3. REAL ESTATE INVESTMENTS, NET
The following table summarizes the Company’s investment in owned properties as of March 31, 2021 and December 31, 2020 (dollars in thousands):
March 31, 2021December 31, 2020
Land$243,457 $205,356 
Buildings and improvements1,578,754 1,477,849 
Integral equipment, furniture and fixtures101,131 97,836 
Identified intangible assets2,658 2,352 
Real estate investments1,926,000 1,783,393 
Accumulated depreciation and amortization(348,550)(335,294)
Real estate investments, net$1,577,450 $1,448,099 
As of March 31, 2021, all 222 of the Company’s facilities were leased to various operators under triple-net leases. All of these leases contain annual escalators based on the percentage change in the Consumer Price Index (but not less than zero), some of which are subject to a cap, or fixed rent escalators.
As of March 31, 2021, the Company’s total future contractual minimum rental income for all of its tenants, excluding operating expense reimbursements, were (dollars in thousands): 
YearAmount
2021 (nine months)$132,001 
2022176,082 
2023175,777 
2024174,467 
2025174,441 
2026171,488 
Thereafter860,010 
Total$1,864,266 
Tenant Purchase Options
Certain of the Company’s operators hold purchase options allowing them to acquire properties they currently lease from the Company. A summary of these purchase options is presented below (dollars in thousands):
Asset TypePropertiesLease Expiration1st Option Open Date
Option Type(1)
Current Cash Rent(2)
ALF7October 20341/1/2021A$3,207 
SNF11November 20301/1/2022C4,800 
SNF1March 20294/1/2022
B / C(3)
766 
SNF / Campus2October 20321/1/2023B959 
SNF4November 203412/1/2024B3,789 
ALF2October 20341/1/2026A1,559 
(1) Option type includes:
A - Fixed base price plus a specified share on any appreciation.
B - Fixed base price.
C - Fixed capitalization rate on lease revenue.
(2) Based on annualized cash revenue for contracts in place at March 31, 2021.
(3) Purchase option reflects two option types.
7

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


Rental Income
The following table summarizes components of the Company’s rental income (dollars in thousands):
For the Three Months Ended March 31,
Rental Income20212020
Contractual rent due(1)
$45,171 $42,438 
Straight-line rent12 26 
Lease termination revenue(2)
63  
Total$45,246 $42,464 
(1) Includes initial cash rent and tenant operating expense reimbursements, as adjusted for applicable rental escalators and rent increases due to capital expenditures funded by the Company. For tenants on a cash basis, this represents the lesser of the amount that would be recognized on a straight-line basis or cash that has been received.
(2) During the three months ended March 31, 2021, in connection with the agreement to terminate its lease agreements with affiliates of Metron Integrated Health Systems (“Metron”) and to sell the facilities to a third-party, the Company received $0.1 million from Metron affiliates.
Recent Real Estate Acquisitions
The following table summarizes the Company’s acquisitions for the three months ended March 31, 2021 (dollars in thousands):
Type of Property
Purchase Price(1)
Initial Annual Cash RentNumber of Properties
Number of Beds/Units(2)
Skilled nursing$15,800 $1,492 1 145 
Multi-service campuses(3)
125,708 8,604 4 640 
Total$141,508 $10,096 5 785 
(1) Purchase price includes capitalized acquisition costs.
(2) The number of beds/units includes operating beds at the acquisition date.
(3) Initial annual cash rent represents the first twelve months of rent upon commencement of the Company’s long-term net leases, which is scheduled to occur upon the tenants’ receipt of licensing approval and increases to $9.4 million in the second year with Consumer Price Index (“CPI”) based annual escalators thereafter. The facilities are currently being leased back to the seller under a short-term lease with a term of less than one year.

Asset Sales and Assets Held for Sale
As of March 31, 2021, there were no assets classified as held for sale. During the fourth quarter of 2020, the Company met the criteria to classify one skilled nursing facility operated by affiliates of Five Oaks Healthcare, LLC as held for sale. Assets held for sale include the net book value of property the Company plans to sell within the next year. If the determination is made that the Company no longer expects to sell an asset within the next year, the asset is reclassified out of assets held for sale. On February 1, 2021, the Company closed on the sale of the one skilled nursing facility consisting of 90 beds located in Washington with a carrying value of $7.2 million, for net sales proceeds of $7.0 million. The Company recorded a loss of $0.2 million in connection with the sale.
On November 1, 2020, the Company sold the one remaining owned and operated independent living facility consisting of 168 units located in Texas with an aggregate carrying value of $4.2 million for gross proceeds of $4.5 million. In connection with the sale, the Company recognized a gain of $20,000 during the three months ended December 31, 2020.
8

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


On February 14, 2020, the Company closed on the sale of six skilled nursing facilities formerly operated by affiliates of Metron. In connection with the sale for $36.0 million, the Company received $3.5 million in cash and provided subsidiaries of Cascade Capital Group, LLC (“Cascade”), the purchaser of the properties, with a short-term mortgage loan secured by these properties for $32.4 million. The mortgage loan bore interest at 7.5% and initially had a maturity date of March 31, 2020. In connection with the sale, the Company recognized a loss of approximately $0.1 million. In April 2020, the mortgage loan was settled with $18.9 million in cash and a new mortgage loan for $13.9 million. In July 2020, the Company received prepayment in full, including accrued interest, for the new $13.9 million mortgage loan. See Note 4, Other Real Estate Investments, Net, for further detail on the new mortgage loan.

Lease Amendments
Twenty/20 Lease Termination and New Noble Master Lease. On December 1, 2020, five assisted living facilities in Virginia operated by Twenty/20 Management, Inc. (“Twenty/20”) were transferred to affiliates of Noble VA Holdings, LLC (“Noble”). In connection with the transfer, the Company entered into a new triple-net master lease with Noble. The new lease has a remaining initial term of approximately 14 years, with two five-year renewal options and CPI-based rent escalators. Initial annual cash rent under the new lease is approximately $3.2 million.

4. OTHER REAL ESTATE INVESTMENTS, NET
Mezzanine Loan Receivable—In November 2020, the Company provided Next VA Star Realty Holdings, LLC a mezzanine loan for nine skilled nursing facilities secured by membership interests in affiliates of Next VA Star Realty Holdings, LLC for approximately $15.0 million, at an annual interest rate of 12%. The loan requires monthly interest payments, is set to mature on November 30, 2025, and may (subject to certain restrictions) be prepaid before the maturity date if paid in full and for an exit fee ranging from 1% to 3% of the loan plus unpaid interest payments equal to 24 months (less the amount of monthly interest payments made by the borrower through the date of prepayment). During the three months ended March 31, 2021, the Company recognized $0.5 million of interest income related to its mezzanine loan.
Mortgage Loans Receivable—In July 2019, the Company provided MCRC, LLC a real estate loan secured by a 176-bed skilled nursing facility in Manteca, California for $3.0 million, which bore a fixed interest rate of 8% and required monthly interest payments. Concurrently, the Company entered into a purchase and sale agreement to purchase the Manteca facility from MCRC, LLC for approximately $16.4 million subject to normal diligence and other contingencies. The loan documents provided for a maturity date of the earlier to occur of the closing date of the acquisition, or five business days following the termination of the purchase and sale agreement.  MCRC, LLC breached its obligation to sell the Manteca facility to the Company on the terms outlined in the purchase and sale agreement and to repay the real estate loan upon its stated maturity. As a result, the Company commenced non-judicial foreclosure proceedings with respect to the Manteca facility. In January 2020, the borrower further collateralized the loan by causing one of its affiliates to grant the Company a deed of trust in the real estate and improvements that constitute Palm Gardens Assisted Living Facility in Yolo County, California. During the three months ended June 30, 2020, payment for the loan principal and accrued interest, including default interest, as well as reimbursement for attorney’s fees and certain other costs of suit, were received in full by the Company and, as a result, the Company withdrew all foreclosure-related proceedings related to the Manteca facility loan.
In September 2019, the Company provided affiliates of CommuniCare a $26.5 million loan secured by mortgages on the three skilled nursing facilities sold to CommuniCare, which bore a fixed interest rate of 10%. The mortgage loan, which required CommuniCare to make monthly interest payments, was set to mature on February 29, 2020 and included an option to be prepaid before the maturity date. In January 2020, the Company amended the mortgage loan’s maturity date to April 30, 2020. In April 2020, the Company amended the mortgage loan’s maturity date to May 29, 2020. During the three months ended June 30, 2020, payment for the mortgage loan and accrued interest was received in full by the Company.
In February 2020, the Company provided subsidiaries of Cascade a $32.4 million loan secured by mortgages on the six skilled nursing facilities formerly operated by affiliates of Metron sold to Cascade in February 2020, as discussed in Note 3, Real Estate Investments, Net. The mortgage loan bore interest at 7.5% and initially had a maturity date of March 31, 2020. In April 2020, the mortgage loan was settled in connection with a new mortgage loan transaction between the Company and a third-party institutional lender as co-lenders, pursuant to which the Company received $18.9 million in cash and a new mortgage loan for $13.9 million. The new mortgage loan with Cascade was secured by the same six skilled nursing facilities purchased by Cascade and was for a combined principal amount of $33.9 million, with the Company’s $13.9 million portion of the indebtedness initially bearing interest at a variable rate equal to LIBOR plus 4.00%, subject to a LIBOR floor of 1.75%. The new mortgage loan had a maturity date of April 29, 2022 and included two six-month extension options. In July 2020, prepayment for the mortgage loan of $13.9 million and accrued interest was received in full by the Company.
9

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


As of March 31, 2021, the Company had no remaining mortgage loan receivables.
During the three months ended March 31, 2021 and 2020, the Company recognized no interest income and $1.1 million of interest income, respectively, related to its mortgage loans. During both the three months ended March 31, 2021 and 2020, the Company recognized $0.1 million of interest income related to its other loans receivable.
Preferred Equity Investments—In September 2016, the Company completed a $2.3 million preferred equity investment with an affiliate of Cascadia Development, LLC. The preferred equity investment yielded a return equal to prime plus 9.5% but in no event less than 12.0% calculated on a quarterly basis on the outstanding carrying value of the investment. The investment was used to develop a 99-bed skilled nursing facility in Boise, Idaho. In connection with its investment, the Company obtained an option to purchase the development at a fixed-formula price upon stabilization, with an initial lease yield of at least 9.0%. The project was completed in the first quarter of 2018 and began lease-up during the second quarter of 2018. In January 2020, the Company purchased the skilled nursing facility for approximately $18.7 million, inclusive of transaction costs. The Company paid $15.0 million after receiving back its initial investment of $2.3 million and cumulative contractual preferred return through January 17, 2020, the acquisition date, of $1.4 million, of which less than $0.1 million was recognized as interest income during the three months ended March 31, 2020. The Company did not recognize any interest income during the three months ended March 31, 2021 related to preferred equity investments. As of March 31, 2021, the Company had no remaining preferred equity investments.
5. FAIR VALUE MEASUREMENTS
The Company determines fair value based on quoted prices when available or through the use of alternative approaches, such as discounting the expected cash flows using market interest rates commensurate with the credit quality and duration of the investment. GAAP guidance defines three levels of inputs that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability or can be corroborated with observable market data for substantially the entire contractual term of the asset or liability.

Level 3 – Unobservable inputs reflect the entity’s own assumptions about the assumptions that market participants would use in the pricing of the asset or liability and are consequently not based on market activity, but rather through particular valuation techniques.

The determination of where an asset or liability falls in the hierarchy requires significant judgment and considers factors specific to the asset or liability. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company evaluates its hierarchy disclosures each quarter and, depending on various factors, it is possible that an asset or liability may be classified differently from quarter to quarter. Changes in the type of inputs may result in a reclassification for certain assets. The Company does not expect that changes in classifications between levels will be frequent.
Items Measured at Fair Value on a Recurring Basis
The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020, aggregated by the level in the fair value hierarchy within which those instruments fall (dollars in thousands):
Level 1Level 2Level 3
Balance as of March 31, 2021
Assets:
Mezzanine loan receivable$ $ $15,155 $15,155 

Level 1Level 2Level 3
Balance as of December 31, 2020
Assets:
Mezzanine loan receivable$ $ $15,000 $15,000 

10

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


Mezzanine loan receivable: The fair value of the mezzanine loan receivable was estimated using an internal valuation model that considered the expected future cash flows of the investment, the underlying collateral value, market interest rates and other credit enhancements. As such, the Company classifies the instrument as Level 3 due to the significant unobservable inputs used in determining market interest rates for investments with similar terms. Future changes in market interest rates could materially impact the estimated discounted cash flows. As of March 31, 2021 and December 31, 2020, the Company did not have any loans that were 90 days or more past due.
For the three months ended March 31, 2021, there were no changes in assets and liabilities with Level 3 inputs in the fair value hierarchy.

Items Disclosed at Fair Value

Considerable judgment is necessary to estimate the fair value disclosure of financial instruments. The estimates of fair value presented herein are not necessarily indicative of the amounts that could be realized upon disposition of the financial instruments. A summary of the face values, carrying amounts and fair values of the Company’s financial instruments as of March 31, 2021 and December 31, 2020 using Level 2 inputs for the Notes (as defined in Note 6, Debt, below), is as follows (dollars in thousands):  

 March 31, 2021December 31, 2020
 LevelFace
Value
Carrying
Amount
Fair
Value
Face
Value
Carrying
Amount
Fair
Value
Financial liabilities:
Senior unsecured notes payable2$300,000 $296,858 $309,000 $300,000 $296,669 $311,430 

Cash and cash equivalents, accounts and other receivables, other loans receivable, and accounts payable and accrued liabilities: These balances approximate their fair values due to the short-term nature of these instruments.

Unsecured revolving credit facility and senior unsecured term loan: The fair values approximate their carrying values as the interest rates are variable and approximate prevailing market interest rates for similar debt arrangements.

6. DEBT
The following table summarizes the balance of the Company’s indebtedness as of March 31, 2021 and December 31, 2020 (dollars in thousands):
March 31, 2021December 31, 2020
Principal AmountDeferred Loan FeesCarrying ValuePrincipal AmountDeferred Loan FeesCarrying Value
Senior unsecured notes payable$300,000 $(3,142)$296,858 $300,000 $(3,331)$296,669 
Senior unsecured term loan200,000 (1,022)198,978 200,000 (1,075)198,925 
Unsecured revolving credit facility170,000  170,000 50,000  50,000 
$670,000 $(4,164)$665,836 $550,000 $(4,406)$545,594 
Senior Unsecured Notes Payable
On May 10, 2017, the Company’s wholly owned subsidiary, CTR Partnership, L.P. (the “Operating Partnership”), and its wholly owned subsidiary, CareTrust Capital Corp. (together with the Operating Partnership, the “Issuers”), completed an underwritten public offering of $300.0 million aggregate principal amount of 5.25% Senior Notes due 2025 (the “Notes”). The Notes were issued at par, resulting in gross proceeds of $300.0 million and net proceeds of approximately $294.0 million after deducting underwriting fees and other offering expenses. The Notes mature on June 1, 2025 and bear interest at a rate of 5.25% per year. Interest on the Notes is payable on June 1 and December 1 of each year.
As of June 1, 2020, the Issuers may redeem the Notes any time at the redemption prices set forth in the indenture. As of March 31, 2021, the Issuers have not elected to redeem any of the Notes. If certain changes of control of the Company occur, holders of the Notes will have the right to require the Issuers to repurchase their Notes at 101% of the principal amount plus accrued and unpaid interest, if any, to, but not including, the repurchase date.
11

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


The obligations under the Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by the Company and certain of the Company’s wholly owned existing and, subject to certain exceptions, future material subsidiaries (other than the Issuers); provided, however, that such guarantees are subject to automatic release under certain customary circumstances.
The indenture contains customary covenants such as limiting the ability of the Company and its restricted subsidiaries to: incur or guarantee additional indebtedness; incur or guarantee secured indebtedness; pay dividends or distributions on, or redeem or repurchase, capital stock; make certain investments or other restricted payments; sell assets; enter into transactions with affiliates; merge or consolidate or sell all or substantially all of their assets; and create restrictions on the ability of the Issuers and their restricted subsidiaries to pay dividends or other amounts to the Issuers. The indenture also requires the Company and its restricted subsidiaries to maintain a specified ratio of unencumbered assets to unsecured indebtedness. These covenants are subject to a number of important and significant limitations, qualifications and exceptions. The indenture also contains customary events of default.
As of March 31, 2021, the Company was in compliance with all applicable financial covenants under the indenture.

Unsecured Revolving Credit Facility and Term Loan
On February 8, 2019, the Operating Partnership, as the borrower, the Company, as guarantor, CareTrust GP, LLC, and certain of the Operating Partnership’s wholly owned subsidiaries entered into an amended and restated credit and guaranty agreement with KeyBank National Association, as administrative agent, an issuing bank and swingline lender, and the lenders party thereto (the “Amended Credit Agreement”). The Amended Credit Agreement provides for: (i) an unsecured revolving credit facility (the “Revolving Facility”) with revolving commitments in an aggregate principal amount of $600.0 million, including a letter of credit subfacility for 10% of the then available revolving commitments and a swingline loan subfacility for 10% of the then available revolving commitments and (ii) an unsecured term loan credit facility (the “Term Loan” and, together with the Revolving Facility, the “Amended Credit Facility”) in an aggregate principal amount of $200.0 million. Borrowing availability under the Revolving Facility is subject to no default or event of default under the Amended Credit Agreement having occurred at the time of borrowing. The proceeds of the Term Loan were used, in part, to repay in full all outstanding borrowings under the Company’s prior term loan and revolving facility under its prior credit agreement. Future borrowings under the Amended Credit Facility will be used for working capital purposes, for capital expenditures, to fund acquisitions and for general corporate purposes.
The interest rates applicable to loans under the Revolving Facility are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.10% to 0.55% per annum or LIBOR plus a margin ranging from 1.10% to 1.55% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). The interest rates applicable to loans under the Term Loan are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.50% to 1.20% per annum or LIBOR plus a margin ranging from 1.50% to 2.20% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). In addition, the Operating Partnership will pay a facility fee on the revolving commitments under the Revolving Facility ranging from 0.15% to 0.35% per annum, based on the debt to asset value ratio of the Company and its consolidated subsidiaries (unless the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt and the Operating Partnership elects to decrease the applicable margin as described above, in which case the Operating Partnership will pay a facility fee on the revolving commitments ranging from 0.125% to 0.30% per annum based on the credit ratings of the Company’s senior long-term unsecured debt). As of March 31, 2021, the Operating Partnership had $200.0 million outstanding under the Term Loan and $170.0 million of borrowings outstanding under the Revolving Facility.
The Revolving Facility has a maturity date of February 8, 2023, and includes, at the sole discretion of the Operating Partnership, two, six-month extension options. The Term Loan has a maturity date of February 8, 2026.
The Amended Credit Facility is guaranteed, jointly and severally, by the Company and its wholly owned subsidiaries that are party to the Amended Credit Agreement (other than the Operating Partnership). The Amended Credit Agreement contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend organizational documents and pay certain dividends and other restricted
12

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


payments. The Amended Credit Agreement requires the Company to comply with financial maintenance covenants to be tested quarterly, consisting of a maximum debt to asset value ratio, a minimum fixed charge coverage ratio, a minimum tangible net worth, a maximum cash distributions to operating income ratio, a maximum secured debt to asset value ratio, a maximum secured recourse debt to asset value ratio, a maximum unsecured debt to unencumbered properties asset value ratio, a minimum unsecured interest coverage ratio and a minimum rent coverage ratio. The Amended Credit Agreement also contains certain customary events of default, including the failure to make timely payments under the Amended Credit Facility or other material indebtedness, the failure to satisfy certain covenants (including the financial maintenance covenants), the occurrence of change of control and specified events of bankruptcy and insolvency.
As of March 31, 2021, the Company was in compliance with all applicable financial covenants under the Amended Credit Agreement.

7. EQUITY
Common Stock
At-The-Market Offering—On March 10, 2020, the Company entered into a new equity distribution agreement to issue and sell, from time to time, up to $500.0 million in aggregate offering price of its common stock through an “at-the-market” equity offering program (the “New ATM Program”). In connection with the entry into the equity distribution agreement and the commencement of the New ATM Program, the Company’s “at-the-market” equity offering program pursuant to the Company’s prior equity distribution agreement, dated as of March 4, 2019, was terminated (the “Prior ATM Program”).
There was no Prior ATM Program or New ATM Program activity for the three months ended March 31, 2020. The following table summarizes the New ATM Program activity for the three months ended March 31, 2021 (in thousands, except per share amounts).
For the Three Months Ended
March 31, 2021
Number of shares702 
Average sales price per share$23.62 
Gross proceeds(1)
$16,579 
(1) Total gross proceeds is before $0.2 million of commissions paid to the sales agents during the three months ended March 31, 2021 under the New ATM Program.
As of March 31, 2021, the Company had $483.4 million available for future issuances under the New ATM Program.
Share Repurchase Program—On March 20, 2020, the Company’s Board of Directors authorized a share repurchase program to repurchase up to $150.0 million of outstanding shares of the Company’s common stock (the “Repurchase Program”). Repurchases under the Repurchase Program, which expires on March 31, 2023, may be made through open market purchases, privately negotiated transactions, structured or derivative transactions, including accelerated share repurchase transactions, or other methods of acquiring shares, in each case subject to market conditions and at such times as shall be permitted by applicable securities laws and determined by management. Repurchases under the Repurchase Program may also be made pursuant to a plan adopted under Rule 10b5-1 promulgated under the Exchange Act. The Company expects to finance any share repurchases under the Repurchase Program using available cash and may also use short-term borrowings under the Revolving Facility. The Company did not repurchase any shares of common stock under the Repurchase Program during the three months ended March 31, 2021 and 2020. The Repurchase Program may be modified, discontinued or suspended at any time.
13

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


Dividends on Common StockThe following table summarizes the cash dividends on the Company’s common stock declared by the Company’s Board of Directors for the first three months of 2021 (dollars in thousands, except per share amounts):
For the Three Months Ended
March 31, 2021
Dividends declared per share$0.265 
Dividends payment dateApril 15, 2021
Dividends payable as of record date$25,633 
Dividends record dateMarch 31, 2021

8. STOCK-BASED COMPENSATION
All stock-based awards are subject to the terms of the CareTrust REIT, Inc. and CTR Partnership, L.P. Incentive Award Plan (the “Plan”). The Plan provides for the granting of stock-based compensation, including stock options, restricted stock, performance awards, restricted stock units and other incentive awards to officers, employees and directors in connection with their employment with or services provided to the Company.
Restricted Stock Awards—In connection with the separation of the healthcare business and real estate business of the Ensign Group, Inc. (“Ensign”) into two separate and independently publicly traded companies (the “Spin-Off”) on June 1, 2014, employees of Ensign who had unvested shares of restricted stock were given one share of CareTrust REIT unvested restricted stock totaling 207,580 shares at the Spin-Off. These restricted shares were subject to a time vesting provision only and the Company did not recognize any stock compensation expense associated with these awards. During the year ended December 31, 2020, 1,760 shares were forfeited. At March 31, 2021, there were no unvested restricted stock awards outstanding.
In January 2021 and February 2021, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted 140,514 and 99,189 shares of restricted stock, respectively, to officers and employees. Each share had a fair market value on the date of grant of $22.48 and $22.18 per share, respectively, based on the closing market price of the Company’s common stock on that date, and the shares vest in three equal annual installments beginning on the first anniversary of the grant date.
In January 2021, the Compensation Committee granted 108,414 performance stock awards to officers. Each share had a fair market value on the date of grant of $22.48 per share, based on the closing market price of the Company’s common stock on that date. Performance stock awards are subject to both time and performance based conditions and vest over a one-to three-year period. The amount of such performance awards that will ultimately vest is dependent on the Company’s Normalized Funds from Operations (“NFFO”) per share, as defined by the Compensation Committee, meeting or exceeding a specified per share amount for the applicable vesting period.
Additionally, in February 2021, the Compensation Committee granted 99,189 performance stock awards to officers. Each share had an estimated fair market value on the date of grant of $27.98 per share. Performance stock awards are subject to both time and performance based conditions and cliff vest over a three-year period. The amount of such performance awards that will ultimately vest is dependent on the Company’s total shareholder return (“TSR”) performance relative to a custom TSR peer group consisting of 16 other publicly traded healthcare REITs and will range from 0% to 200% of the TSR awards initially granted. Compensation expense for awards with performance-based vesting conditions is recognized based upon the grant date fair value per share for each component multiplied by the estimated number of performance stock awards to be earned after considering the Company’s expectation of future performance and is recognized provided that the requisite service is rendered, regardless of when, if ever, the market condition is satisfied. Forfeitures of stock-based awards are recognized as they occur.
14

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


The fair value of the TSR-based performance stock awards is estimated on the date of the grant using a Monte Carlo valuation model. The risk-free rate is based on the U.S. Treasury yield curve in effect at the grant date for the expected performance period. Expected volatility is based on historical volatility for the most recent 2.84 year period ending on the grant date for the Company and the selected TSR peer group, and is calculated on a daily basis. The following are the key assumptions used in this valuation:
For the Three Months Ended March 31, 2021
Risk free interest rate0.27 %
Expected stock price volatility52.93 %
Expected service period2.84 years
Expected dividend yield (assuming full reinvestment) %
The following table summarizes the stock-based compensation expense recognized (dollars in thousands):
 For the Three Months Ended March 31,
 20212020
Stock-based compensation expense$1,585 $884 
As of March 31, 2021, there was $14.5 million of unamortized stock-based compensation expense related to unvested awards and the weighted-average remaining vesting period of such awards was 2.5 years. 
9. EARNINGS PER COMMON SHARE
The following table presents the calculation of basic and diluted earnings per common share (“EPS”) for the Company’s common stock for the three months ended March 31, 2021 and 2020, and reconciles the weighted-average common shares outstanding used in the calculation of basic EPS to the weighted-average common shares outstanding used in the calculation of diluted EPS (amounts in thousands, except per share amounts):
 
 For the Three Months Ended March 31,
 20212020
Numerator:
Net income$20,486 $19,325 
Less: Net income allocated to participating securities(119)(75)
Numerator for basic and diluted earnings available to common stockholders$20,367 $19,250 
Denominator:
Weighted-average basic common shares outstanding95,378 95,161 
Weighted-average diluted common shares outstanding95,385 95,161 
Earnings per common share, basic$0.21 $0.20 
Earnings per common share, diluted$0.21 $0.20 
The Company’s unvested restricted shares associated with its incentive award plan and unvested restricted shares issued to employees of Ensign at the Spin-Off have been excluded from the above calculation of earnings per diluted share for the three months ended March 31, 2021 and 2020, when their inclusion would have been anti-dilutive.
10. COMMITMENTS AND CONTINGENCIES
The Company and its subsidiaries are and may become from time to time a party to various claims and lawsuits arising in the ordinary course of business, which are not individually or in the aggregate anticipated to have a material adverse effect on the Company’s results of operations, financial condition or cash flows. Claims and lawsuits may include matters involving general or professional liability asserted against the Company’s tenants, which are the responsibility of the
15

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


Company’s tenants and for which the Company is entitled to be indemnified by its tenants under the insurance and indemnification provisions in the applicable leases.
Capital expenditures for each property leased under the Company’s triple-net leases are generally the responsibility of the tenant, except that, for the facilities leased to subsidiaries of Ensign and The Pennant Group, Inc. (“Pennant”), the tenant will have an option to require the Company to finance certain capital expenditures up to an aggregate of 20% of the Company’s initial investment in such property, subject to a corresponding rent increase at the time of funding. For the Company’s other triple-net master leases, subject to approval by the Company, the tenants may request capital expenditure funding that would generally be subject to a corresponding rent increase at the time of funding and which are subject to tenant compliance with the conditions to the Company’s approval and funding of their requests. As of March 31, 2021, the Company had committed to fund certain capital improvements at certain triple-net leased facilities totaling $14.1 million, of which $13.1 million is subject to rent increase at the time of funding.

11. CONCENTRATION OF RISK
Major operator concentrations – As of March 31, 2021, Ensign leased 89 skilled nursing, multi-service campuses, assisted living and independent living facilities which had a total of 9,551 beds and units and are located in Arizona, California, Colorado, Idaho, Iowa, Nebraska, Nevada, Texas, Utah and Washington. The four states in which Ensign leases the highest concentration of properties by rental revenues as of March 31, 2021 are Texas, California, Arizona and Utah. During both the three months ended March 31, 2021 and 2020, Ensign represented 32% of the Company’s rental income, exclusive of operating expense reimbursements.
Ensign is subject to the registration and reporting requirements of the SEC and is required to file with the SEC annual reports containing audited financial information and quarterly reports containing unaudited financial information. Ensign’s financial statements, as filed with the SEC, can be found at http://www.sec.gov. The Company has not verified this information through an independent investigation or otherwise.
As of March 31, 2021, Priority Management Group (“PMG”) leased 15 skilled nursing and campus facilities which had a total of 2,144 beds and units, and are located in Louisiana and Texas. During both the three months ended March 31, 2021 and 2020, PMG represented 16% of the Company’s rental income, exclusive of operating expense reimbursements.

12. SUBSEQUENT EVENTS
The Company evaluates subsequent events in accordance with ASC 855, Subsequent Events. The Company evaluates subsequent events up until the date the condensed consolidated financial statements are issued.
Recent Acquisition
In April 2021, the Company acquired one skilled nursing facility with the Company’s existing tenant Bayshire, LLC (“Bayshire”). The amended lease with Bayshire has a remaining term of approximately 13 years. The purchase price for the facility was approximately $9.7 million, which includes an estimated purchase price and capitalized acquisition costs. The estimated contractual initial annual cash rent from the acquisition is approximately $0.8 million and increases to $0.9 million in the second year with CPI-based annual escalators thereafter. The acquisition was funded using cash on hand.
16

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Forward-Looking Statements
Certain statements in this report may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Those forward-looking statements include all statements that are not historical statements of fact and those regarding our intent, belief or expectations, including, but not limited to, statements regarding: future financing plans, business strategies, growth prospects and operating and financial performance; expectations regarding the making of distributions and the payment of dividends; and compliance with and changes in governmental regulations.

Words such as “anticipate(s),” “expect(s),” “intend(s),” “plan(s),” “believe(s),” “may,” “will,” “would,” “could,” “should,” “seek(s)” and similar expressions, or the negative of these terms, are intended to identify such forward-looking statements. These statements are based on management’s current expectations and beliefs and are subject to a number of risks and uncertainties that could lead to actual results differing materially from those projected, forecasted or expected. Although we believe that the assumptions underlying the forward-looking statements are reasonable, we can give no assurance that our expectations will be attained. Factors which could have a material adverse effect on our operations and future prospects or which could cause actual results to differ materially from our expectations include, but are not limited to: (i) the COVID-19 pandemic and the measures taken to prevent its spread and the related impact on our business or the businesses of our tenants; (ii) the ability and willingness of our tenants to meet and/or perform their obligations under the triple-net leases we have entered into with them, including, without limitation, their respective obligations to indemnify, defend and hold us harmless from and against various claims, litigation and liabilities; (iii) the ability of our tenants to comply with applicable laws, rules and regulations in the operation of the properties we lease to them; (iv) the ability and willingness of our tenants to renew their leases with us upon their expiration, and the ability to reposition our properties on the same or better terms in the event of nonrenewal or in the event we replace an existing tenant, as well as any obligations, including indemnification obligations, we may incur in connection with the replacement of an existing tenant; (v) the availability of and the ability to identify (a) tenants who meet our credit and operating standards, and (b) suitable acquisition opportunities, and the ability to acquire and lease the respective properties to such tenants on favorable terms; (vi) the ability to generate sufficient cash flows to service our outstanding indebtedness; (vii) access to debt and equity capital markets; (viii) fluctuating interest rates; (ix) the ability to retain our key management personnel; (x) the ability to maintain our status as a real estate investment trust (“REIT”); (xi) changes in the U.S. tax law and other state, federal or local laws, whether or not specific to REITs; (xii) other risks inherent in the real estate business, including potential liability relating to environmental matters and illiquidity of real estate investments; and (xiii) any additional factors included under “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020, including in the section entitled “Risk Factors” in Item 1A of Part I of such report, as such risk factors may be amended, supplemented or superseded from time to time by other reports we file with the Securities and Exchange Commission (the “SEC”).
Forward-looking statements speak only as of the date of this report. Except in the normal course of our public disclosure obligations, we expressly disclaim any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any statement is based.
Overview
CareTrust REIT is a self-administered, publicly-traded REIT engaged in the ownership, acquisition, development and leasing of seniors housing and healthcare-related properties. As of March 31, 2021, we owned and leased to independent operators, 222 skilled nursing, multi-service campuses, assisted living and independent living facilities consisting of 23,222 operational beds and units located in 28 states with the highest concentration of properties by rental revenues located in California, Texas, Louisiana, Idaho and Arizona. As of March 31, 2021, we also had other real estate investments consisting of one mezzanine loan receivable with a carrying value of $15.2 million.
We generate revenues primarily by leasing healthcare-related properties to healthcare operators in triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property (including property taxes, insurance, maintenance and repair costs and capital expenditures, subject to certain exceptions in the case of properties leased to Ensign and Pennant). We conduct and manage our business as one operating segment for internal reporting and internal decision-making purposes. We expect to grow our portfolio by pursuing opportunities to acquire additional properties that will be leased to a diverse group of local, regional and national healthcare providers, which may include other skilled nursing operators, as well as seniors housing operators and related businesses. We also anticipate diversifying our portfolio over time, including by acquiring properties in different geographic markets, and in different asset classes. In addition, we actively monitor the clinical, regulatory and financial operating results of our tenants, and work to identify opportunities within their operations and markets that could improve their operating results at our facilities. We communicate such observations to our
17

tenants; however, we have no contractual obligation to do so. Moreover, our tenants have sole discretion with respect to the day-to-day operation of the facilities they lease from us, and how and whether to implement any observation we may share with them. We also actively monitor the overall occupancy, skilled mix, and other operating metrics of our tenants on at least a monthly basis including, beginning in the quarter ended June 30, 2020, any stimulus funds received by each tenant. We have replaced tenants in the past, and may elect to replace tenants in the future, if they fail to meet the terms and conditions of their leases with us. The replacement tenants may include tenants with whom we have had no prior landlord-tenant relationship as well as current tenants with whom we are comfortable expanding our relationships. We have also provided select tenants with strategic capital for facility upkeep and modernization, as well as short-term working capital loans when they are awaiting licensure and certification or conducting turnaround work in one or more of our properties, and we may continue to do so in the future. In addition, we periodically reassess the investments we have made and the tenant relationships we have entered into, and have selectively disposed of facilities or investments, or terminated such relationships, and we expect to continue making such reassessments and, where appropriate, taking such actions.

Recent Developments

COVID-19 Update
The COVID-19 pandemic has led governments and other authorities around the world, including federal, state and local authorities in the United States, to impose measures intended to reduce its spread, including restrictions on freedom of movement and business operations such as travel bans, border closings, business limitations and closures (subject to exceptions for essential operations and businesses), quarantines and shelter-in-place orders. Although most of these governmental restrictions have since been lifted or scaled back, resurgences of COVID-19 and the emergence of new variants thereof have resulted in the reimposition of certain restrictions and may lead to other restrictions being implemented in response to efforts to reduce the spread of COVID-19. Given the dynamic nature of these circumstances and the related adverse impact these restrictions have had, and may continue to have, on the economy generally, our business, results of operations and financial condition may be adversely impacted by the COVID-19 pandemic.
Tenants of our properties operating pursuant to triple-net master leases have been adversely impacted, and we expect that they will continue to be adversely impacted, by the COVID-19 pandemic. Our tenants are experiencing increased operating costs as a result of actions they are taking to prevent or mitigate the outbreak or spread of COVID-19 at their facilities, including in connection with their implementation of safety protocols and procedures and other regulatory requirements. To help offset these costs as well as occupancy declines, various relief programs have been enacted by the government, including the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), which have provided, and we expect will continue to provide some benefits to our tenants subject to the programs’ respective terms and conditions (the “Provider Relief Funds”). The estimated federal and state COVID-19-related relief approved, received and retained to date by our operators, as reported by our operators, is approximately $166.1 million. At March 31, 2021, two of our operators who have received Provider Relief Funds have disclosed that they have returned, or plan to return, all or a portion of the Provider Relief Funds issued to them.
At a portfolio wide level, occupancy levels at our seniors housing facilities remained relatively stable from the onset of the COVID-19 pandemic until the beginning of the fourth quarter of 2020, during which we began to see a decline, and occupancy levels declined further in the first quarter of 2021. Occupancy levels at our skilled nursing facilities (“SNFs”), which declined at the onset of the COVID-19 pandemic and continued to decline during the remainder of 2020, started to stabilize during the first quarter of 2021 compared to occupancy levels in the fourth quarter of 2020. Beginning in early 2020, the federal government temporarily suspended the three-day hospital stay requirement for a patient’s Medicare benefits to refresh. Providers can now “skill in place,” eliminating the risk of transferring the patient to the hospital. Because of this temporary rule change, overall skilled mix increased in the three months ended March 31, 2021 compared to the three months ended March 31, 2020. An increase in skilled mix can, but may not necessarily, offset some or all of the adverse financial impact to the operator of the SNF from a decline in occupancy. However, the skilled mix in our SNFs during the three months ended March 31, 2021 was lower than the peak level seen in December 2020, and we anticipate that skilled mix in our SNFs will decline as cases of COVID-19 decline.
The higher operating costs affecting our tenants, and the impact of lower occupancy levels, have adversely impacted and may continue to adversely impact the ability of our tenants to satisfy their rental obligations to us in full or on a timely basis. While we have not seen a need to grant any rent relief to any tenant to date, future adverse changes to tenants’ operating fundamentals, or a reduction in or discontinuation of government support, could change our expectations. Approximately 100.0% of our contractual rent obligations due for both the first quarter of 2021 and April 2021 have been collected from our tenants.
18

Recently, a number of COVID-19 vaccines were provided emergency use authorization. As of May 6, 2021, based on information provided by operators who have reported such information to us, the majority of our operators’ residents have been fully vaccinated, while less than half of such operators’ staff have received the first dose.
The duration and extent of the COVID-19 pandemic’s effect on our operational and financial performance, and the operational and financial performance of our tenants, will depend on future developments, which are highly uncertain and cannot be predicted at this time, including new information which may emerge concerning the severity of COVID-19, timing of vaccine rollouts, public acceptance and usage of vaccines and the effectiveness of vaccines in limiting the spread of COVID-19 and its variants, actions taken to contain the spread of COVID-19, resurgences of COVID-19 and its variants that may continue to occur, and how quickly and to what extent normal economic and operating conditions can resume. The adverse impact of the COVID-19 pandemic on our business, results of operations and financial condition could be material.

Sale of Real Estate
On February 1, 2021, we closed on the sale of one skilled nursing facility consisting of 90 beds located in Washington with a carrying value of $7.2 million, for net sales proceeds of $7.0 million. We recorded a loss of $0.2 million in connection with the sale. The facility was classified as held for sale as of December 31, 2020.

Recent Investments
From January 1, 2021 through May 6, 2021, we acquired 2 skilled nursing facilities and 4 multi-service campuses for approximately $151.2 million, which includes capitalized acquisition costs. These acquisitions are expected to generate initial annual cash revenues of approximately $10.9 million and an initial blended yield of approximately 7.2%. See Note 3, Real Estate Investments, Net in the Notes to condensed consolidated financial statements for additional information.

At-The-Market Offering of Common Stock
On March 10, 2020, we entered into a new equity distribution agreement to issue and sell, from time to time, up to $500.0 million in aggregate offering price of our common stock through an “at-the-market” equity offering program (the “New ATM Program”). In connection with the entry into the equity distribution agreement and the commencement of the New ATM Program, our “at-the-market” equity offering program pursuant to our prior equity distribution agreement, dated as of March 4, 2019, was terminated (the “Prior ATM Program”).
There was no Prior ATM Program or New ATM Program activity for the three months ended March 31, 2020. The following table summarizes the New ATM Program activity for the three months ended March 31, 2021 (in thousands, except per share amounts).
For the Three Months Ended
March 31, 2021
Number of shares702 
Average sales price per share$23.62 
Gross proceeds(1)
$16,579 
(1) Total gross proceeds is before $0.2 million of commissions paid to the sales agents during the three months ended March 31, 2021 under the New ATM Program.
As of March 31, 2021, the Company had $483.4 million available for future issuances under the New ATM Program.

19

Results of Operations
Operating Results
Three Months Ended March 31, 2021 Compared to Three Months Ended March 31, 2020: 
 Three Months Ended March 31,Increase
(Decrease)
Percentage
Difference
 20212020
 (dollars in thousands)
Revenues:
Rental income$45,246 $42,464 $2,782 %
Independent living facilities— 625 (625)(100)%
Interest and other income505 1,251 (746)(60)%
Expenses:
Depreciation and amortization13,473 13,160 313 %
Interest expense5,762 6,714 (952)(14)%
Property taxes696 485 211 44 %
Independent living facilities — 546 (546)(100)%
General and administrative5,142 4,054 1,088 27 %
Other loss:
Loss on sale of real estate(192)(56)(136)243 %
    
Rental income. The $2.8 million, or 7%, increase in rental income is primarily due to a $2.3 million increase in rental income from real estate investments made after January 1, 2020, $0.8 million from contractual increases in rental rates for our existing tenants, a $0.3 million increase in cash rents due to lease amendments and $0.1 million of lease termination revenue, partially offset by a $0.6 million decrease in rental income due to the disposal of assets in February 2020 and February 2021 and a $0.1 million decrease in tenant reimbursements.
Independent living facilities. The $0.6 million, or 100%, decrease in revenues from our ILFs was due to the sale of our one remaining ILF to a third party in November 2020. The $0.5 million, or 100%, decrease in expenses was for the same reasons indicated for the decrease in revenues.
Interest and other income. The $0.7 million, or 60%, decrease in interest and other income was primarily due to a decrease in interest income of $1.2 million due to the repayment of mortgage loans and other loans receivable primarily by Manteca in May 2020, CommuniCare in May 2020 and Cascade in July 2020, partially offset by approximately $0.5 million of interest income related to our mezzanine loan to Next VA Star Realty Holdings, LLC originated in November 2020. See Note 4, Other Real Estate Investments, Net.
Depreciation and amortization. The $0.3 million, or 2%, increase in depreciation and amortization was primarily due to an increase in depreciation and amortization of $0.7 million related to new real estate investments made after January 1, 2020, partially offset by $0.3 million due to assets becoming fully depreciated after January 1, 2020 and $0.1 million of depreciation related to the disposal of assets.
Interest expense. The $1.0 million, or 14%, decrease in interest expense was primarily due to lower weighted average interest rates, partially offset by a higher weighted average debt balance of approximately $23.9 million for the three months ended March 31, 2021 compared to the three months ended March 31, 2020.
Property taxes. The $0.2 million, or 44%, increase was primarily due to a $0.3 million decline in property taxes realized upon disposition of assets in February 2020 and the transfer of certain properties to new operators in January 2021 that do not make direct tax payments, partially offset by a decrease of $0.1 million of property taxes due to annual reassessments and decreased effective tax rates.
General and administrative expense. The $1.1 million, or 27%, increase was primarily related to higher stock compensation expense of $0.7 million, higher cash wages of $0.2 million, increased professional service fees of $0.1 million and $0.1 million of other general and administrative expense compared to the prior period.
20

Loss on sale of real estate. During the three months ended March 31, 2021, we recorded a $0.2 million loss on sale of real estate related to the sale of one skilled nursing facility. During the three months ended March 31, 2020, we recorded a $0.1 million loss on sale of real estate related to the sale of six skilled nursing facilities.
Liquidity and Capital Resources
To qualify as a REIT for federal income tax purposes, we are required to distribute at least 90% of our REIT taxable income, determined without regard to the dividends paid deduction and excluding any net capital gains, to our stockholders on an annual basis. Accordingly, we intend to make, but are not contractually bound to make, regular quarterly dividends to common stockholders from cash flow from operating activities. All such dividends are at the discretion of our board of directors.
As of March 31, 2021, we had cash and cash equivalents of $30.5 million.
During the three months ended March 31, 2021, we sold 702,000 shares of common stock under our New ATM Program for gross proceeds of $16.6 million. As of March 31, 2021, we had $483.4 million available for future issuances under the New ATM Program.
As of March 31, 2021, we also had $170.0 million in borrowings outstanding and $430.0 million of availability remaining under the Revolving Facility (as defined below). We believe that our available cash, expected operating cash flows, and the availability under the New ATM Program and Amended Credit Facility (as defined below) will provide sufficient funds for our operations, anticipated scheduled debt service payments and projected dividend payments for at least the next twelve months.
We intend to invest in and/or develop additional healthcare properties as suitable opportunities arise and adequate sources of financing are available. We expect that future investments in and/or development of properties, including any improvements or renovations of current or newly-acquired properties, will depend on and will be financed by, in whole or in part, our existing cash, borrowings available to us under the Amended Credit Facility, future borrowings or the proceeds from sales of shares of our common stock pursuant to our New ATM Program or additional issuances of common stock or other securities. In addition, we may seek financing from U.S. government agencies, including through Fannie Mae and the U.S. Department of Housing and Urban Development, in appropriate circumstances in connection with acquisitions and refinancing of existing mortgage loans.
We have filed an automatic shelf registration statement with the U.S. Securities and Exchange Commission that expires in March 2023, which will allow us or certain of our subsidiaries, as applicable, to offer and sell shares of common stock, preferred stock, warrants, rights, units and debt securities through underwriters, dealers or agents or directly to purchasers, in one or more offerings on a continuous or delayed basis, in amounts, at prices and on terms we determine at the time of the offering.
Although we are subject to restrictions on our ability to incur indebtedness, we expect that we will be able to refinance existing indebtedness or incur additional indebtedness for acquisitions or other purposes, if needed. However, there can be no assurance that we will be able to refinance our indebtedness, incur additional indebtedness or access additional sources of capital, such as by issuing common stock or other debt or equity securities, on terms that are acceptable to us or at all.
21

Cash Flows
The following table presents selected data from our condensed consolidated statements of cash flows for the periods presented (dollars in thousands): 
 For the Three Months Ended March 31,
 20212020
 
Net cash provided by operating activities$33,949 $36,518 
Net cash used in investing activities(133,300)(24,300)
Net cash provided by (used in) financing activities110,901 (8,608)
Net increase in cash and cash equivalents11,550 3,610 
Cash and cash equivalents, beginning of period18,919 20,327 
Cash and cash equivalents, end of period$30,469 $23,937 
Net cash provided by operating activities decreased $2.6 million for the three months ended March 31, 2021 compared to the three months ended March 31, 2020, primarily due to a decrease of $2.1 million in interest and other income due to the repayments of our preferred equity investment, mortgages and other loans, a change in operating assets and liabilities of $1.4 million, an increase of $0.4 million in cash paid for general and administrative expenses, a decrease of $0.1 million in net operating income from our previously owned ILF, partially offset by a decrease of $1.0 million in interest paid on outstanding indebtedness due to lower weighted average interest rates, partially offset by a higher weighted average debt balance and a $0.4 million net increase in cash rent.
Cash used in investing activities for the three months ended March 31, 2021 was primarily comprised of $138.9 million in acquisitions of real estate and investments in other loans, $1.3 million of purchases of equipment, furniture and fixtures and improvements to real estate, partially offset by $6.8 million in net proceeds from real estate sales and $0.1 million of payments received from other loans receivable. Cash used in investing activities for the three months ended March 31, 2020 was primarily comprised of $27.0 million in acquisitions of real estate and investments in real estate mortgage loans and $2.4 million of purchases of equipment, furniture and fixtures and improvements to real estate partially offset by $3.0 million of payments received from our preferred equity investment and mortgage and other loans receivable and $2.1 million in net proceeds from real estate sales.
Our cash flows provided by financing activities for the three months ended March 31, 2021 were primarily comprised of $120.0 million in borrowings under our Amended Credit Facility (as defined below), $16.2 million of net proceeds from the issuance of common stock, partially offset by $24.0 million in dividends paid and $1.3 million net settlement adjustment on restricted stock. Our cash flows used in financing activities for the three months ended March 31, 2020 were primarily comprised of $21.5 million in dividends paid and a $2.0 million net settlement adjustment on restricted stock, partially offset by $15.0 million in net borrowings under our Amended Credit Facility.
Indebtedness
5.25% Senior Unsecured Notes due 2025 and Issuer and Guarantor Financial Information
On May 10, 2017, the Issuers completed a public offering of $300.0 million aggregate principal amount of the Notes. The Notes were issued at par, resulting in gross proceeds of $300.0 million and net proceeds of approximately $294.0 million after deducting underwriting fees and other offering expenses. The Notes mature on June 1, 2025 and bear interest at a rate of 5.25% per year. Interest on the Notes is payable on June 1 and December 1 of each year, beginning on December 1, 2017.
As of June 1, 2020, the Issuers may redeem the Notes any time at the redemption prices set forth in the indenture. As of March 31, 2021, the Issuers have not elected to redeem any of the Notes. If certain changes of control of CareTrust REIT occur, holders of the Notes will have the right to require the Issuers to repurchase their Notes at 101% of the principal amount plus accrued and unpaid interest, if any, to, but not including, the repurchase date.
The obligations under the Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by CareTrust REIT (the “Parent Guarantor”) and CareTrust REIT’s wholly owned existing and, subject to certain exceptions, future material subsidiaries (other than the Issuers) (the “Subsidiary Guarantors”); provided, however, that such guarantees are subject to automatic release under certain customary circumstances, including if the Subsidiary Guarantor is sold
22

or sells all or substantially all of its assets, the Subsidiary Guarantor is designated “unrestricted” for covenant purposes under the indenture, the Subsidiary Guarantor’s guarantee of other indebtedness which resulted in the creation of the guarantee of the Notes is terminated or released, or the requirements for legal defeasance or covenant defeasance or to discharge the indenture have been satisfied.
The following provides information regarding the entity structure of the Parent Guarantor, the Issuers and the Subsidiary Guarantors:
CareTrust REIT, Inc. – The Parent Guarantor was formed on October 29, 2013 in connection with the separation of Ensign’s healthcare business and its real estate business into two separate and independently publicly traded companies (the “Spin-Off”). The Parent Guarantor was a wholly owned subsidiary of Ensign prior to the effective date of the Spin-Off on June 1, 2014. The Parent Guarantor has not conducted any operations or had any business since the Spin-Off.
CTR Partnership, L.P. and CareTrust Capital Corp. – The Issuers, each of which is a wholly owned subsidiary of the Parent Guarantor, were formed on May 8, 2014 and May 9, 2014, respectively, in anticipation of the Spin-Off and the related transactions. The Issuers did not conduct any operations or have any business prior to the date of the consummation of the Spin-Off related transactions. The Operating Partnership directly invests in real estate and real estate related assets and therefore does not rely solely on the cash flow generated by the Subsidiary Guarantors and their ability to make cash available to the Issuers, by dividend or otherwise. However, in the event that the earnings or available assets of the Issuers are insufficient, the Issuers’ ability to pay principal and interest on the Notes could be dependent on the cash flow generated by the Subsidiary Guarantors and their ability to make such cash available to the Issuers. CareTrust Capital Corp., a co-issuer of the Notes, has no material assets and conducts no operations. Therefore, it has no independent ability to service the interest and principal obligations under the Notes.
Subsidiary Guarantors – The Subsidiary Guarantors consist of all of the subsidiaries of the Parent Guarantor other than the Issuers. The Parent Guarantor conducts a substantial portion of its business operations through the Subsidiary Guarantors.
The assets and liabilities and results of operations of the combined guarantors (the Parent Guarantor and the Subsidiary Guarantors) and the Issuers of the Notes are not materially different than the corresponding amounts presented in our condensed consolidated financial statements.
The indenture contains customary covenants such as limiting the ability of CareTrust REIT and its restricted subsidiaries to: incur or guarantee additional indebtedness; incur or guarantee secured indebtedness; make certain investments or other restricted payments; sell assets; enter into transactions with affiliates; merge or consolidate or sell all or substantially all of their assets, and pay dividends or distributions on, or redeem or repurchase, capital stock, including a restriction on the ability of the Issuers and their restricted subsidiaries to pay dividends or other amounts to the Issuers, subject to certain other exceptions, unless: (i) there is no default or event of default under the indenture; (ii) the Issuers are in compliance with specified limitations on indebtedness under the indenture; and (iii) the payments do not exceed a specified restricted payment basket. Dividends or distributions are also permitted if the Parent Guarantor’s board of directors believes in good faith they are necessary to maintain Parent Guarantor’s REIT status or to avoid any excise tax or income tax imposed on Parent Guarantor, provided there is no default or event of default under the indenture. Further, the Issuers and their restricted subsidiaries are not permitted to create or cause to become effective any encumbrance or restriction on the ability of the Issuers to, among other things, pay dividends or make distributions, pay indebtedness, make loans or advances to the Issuers or their restricted subsidiaries or transfer property or assets to the Issuers or their restricted subsidiaries, other than in connection with certain customary exceptions such as in respect of the indenture or the Amended Credit Facility.
The indenture also requires CareTrust REIT and its restricted subsidiaries to maintain a specified ratio of unencumbered assets to unsecured indebtedness. These covenants are subject to a number of important and significant limitations, qualifications and exceptions. The indenture also contains customary events of default.
As of March 31, 2021, we were in compliance with all applicable financial covenants under the indenture.
Unsecured Revolving Credit Facility and Term Loan
On February 8, 2019, the Operating Partnership, as the borrower, the Company, as guarantor, CareTrust GP, LLC, and certain of the Operating Partnership’s wholly owned subsidiaries entered into an amended and restated credit and guaranty agreement with KeyBank National Association, as administrative agent, an issuing bank and swingline lender, and the lenders party thereto (the “Amended Credit Agreement”). The Amended Credit Agreement provides for: (i) an unsecured revolving
23

credit facility (the “Revolving Facility”) with revolving commitments in an aggregate principal amount of $600.0 million, including a letter of credit subfacility for 10% of the then available revolving commitments and a swingline loan subfacility for 10% of the then available revolving commitments and (ii) an unsecured term loan credit facility (the “Term Loan” and, together with the Revolving Facility, the “Amended Credit Facility”) in an aggregate principal amount of $200.0 million. Borrowing availability under the Revolving Facility is subject to no default or event of default under the Amended Credit Agreement having occurred at the time of borrowing. The proceeds of the Term Loan were used, in part, to repay in full all outstanding borrowings under our prior term loan and revolving facility under our prior credit agreement. Future borrowings under the Amended Credit Facility will be used for working capital purposes, for capital expenditures, to fund acquisitions and for general corporate purposes.
The interest rates applicable to loans under the Revolving Facility are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.10% to 0.55% per annum or LIBOR plus a margin ranging from 1.10% to 1.55% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). The interest rates applicable to loans under the Term Loan are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.50% to 1.20% per annum or LIBOR plus a margin ranging from 1.50% to 2.20% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). In addition, the Operating Partnership will pay a facility fee on the revolving commitments under the Revolving Facility ranging from 0.15% to 0.35% per annum, based on the debt to asset value ratio of the Company and its consolidated subsidiaries (unless the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt and the Operating Partnership elects to decrease the applicable margin as described above, in which case the Operating Partnership will pay a facility fee on the revolving commitments ranging from 0.125% to 0.30% per annum based off the credit ratings of the Company’s senior long-term unsecured debt). As of March 31, 2021, we had $200.0 million outstanding under the Term Loan and $170.0 million outstanding under the Revolving Facility.
The Revolving Facility has a maturity date of February 8, 2023, and includes, at our sole discretion, two, six-month extension options. The Term Loan has a maturity date of February 8, 2026.
The Amended Credit Facility is guaranteed, jointly and severally, by the Company and its wholly-owned subsidiaries that are party to the Amended Credit Agreement (other than the Operating Partnership). The Amended Credit Agreement contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend organizational documents and pay certain dividends and other restricted payments. The Amended Credit Agreement requires the Company to comply with financial maintenance covenants to be tested quarterly, consisting of a maximum debt to asset value ratio, a minimum fixed charge coverage ratio, a minimum tangible net worth, a maximum cash distributions to operating income ratio, a maximum secured debt to asset value ratio, a maximum secured recourse debt to asset value ratio, a maximum unsecured debt to unencumbered properties asset value ratio, a minimum unsecured interest coverage ratio and a minimum rent coverage ratio. The Amended Credit Agreement also contains certain customary events of default, including the failure to make timely payments under the Amended Credit Facility or other material indebtedness, the failure to satisfy certain covenants (including the financial maintenance covenants), the occurrence of change of control and specified events of bankruptcy and insolvency.
As of March 31, 2021, we were in compliance with all applicable financial covenants under the Amended Credit Agreement.
24

Obligations and Commitments
The following table summarizes our contractual obligations and commitments as of March 31, 2021 (in thousands):

 Payments Due by Period
 TotalLess
than
1 Year
1 Year
to Less
than
3 Years
3 Years
to Less
than
5 Years
More
than
5 years
Senior unsecured notes payable (1)$370,875 $15,750 $31,500 $323,625 $— 
Senior unsecured term loan (2)215,888 3,274 6,539 206,075 — 
Unsecured revolving credit facility (3)175,584 3,005 172,579 — — 
Operating leases3,727 263 284 104 3,076 
Total$766,074 $22,292 $210,902 $529,804 $3,076 
 
(1)Amounts include interest payments of $70.9 million.
(2)Amounts include interest payments of $15.9 million.
(3)Amounts include payments related to the credit facility fee of $1.7 million and interest payments of $3.9 million.
Capital Expenditures
Capital expenditures for each property leased under our triple-net leases are generally the responsibility of the tenant, except that, for the facilities leased to subsidiaries of Ensign and Pennant, the tenant will have an option to require us to finance certain capital expenditures up to an aggregate of 20% of our initial investment in such property, subject to a corresponding rent increase at the time of funding. For our other triple-net master leases, subject to approval by us, the tenants may request capital expenditure funding that would generally be subject to a corresponding rent increase at the time of funding and which are subject to tenant compliance with the conditions to our approval and funding of their requests. As of March 31, 2021, we had committed to fund certain capital improvements at certain triple-net leased facilities totaling $14.1 million, of which $13.1 million is subject to rent increase at the time of funding. We expect the majority of the funding of these commitments to be completed over the next one to two years.
Critical Accounting Policies and Estimates
Our condensed consolidated financial statements included in Item 1 of this Quarterly Report on Form 10-Q have been prepared in accordance with GAAP for interim financial information set forth in the Accounting Standards Codification, as published by the Financial Accounting Standards Board. GAAP requires us to make estimates and assumptions regarding future events that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. We base these estimates on our experience and assumptions we believe to be reasonable under the circumstances. However, if our judgment or interpretation of the facts and circumstances relating to various transactions or other matters had been different, we may have applied a different accounting treatment, resulting in a different presentation of our financial statements. We periodically reevaluate our estimates and assumptions, and in the event they prove to be different from actual results, we make adjustments in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Please refer to “Critical Accounting Policies and Estimates” in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section of our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on February 10, 2021, for further information regarding the critical accounting policies that affect our more significant estimates and judgments used in the preparation of our condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q. There have been no material changes in such critical accounting policies during the three months ended March 31, 2021.
 
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Our primary market risk exposure is interest rate risk with respect to our variable rate indebtedness.
Our Amended Credit Agreement provides for revolving commitments in an aggregate principal amount of $600.0 million from a syndicate of banks and other financial institutions. The interest rates applicable to loans under the Revolving
25

Facility are, at the Company’s option, equal to either a base rate plus a margin ranging from 0.10% to 0.55% per annum or LIBOR plus a margin ranging from 1.10% to 1.55% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). The interest rates applicable to loans under the Term Loan are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.50% to 1.20% per annum or LIBOR plus a margin ranging from 1.50% to 2.20% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). As of March 31, 2021, we had a $200.0 million Term Loan outstanding and had $170.0 million outstanding under the Revolving Facility.
An increase in interest rates could make the financing of any acquisition by us more costly as well as increase the costs of our variable rate debt obligations. Rising interest rates could also limit our ability to refinance our debt when it matures or cause us to pay higher interest rates upon refinancing and increase interest expense on refinanced indebtedness. In addition, the Chief Executive of the U.K. Financial Conduct Authority (the “FCA”), which regulates LIBOR, has announced that the FCA will no longer persuade or compel banks to submit rates for the calculation of LIBOR after 2021. However, for U.S. dollar LIBOR, it appears that the relevant date may be deferred to June 30, 2023 for certain tenors (including overnight and one, three, six and 12 months), at which time the LIBOR administrator has indicated that it intends to cease publication of U.S. dollar LIBOR. Despite this potential deferral, the LIBOR administrator has advised that no new contracts using U.S. dollar LIBOR should be entered into after December 31, 2021. These actions indicate that the continuation of U.S. LIBOR on the current basis cannot and will not be guaranteed after June 30, 2023. Moreover, it is possible that U.S. LIBOR will be discontinued or modified prior to June 30, 2023. When LIBOR ceases to exist, we will need to enter into an amendment to the Amended Credit Agreement and we cannot predict what alternative index would be negotiated with our lenders. If our lenders have increased costs due to changes in LIBOR, we may experience potential increases in interest rates on our variable rate debt, which could adversely impact our interest expense, results of operations and cash flows. Based on our outstanding debt balance as of March 31, 2021 described above and the interest rates applicable to our outstanding debt at March 31, 2021, assuming a 100 basis point increase in the interest rates related to our variable rate debt, interest expense would have increased approximately $0.9 million for the three months ended March 31, 2021.
We may, in the future, manage, or hedge, interest rate risks related to our borrowings by means of interest rate swap agreements. However, the REIT provisions of the Internal Revenue Code of 1986, as amended, substantially limit our ability to hedge our assets and liabilities. See “Risk Factors — Risks Related to Our Status as a REIT — Complying with REIT requirements may limit our ability to hedge effectively and may cause us to incur tax liabilities,” which is included in our Annual Report on Form 10-K for the year ended December 31, 2020. As of March 31, 2021, we had no swap agreements to hedge our interest rate risks. We also expect to manage our exposure to interest rate risk by maintaining a mix of fixed and variable rates for our indebtedness.

Item 4. Controls and Procedures.
Disclosure Controls and Procedures
We maintain disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”)) that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is processed, recorded, summarized and reported within the time periods specified in the SEC’s rules and regulations and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
As of March 31, 2021, we carried out an evaluation, under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, regarding the effectiveness of our disclosure controls and procedures. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective, at the reasonable assurance level, as of March 31, 2021.
Changes in Internal Control over Financial Reporting
There has been no change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended March 31, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
26

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.
The Company and its subsidiaries are and may become from time to time a party to various claims and lawsuits arising in the ordinary course of business, but none of the Company or any of its subsidiaries is, and none of their respective properties are, the subject of any material legal proceedings. Claims and lawsuits may include matters involving general or professional liability asserted against its tenants, which are the responsibility of its tenants and for which the Company is entitled to be indemnified by its tenants under the insurance and indemnification provisions in the applicable leases.

Item 1A. Risk Factors.
We have disclosed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020 risk factors which materially affect our business, financial condition, or results of operations. There have been no material changes from the risk factors previously disclosed.

27


Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
During the three months ended March 31, 2021, we acquired shares of our common stock held by employees who tendered shares to satisfy tax withholding obligations upon the vesting of previously issued restricted stock awards. Specifically, the number of shares of common stock acquired from employees and the average prices paid per share for each month in the first quarter ended March 31, 2021 are as shown in the table below.
PeriodTotal Number of Shares PurchasedAverage Price Paid per Share
January 1 - January 31, 20212,226 $22.46 
February 1 - February 28, 202154,544 23.48 
March 1 - March 31, 2021— — 
Total56,770 $23.44 
On March 20, 2020, our Board of Directors authorized us to repurchase up to $150.0 million of outstanding shares of our common stock (the “Repurchase Program”). Repurchases under the Repurchase Program, which expires on March 31, 2023, may be made through open market purchases, privately negotiated transactions, structured or derivative transactions, including accelerated share repurchase transactions, or other methods of acquiring shares, in each case subject to market conditions and at such times as shall be permitted by applicable securities laws and determined by management. Repurchases under the Repurchase Program may also be made pursuant to a plan adopted under Rule 10b5-1 promulgated under the Exchange Act. We did not repurchase any shares of our common stock under the Repurchase Program during the three months ended March 31, 2021 and $150.0 million remains available for the repurchase of shares of our common stock under the Repurchase Program as of March 31, 2021. The Repurchase Program may be modified, discontinued or suspended at any time.
28


Item 6. Exhibits.
Exhibit
Number
 Description of the Document
 
 
 
 
 
*101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
*101.SCH XBRL Taxonomy Extension Schema Document
*101.CAL XBRL Taxonomy Extension Calculation Linkbase Document
*101.DEFXBRL Taxonomy Extension Definition Linkbase Document
*101.LAB XBRL Taxonomy Extension Label Linkbase Document
*101.PRE XBRL Taxonomy Extension Presentation Linkbase Document
*104Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
* Filed herewith
** Furnished herewith

29

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
CareTrust REIT, Inc.
May 6, 2021By:/s/ Gregory K. Stapley
Gregory K. Stapley
Chief Executive Officer
(duly authorized officer)
May 6, 2021By:/s/ William M. Wagner
William M. Wagner
Chief Financial Officer and Treasurer
(principal financial officer and
principal accounting officer)

30
EX-31.1 2 ctre20210331q1ex311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION
I, Gregory K. Stapley, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of CareTrust REIT, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
By:/s/ Gregory K. Stapley
Gregory K. Stapley
Chief Executive Officer
Date: May 6, 2021

EX-31.2 3 ctre20210331q1ex312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION
I, William M. Wagner, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of CareTrust REIT, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
By:/s/ William M. Wagner
William M. Wagner
Chief Financial Officer and Treasurer
Date: May 6, 2021

EX-32.1 4 ctre20210331q1ex321.htm EX-32.1 Document

Exhibit 32.1
Certification of Chief Executive Officer and
Chief Financial Officer Pursuant to
18 U.S.C. Section 1350, As Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report on Form 10-Q of CareTrust REIT, Inc. (the “Company”) for the quarterly period ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Gregory K. Stapley, as Chief Executive Officer of the Company, and William M. Wagner, as Chief Financial Officer and Treasurer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to their knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
/s/ Gregory K. Stapley
Name:Gregory K. Stapley
Title:Chief Executive Officer
Date:May 6, 2021
/s/ William M. Wagner
Name:William M. Wagner
Title:Chief Financial Officer and Treasurer
Date:May 6, 2021


EX-101.SCH 5 ctre-20210331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Income Statements link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Equity link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statements of Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Organization (Details) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 2105103 - Disclosure - Real Estate Investments, Net link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Real Estate Investments, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Real Estate Investments, Net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Real Estate Investments, Net - Investment in Owned Properties (Details) link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - Real Estate Investments, Net - Future Contractual Minimum Rental Income (Details) link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - Real Estate Investments, Net - Tenant Purchase Options (Details) link:presentationLink link:calculationLink link:definitionLink 2411406 - Disclosure - Real Estate Investments, Net - Rental Income (Details) link:presentationLink link:calculationLink link:definitionLink 2412407 - Disclosure - Real Estate Investments, Net - Recent Real Estate Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 2413408 - Disclosure - Real Estate Investments, Net - Asset Sales and Assets Held for Sale Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2414409 - Disclosure - Real Estate Investments, Net - Lease Amendments Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2115104 - Disclosure - Other Real Estate Investments, Net link:presentationLink link:calculationLink link:definitionLink 2416410 - Disclosure - Other Real Estate Investments, Net (Details) link:presentationLink link:calculationLink link:definitionLink 2117105 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2318302 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2419411 - Disclosure - Fair Value Measurements - Items Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2420412 - Disclosure - Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2421413 - Disclosure - Fair Value Measurements - Face Value, Carrying Amount and Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2122106 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2323303 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2424414 - Disclosure - Debt - Schedule of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2425415 - Disclosure - Debt - Senior Unsecured Notes Payable Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2426416 - Disclosure - Debt - Unsecured Revolving Credit Facility and Term Loan Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2127107 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 2328304 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2429417 - Disclosure - Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2430418 - Disclosure - Equity - At-The-Market Offering (Details) link:presentationLink link:calculationLink link:definitionLink 2431419 - Disclosure - Equity - Dividends on Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2132108 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2333305 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2434420 - Disclosure - Stock-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2435421 - Disclosure - Stock-Based Compensation - Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 2436422 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2137109 - Disclosure - Earnings Per Common Share link:presentationLink link:calculationLink link:definitionLink 2338306 - Disclosure - Earnings Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2439423 - Disclosure - Earnings Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 2140110 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2441424 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2142111 - Disclosure - Concentration of Risk link:presentationLink link:calculationLink link:definitionLink 2443425 - Disclosure - Concentration of Risk (Details) link:presentationLink link:calculationLink link:definitionLink 2144112 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2445426 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 ctre-20210331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 ctre-20210331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 ctre-20210331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Number of awards granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Document Type Document Type Receivable Type [Axis] Receivable Type [Axis] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Skilled nursing, multi-service campuses, assisted living and independent living facilities Skilled Nursing, Multi Service Campuses, Assisted Living, and Independent Living Facilities [Member] Skilled Nursing, Multi Service Campuses, Assisted Living, and Independent Living Facilities Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Combined principal amount of loan Mortgage Loan, Combined Principal Mortgage Loan, Combined Principal Real Estate Properties [Line Items] Real Estate Properties [Line Items] Officers and employees Officer And Employee [Member] Officer And Employee Level 3 Fair Value, Inputs, Level 3 [Member] Schedule of Real Estate Acquisitions Schedule Of Assets Acquisitions [Table Text Block] Schedule Of Assets Acquisitions [Table Text Block] Deferred Loan Fees Debt Issuance Costs, Gross Dividends on common stock Dividends, Common Stock [Abstract] Statistical Measurement [Domain] Statistical Measurement [Domain] Liabilities and Equity: Liabilities and Equity [Abstract] Unsecured revolving credit facility Revolving Facility Line of Credit [Member] 2026 Lessor, Operating Lease, Payment to be Received, Year Five Risks and Uncertainties [Abstract] Risks and Uncertainties [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Thereafter Lessor, Operating Lease, Payment to be Received, after Year Five Security Exchange Name Security Exchange Name Less: Net income allocated to participating securities Undistributed Earnings (Loss) Allocated to Participating Securities, Basic and Diluted Undistributed earnings (loss) allocated to participating securities, basic and diluted. Lease Arrangements [Domain] Lease Arrangements [Domain] Lease Arrangements Other real estate investments, net Real Estate Investments, Joint Ventures Performance stock award Performance Shares [Member] Variable Rate [Domain] Variable Rate [Domain] Variable Rate [Axis] Variable Rate [Axis] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Commitments and contingencies Commitments and Contingencies Assets: Assets [Abstract] Investment, Name [Axis] Investment, Name [Axis] Vesting period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Accounting Policies [Abstract] Accounting Policies [Abstract] Entity Address, State or Province Entity Address, State or Province Financial Asset, Aging [Axis] Financial Asset, Period Past Due [Axis] Other Commitments [Table] Other Commitments [Table] Acquisitions of real estate, net of deposits applied Payment to acquire facility Payments to Acquire Commercial Real Estate Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] 2021 (nine months) Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year Authorized aggregate offering price of common stock Securities Offering, Authorized Amount Securities Offering, Authorized Amount Shares repurchased (in shares) Treasury Stock, Shares, Acquired Unamortized stock-based compensation expense related to unvested awards Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Average sales price per share (usd per share) Shares Issued During Period, Average Price Per Share Shares Issued During Period, Average Price Per Share Initial Annual Cash Rent Initial annual cash rents Operating Leases, Anticipated Initial Annual Lease Revenues Operating Leases, Anticipated Initial Annual Lease Revenues Customer [Axis] Customer [Axis] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Preferred stock, $0.01 par value; 100,000,000 shares authorized, no shares issued and outstanding as of March 31, 2021 and December 31, 2020 Preferred Stock, Value, Issued Senior unsecured notes payable Senior Unsecured Notes [Member] Senior Unsecured Notes [Member] Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Amortization of stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Number of Properties Number of properties acquired Number Of Properties Acquired Number Of Properties Acquired Independent living facilities Revenue from Contract with Customer, Excluding Assessed Tax Measurement Frequency [Domain] Measurement Frequency [Domain] Concentration risk (percent) Concentration Risk, Percentage Numerator for basic and diluted earnings available to common stockholders Net Income Loss Available To Common Stockholders Basic And Diluted Net income (loss) available to common stockholders basic and diluted. Loans receivable exit fee (percent) Loans Receivable, Exit Fee, Percent Loans Receivable, Exit Fee, Percent Statement [Line Items] Statement [Line Items] Loan receivable interest rate (percent) Loans Receivable, Fixed Interest Rate Loans Receivable, Fixed Interest Rate Lease termination revenue Gain (Loss) on Termination of Lease Forecast Forecast [Member] Borrowings under unsecured revolving credit facility Proceeds from Long-term Lines of Credit Independent living facilities, cost of services Cost, Product and Service [Extensible List] Statement [Table] Statement [Table] Statistical Measurement [Axis] Statistical Measurement [Axis] Increase in dividends payable Increase Decrease In Dividends Payable Increase Decrease In Dividends Payable Credit Facility [Axis] Credit Facility [Axis] Purchase and sale agreement amount Purchase And Sale Agreement, Amount Purchase And Sale Agreement, Amount Bayshire, LLC Bayshire, LLC [Member] Bayshire, LLC Preferred stock, issued (shares) Preferred Stock, Shares Issued Land Land Total Lessor, Operating Lease, Payments to be Received Number of units in property sold Number Of Units In Property Sold Number Of Units In Property Sold Interest income related to preferred equity investments Interest Income, Other Entity Small Business Entity Small Business Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Number of Beds/Units Number Of Beds Or Units In Properties Acquired Number Of Beds Or Units In Properties Acquired Debt Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Proceeds from (costs paid for) the issuance of common stock, net Gross proceeds Proceeds from Issuance of Common Stock Schedule of Rental Income Operating Lease, Lease Income [Table Text Block] Number of equal annual vesting installments Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting, Number Of Equal Annual Installments Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting, Number of Equal Annual Installments Financial Asset, Aging [Domain] Financial Asset, Period Past Due [Domain] Amendment Flag Amendment Flag Reconciliation of Weighted-Average Common Shares Outstanding Used in Calculation of Basic EPS to Diluted EPS Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Valuation Assumptions Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Metron skilled nursing facilities Metron Skilled Nursing Facilities [Member] Metron Skilled Nursing Facilities [Member] Weighted-average number of common shares: Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Schedule of Items Measured at Fair Value on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Unsecured revolving credit facility Long-term Line of Credit Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Entity Central Index Key Entity Central Index Key Measurement Frequency [Axis] Measurement Frequency [Axis] Proceeds from settlement of loan Proceeds from Loans LIBOR floor for loan (percent) Loans Receivable, LIBOR Floor, Percentage Loans Receivable, LIBOR Floor, Percentage Current Cash Rent Lessor, Annualized Cash Revenue For Contracts In Place Lessor, Annualized Cash Revenue For Contracts In Place Summary of Face Value, Carrying Amount and Fair Value of Financial Instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Cascadia Development, Boise ID Preferred Equity Investment Cascadia Development Boise ID [Member] Preferred Equity Investment Cascadia Development Boise ID Fair Value Measurement [Domain] Fair Value Measurement [Domain] Financing Receivable, Past Due [Table] Financing Receivable, Past Due [Table] Senior unsecured notes payable Senior Notes [Member] Accounts payable and accrued liabilities Accounts Payable and Other Accrued Liabilities Cascade Capital Group, LLC Cascade Capital Group LLC [Member] Cascade Capital Group LLC Subsequent Events Subsequent Events [Text Block] Real Estate [Table] Real Estate [Table] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Net proceeds from issuance of senior notes Proceeds from Debt, Net of Issuance Costs Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Other Commitments [Line Items] Other Commitments [Line Items] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Vesting of restricted common stock, net of shares withheld for employee taxes (in shares) Restricted Stock, Shares Issued Net of Shares for Tax Withholdings 5.25% Senior Notes due 2025 Five Point Two Five Senior Notes Due 2025 [Member] Five Point Two Five Senior Notes Due 2025 [Member] Line of Credit Facility [Table] Line of Credit Facility [Table] Number of days after termination of purchase and sale agreement for maturity Purchase And Sale Agreement, Maturity Date Option, Number Of Days After Termination Purchase And Sale Agreement, Maturity Date Option, Number Of Days After Termination Buildings and improvements Investment Building and Building Improvements Interest and other income Interest and Other Income Issuance of common stock, net Stock Issued During Period, Value, New Issues Concentration Risk [Table] Concentration Risk [Table] Total assets Assets Scenario [Axis] Scenario [Axis] Unvested stock awards outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Noble Noble VA Holdings LLC [Member] Noble VA Holdings LLC Title of 12(b) Security Title of 12(b) Security Disposal Group Classification [Axis] Disposal Group Classification [Axis] Schedule of Real Estate Properties [Table] Schedule of Real Estate Properties [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Lessor, Lease, Description [Table] Lessor, Lease, Description [Table] Ensign and Pennant Ensign And Pennant [Member] Ensign And Pennant 2023 Lessor, Operating Lease, Payment to be Received, Year Two Interest expense Interest Expense Depreciation and amortization (including below-market ground leases) Depreciation, Depletion and Amortization Ensign Ensign [Member] Ensign [Member] Total liabilities Liabilities Noble triple-net master lease Noble Triple-Net Master Lease [Member] Noble Triple-Net Master Lease Mezzanine loan receivable Mezzanine Loan [Member] Mezzanine Loan Gross proceeds from issuance of senior notes Proceeds from Issuance of Unsecured Debt Weighted average remaining vesting period related to expense recognition Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Aggregate required financing of capital expenditures as percentage of initial investment in property (percent) Aggregate Required Financing Of Capital Expenditures As Percentage Of Initial Investment In Property Aggregate Required Financing Of Capital Expenditures As Percentage Of Initial Investment In Property Expected stock price volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Summary of the At-The-Market Offering Program Schedule of Stock by Class [Table Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Level 1 Fair Value, Inputs, Level 1 [Member] Principal payments received on real estate mortgage and other loans receivable Proceeds from Collection of Loans Receivable Real Estate [Abstract] Real Estate [Abstract] SNF Skilled Nursing Facility [Member] Skilled Nursing Facility [Member] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Number of states with properties Number of States in which Entity Operates Debt Instrument [Axis] Debt Instrument [Axis] Additional Paid-in Capital Additional Paid-in Capital [Member] Schedule of Valuation Assumptions Schedule Of Share-Based Payment Award, Performance Stock Award, Valuation Assumptions [Table Text Block] Schedule Of Share-Based Payment Award, Performance Stock Award, Valuation Assumptions Cumulative Distributions in Excess of Earnings Accumulated Distributions in Excess of Net Income [Member] Lease Expiration October 2034, First option 2026 Properties With Purchase Option, Lease Expiration October 2034. First Option 2026 [Member] Properties With Purchase Option, Lease Expiration October 2034. First Option 2026 Class of Stock [Line Items] Class of Stock [Line Items] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Loss on sale of real estate Loss on sale of real estate Gain (loss) on sale of real estate Gains (Losses) on Sales of Investment Real Estate Number of properties sold Number Of Properties Sold Number Of Properties Sold Preferred equity investment Equity Method Investments Common stock, outstanding (shares) Common Stock, Shares, Outstanding Revolving credit facility Revolving Credit Facility [Member] Number of extension options Loan Receivable, Number Of Extension Options Loan Receivable, Number Of Extension Options Cumulative distributions in excess of earnings Accumulated Distributions in Excess of Net Income Subsequent event Subsequent Event [Member] Common stock, authorized (shares) Common Stock, Shares Authorized Concentration Risk Type [Axis] Concentration Risk Type [Axis] Assets held for sale, net Assets Held-for-sale, Not Part of Disposal Group Summary of Investment in Owned Properties Schedule of Real Estate Properties [Table Text Block] Fair Value Estimate of Fair Value Measurement [Member] Income Statement [Abstract] Income Statement [Abstract] Prepaid expenses and other assets, net Increase (Decrease) in Prepaid Expense and Other Assets New Revolving Facility New Revolving Facility [Member] New Revolving Facility [Member] Name of Property [Domain] Name of Property [Domain] Certain capital improvements at triple-net leased facilities Capital Improvements At Triple Net Leased Facilities [Member] Capital Improvements At Triple Net Leased Facilities Officers Officer [Member] Number of facilities in agreement secured by membership interests Loan Receivable, Number Of Facilities In Agreement Secured By Membership Interests Loan Receivable, Number Of Facilities In Agreement Secured By Membership Interests Expected dividend yield (assuming full reinvestment) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Scenario [Domain] Scenario [Domain] Counterparty Name [Domain] Counterparty Name [Domain] City Area Code City Area Code Document Period End Date Document Period End Date Schedule of Dividends on Common Stock Dividends Declared [Table Text Block] Share repurchase program authorization Stock Repurchase Program, Authorized Amount Property taxes Real Estate Tax Expense Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Net-settle adjustment on restricted stock Payment, Tax Withholding, Share-based Payment Arrangement Vesting of restricted common stock, net of shares withheld for employee taxes Restricted Stock, Value, Shares Issued Net of Tax Withholdings Cover [Abstract] Cover [Abstract] Base Rate Base Rate [Member] Future Contractual Minimum Rental Income Lessor, Operating Lease, Payments, Fiscal Year Maturity [Abstract] Interest income distribution from other real estate investment Proceeds from Equity Method Investment, Distribution Integral equipment, furniture and fixtures Fixtures and Equipment, Gross Carrying Value Outstanding borrowings Long-term Debt Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Independent living facilities Cost of Goods and Services Sold Total expenses Costs and Expenses Equity Components [Axis] Equity Components [Axis] Restricted stock award Restricted Stock [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Minimum Minimum [Member] Other Real Estate Investments, Net Other Real Estate Investments [Text Block] Other Real Estate Investments Historical volatility term basis for expected volatility assumption Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Term For Expected Volatility Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Historical Volatility Term For Expected Volatility Greater than 90 days past due Financial Asset, Equal to or Greater than 90 Days Past Due [Member] Entity Interactive Data Current Entity Interactive Data Current ATM Program At-The-Market Offering Program [Member] At-The-Market Offering Program [Member] Revenues: Revenues [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Equity Stockholders' Equity Note Disclosure [Text Block] Real Estate [Line Items] Real Estate [Line Items] Investment in real estate mortgage and other loans receivable Payments to Acquire Loans Receivable Facility fee on revolving commitment fees (percent) Line of Credit Facility, Commitment Fee Percentage Customer [Domain] Customer [Domain] Lease Expiration October 2032, First option 2023 Properties With Purchase Option, Lease Expiration October 2032, First Option 2023 [Member] Properties With Purchase Option, Lease Expiration October 2032, First Option 2023 Additional paid-in capital Additional Paid in Capital, Common Stock Entity Registrant Name Entity Registrant Name Subsequent Event Type [Domain] Subsequent Event Type [Domain] Number of renewal options Lessor, Operating Lease, Number Of Renewal Options Lessor, Operating Lease, Number Of Renewal Options Business Acquisition [Line Items] Business Acquisition [Line Items] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Concentration Risk [Line Items] Concentration Risk [Line Items] Assets: Assets, Fair Value Disclosure [Abstract] Real estate investments Real Estate Investment Property, at Cost Number of states where Ensign leases the highest concentration of properties Concentration Risk, Number Of States Number of states where the entity's major tenants lease the highest concentration of properties. Deferred financing costs, net Debt Issuance Costs, Net Ensign Employees Ensign Employees [Member] Ensign Employees [Member] Percentage of awards to vest relative To initial grant based on TSR performance Share-Based Compensation Arrangement By Share-Based Payment Award, TSR Performance, Percentage To Vest Relative To Initial Grant Share-Based Compensation Arrangement By Share-Based Payment Award, TSR Performance, Percentage To Vest Relative To Initial Grant Dividends paid on common stock Payments of Ordinary Dividends, Common Stock Next VA Star Realty Holdings LLC Next VA Star Realty Holdings LLC [Member] Next VA Star Realty Holdings LLC Portion of funding commitment subject to rent increase at time of funding Portion Of Commitment Subject To Rent Increase At Time Of Funding Portion Of Commitment Subject To Rent Increase At Time Of Funding Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code ALF Assisted living Assisted Living Facility [Member] Assisted Living Facility [Member] Dividends record date Dividends Payable, Date of Record Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Rental income Total rental income Operating Lease, Lease Income Straight-line rental income Straight-line rent Straight Line Rent Sale of Stock [Axis] Sale of Stock [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Contractual rent due Operating Lease, Lease Income, Lease Payments Dividends payment date Dividends Payable, Date to be Paid SNF / Campus Skilled nursing and campus facilities Skilled Nursing And Campus Facilities [Member] Skilled Nursing And Campus Facilities Disposed of by sale Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Document Transition Report Document Transition Report Title of Individual [Axis] Title of Individual [Axis] Numerator: Net Income (Loss) Attributable to Parent [Abstract] Other loss: Nonoperating Income (Expense) [Abstract] Common dividends (in usd per share) Dividends declared per share Common Stock, Dividends, Per Share, Declared Senior unsecured notes payable - face value Debt instrument face amount Debt Instrument, Face Amount Level 2 Fair Value, Inputs, Level 2 [Member] Transfer of pre-acquisition costs to acquired assets Transfer Of Preacquisition Costs To Acquired Assets Transfer Of Preacquisition Costs To Acquired Assets Document Quarterly Report Document Quarterly Report Equity [Abstract] Equity [Abstract] Lease Expiration November 2034, First option 2024 Properties With Purchase Option, Lease Expiration November 2034, First Option 2024 [Member] Properties With Purchase Option, Lease Expiration November 2034, First Option 2024 Issuance of common stock, net Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs PMG Priority Management Group LLC [Member] Priority Management Group LLC Supplemental schedule of noncash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Redemption price, percentage upon change of control (percent) Debt Instrument Redemption Price Upon Change Of Control As Percentage Of Principal Amount Debt instrument redemption price upon change of control as percentage of principal amount. Subsequent Event [Line Items] Subsequent Event [Line Items] Customer concentration risk Customer Concentration Risk [Member] Credit Facility [Domain] Credit Facility [Domain] Net proceeds from sales of real estate Proceeds from sale Proceeds from Sale of Real Estate Held-for-investment Diluted (in shares) Weighted-average diluted common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Letter of credit Letter of Credit [Member] Basic (in usd per share) Earnings (loss) per common share, basic (in usd per share) Earnings Per Share, Basic Expected service period Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Entity File Number Entity File Number Shares forfeited (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Debt Disclosure [Abstract] Debt Disclosure [Abstract] Number of extension options Line Of Credit Facility, Number Of Extension Options Line Of Credit Facility, Number Of Extension Options Amortization of deferred financing costs Amortization of Debt Issuance Costs and Discounts 2025 Lessor, Operating Lease, Payment to be Received, Year Four Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Common dividends Dividends payable as of record date Dividends, Common Stock Amortization of stock-based compensation Stock-based compensation expense Share-based Payment Arrangement, Expense Swingline loan Swingline Loan [Member] Swingline Loan [Member] Schedule Of Tenant Purchase Options Schedule Of Tenant Purchase Options [Table Text Block] Schedule Of Tenant Purchase Options Purchase Price Aggregate purchase price Asset Acquisition, Consideration Transferred Asset Acquisition, Consideration Transferred Counterparty Name [Axis] Counterparty Name [Axis] Common stock, $0.01 par value; 500,000,000 shares authorized, 95,981,062 and 95,215,797 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively Common Stock, Value, Issued Disposal Group Name [Axis] Disposal Group Name [Axis] Document Fiscal Year Focus Document Fiscal Year Focus MCRC, LLC Manteca Valley Post Acute [Member] Manteca Valley Post Acute [Member] Lease Expiration October 2034, First option 2021 Properties With Purchase Option, Lease Expiration October 2034, First Option 2021 [Member] Properties With Purchase Option, Lease Expiration October 2034, First Option 2021 Entity Current Reporting Status Entity Current Reporting Status Remaining offering amount available Securities Offering, Remaining Authorized Amount Securities Offering, Remaining Authorized Amount Facility fee on revolving commitment fee based on investment grade ratings (percent) Line Of Credit, Commitment Fee Based On Investment Grade Rating, Percentage Line Of Credit, Commitment Fee Based On Investment Grade Rating, Percentage Receivable [Domain] Receivable [Domain] Subsequent Event [Table] Subsequent Event [Table] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Award grant date fair value (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Common stock, issued (shares) Common Stock, Shares, Issued Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Independent living facilities, revenue services Revenue from Contract with Customer, Product and Service [Extensible List] Metron affiliates Metron Integrated Health Systems Affiliates [Member] Metron Integrated Health Systems Affiliates Senior unsecured notes payable, net Unsecured Long-term Debt, Noncurrent Accounts and other receivables, net Accounts Receivable, after Allowance for Credit Loss Basis of Presentation Basis of Presentation and Significant Accounting Policies [Text Block] Accounts and other receivables, net Increase (Decrease) in Accounts Receivable Debt Instrument [Line Items] Debt Instrument [Line Items] Total equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Proceeds from (costs paid for) the issuance of common stock, net Commissions paid on stock issuance Payments of Stock Issuance Costs Concentration Risk Type [Domain] Concentration Risk Type [Domain] Number of properties transferred Number Of Properties Transferred Number Of Properties Transferred Loan receivable Receivables, Fair Value Disclosure Total liabilities and equity Liabilities and Equity Lease Arrangements [Axis] Lease Arrangements [Axis] Lease Arrangements Entity Address, City or Town Entity Address, City or Town Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Loan receivable Financing Receivable, after Allowance for Credit Loss Purchases of equipment, furniture and fixtures and improvements to real estate Payments To Acquire Equipment, Furniture And Fixtures And Develop Real Estate Assets Payments To Acquire Equipment, Furniture And Fixtures And Develop Real Estate Assets General and administrative General and Administrative Expense Preferred equity investment minimum yield Equity Method Investment, Rate Of Return, Floor Equity Method Investment, Rate Of Return, Floor Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Equity Component [Domain] Equity Component [Domain] Five Oaks Healthcare LLC Five Oaks Healthcare LLC [Member] Five Oaks Healthcare LLC Senior unsecured term loan, net Loans Payable, Noncurrent Number of operational beds and units in facilities Number Of Operational Beds And Units In Facilities Number Of Operational Beds And Units In Facilities Real Estate Investments, Net Real Estate Disclosure [Text Block] Entity Tax Identification Number Entity Tax Identification Number Stock-Based Compensation Share-based Payment Arrangement [Text Block] Net income Net income Net income (loss) Net Income (Loss) Attributable to Parent Change in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] LIBOR London Interbank Offered Rate (LIBOR) [Member] Investment, Name [Domain] Investment, Name [Domain] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Current Fiscal Year End Date Current Fiscal Year End Date Expenses: Operating Expenses [Abstract] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Mortgage loan receivable Mortgage Receivable [Member] Disposal Group Name [Domain] Disposal Group Name [Domain] Skilled nursing Skilled nursing properties Skilled Nursing Properties [Member] Skilled Nursing Properties [Member] Equity: Stockholders' Equity Attributable to Parent [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Mezzanine loan receivable Loans Receivable, Fair Value Disclosure Financial liabilities: Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract] Senior unsecured term loan New Term Loan Senior Unsecured Term Loan [Member] Senior Unsecured Term Loan [Member] Number of facilities Number of Real Estate Properties Extension option term (in months) Line Of Credit Facility Extension Option Term Line of credit facility extension option term. Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Initial lease term (in years) Amended lease term (in years) Lessor, Operating Lease, Term of Contract Other loans receivable Loans Receivable [Member] Entity Filer Category Entity Filer Category Schedule of Stock-Based Compensation Expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Common Stock Common Stock [Member] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Repayment of other real estate investment Return of initial investment Proceeds from Equity Method Investment, Distribution, Return of Capital Anticipated annual cash rent in second year after acquisition Operating Leases, Anticipated Annual Lease Revenues In Second Year After Acquisition Operating Leases, Anticipated Annual Lease Revenues In Second Year After Acquisition Contract purchase price Disposal Group, Including Discontinued Operation, Contract Purchase Price Disposal Group, Including Discontinued Operation, Contract Purchase Price Other Commitments [Axis] Other Commitments [Axis] Other Commitments [Domain] Other Commitments [Domain] Lease Contractual Term [Axis] Lease Contractual Term [Axis] 2022 Lessor, Operating Lease, Payment to be Received, Year One Issuance of common stock, net, (in shares) Number of shares (in shares) Stock Issued During Period, Shares, New Issues Number of beds and units in facilities Number Of Units And Beds In Facilities Number Of Units And Beds In Facilities Lease Expiration November 2030, First option 2022 Properties With Purchase Option, Lease Expiration November 2030, First Option 2022 [Member] Properties With Purchase Option, Lease Expiration November 2030, First Option 2022 Term Loan New Term Loan Feb 2019 [Member] New Term Loan Feb 2019 [Member] Identified intangible assets Finite-Lived Intangible Assets, Gross Rental income, exclusive of operating expense reimbursements Revenue Benchmark [Member] Lessor, Lease, Description [Line Items] Lessor, Lease, Description [Line Items] Held for sale Discontinued Operations, Held-for-sale [Member] Interest rate (percent) Debt Instrument, Interest Rate, Stated Percentage Cumulative contractual preferred return through acquisition date Equity Method Investment, Cumulative Contractual Preferred Return Equity Method Investment, Cumulative Contractual Preferred Return Mortgage loan receivable Financing Receivable, before Allowance for Credit Loss Sale of real estate settled with note receivable Noncash or Part Noncash Divestiture, Amount of Consideration Received Name of Property [Axis] Name of Property [Axis] Extension option term (in months) Loan Receivable, Extension Option, Term Loan Receivable, Extension Option, Term Net increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Initial lease yield (percent) Initial Lease Yield Initial Lease Yield Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Number of beds planned for construction Number Of Beds Planned For Construction Number Of Beds Planned For Construction Basic (in shares) Weighted-average basic common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Basis spread on variable rate (percent) Debt Instrument, Basis Spread on Variable Rate Risk free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Subsequent Events [Abstract] Subsequent Events [Abstract] Sale of Stock [Domain] Sale of Stock [Domain] Carrying Amount Reported Value Measurement [Member] Period of unpaid interest payments due upon prepayment Loan Receivable, Period Of Unpaid Interest Payments Due Upon Prepayment Loan Receivable, Period Of Unpaid Interest Payments Due Upon Prepayment Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Dividends payable Dividends Payable Organization Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Financing Receivable, Past Due [Line Items] Financing Receivable, Past Due [Line Items] Total revenues Revenues Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Number of beds in facility used to secure loan Loan Receivable, Number Of Beds In Property Utilized To Secure Loan Loan Receivable, Number Of Beds In Property Utilized To Secure Loan Lease renewal term (in years) Lessor, Operating Lease, Renewal Term Title of Individual [Domain] Title of Individual [Domain] Diluted (in usd per share) Earnings (loss) per common share, diluted (in usd per share) Earnings Per Share, Diluted Number of operational beds Number Of Operational Beds Number Of Operational Beds Local Phone Number Local Phone Number Properties Number Of Properties With Tenant Purchase Option Number Of Properties With Tenant Purchase Option Interest income Interest and Fee Income, Loans, Commercial, Real Estate Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Escrow deposits for potential acquisitions of real estate Payments for Deposits on Real Estate Acquisitions Principal Amount Outstanding amounts Long-term Debt, Gross Number of publicly traded healthcare REITs in peer group Share-Based Compensation Arrangement By Share-Based Payment Award, Vesting Metric, TSR Performance Peer Group Number Of Companies Share-Based Compensation Arrangement By Share-Based Payment Award, Vesting Metric, TSR Performance Peer Group Number Of Companies Schedule of Debt Instruments Schedule of Long-term Debt Instruments [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Prime Rate Prime Rate [Member] Facilities utilized to secure mortgage loan Loan Receivable, Number Of Facilities Utilized To Secure Mortgage Loan Loan Receivable Number Of Facilities Utilized To Secure Mortgage Loan Entity Emerging Growth Company Entity Emerging Growth Company Basis spread on variable rate for loan (percent) Loans Receivable, Basis Spread on Variable Rate Credit facility borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Award Type [Axis] Award Type [Axis] Prepaid expenses and other assets, net Prepaid Expense and Other Assets CommuniCare CommuniCare [Member] CommuniCare [Member] Lease Contractual Term [Domain] Lease Contractual Term [Domain] Maximum Maximum [Member] Preferred stock, authorized (shares) Preferred Stock, Shares Authorized Preferred stock, outstanding (shares) Preferred Stock, Shares Outstanding Measurement Basis [Axis] Measurement Basis [Axis] Lease Expiration March 2029, First option 2022 Properties With Purchase Option, Lease Expiration March 2029, First Option 2022 [Member] Properties With Purchase Option, Lease Expiration March 2029, First Option 2022 Basis spread of preferred equity investment yield Equity Method Investments, Basis Spread On Variable Rate Equity Method Investments, Basis Spread On Variable Rate Stock awards unvested during spin-off (in shares) Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Spin Off In Period Share based compensation arrangement by share based payment award equity instruments other than options nonvested spin off in period. Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Concentration of Risk Concentration Risk Disclosure [Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] 2024 Lessor, Operating Lease, Payment to be Received, Year Three Award Type [Domain] Award Type [Domain] Schedule of Total Future Contractual Minimum Rental Income Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block] Trading Symbol Trading Symbol Disposal Group Classification [Domain] Disposal Group Classification [Domain] Funding commitment Other Commitment Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Multi-service campuses Multi-Service Campus Properties [Member] Multi-Service Campus Properties [Member] Number of properties held for sale Number Of Properties To Be Sold Number Of Properties To Be Sold Accumulated depreciation and amortization Real Estate Investment Property, Accumulated Depreciation Earnings Per Common Share Earnings Per Share [Text Block] Senior unsecured notes payable Notes Payable, Fair Value Disclosure Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Entity Shell Company Entity Shell Company Recurring Fair Value, Recurring [Member] Real estate investments, net Real estate investments, net Real Estate Investment Property, Net Subfacility capacity as percentage of available revolving commitments (percent) Line Of Credit, Subfacility, Capacity As Percentage Of Available Revolving Commitments Line Of Credit, Subfacility, Capacity As Percentage Of Available Revolving Commitments Owned and operated living facility Owned And Operated Living Facilities [Member] Owned And Operated Living Facilities [Member] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] EX-101.PRE 9 ctre-20210331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 ctre-20210331_htm.xml IDEA: XBRL DOCUMENT 0001590717 2021-01-01 2021-03-31 0001590717 2021-05-05 0001590717 2021-03-31 0001590717 2020-12-31 0001590717 2020-01-01 2020-03-31 0001590717 us-gaap:CommonStockMember 2020-12-31 0001590717 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001590717 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2020-12-31 0001590717 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001590717 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001590717 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2021-01-01 2021-03-31 0001590717 us-gaap:CommonStockMember 2021-03-31 0001590717 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001590717 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2021-03-31 0001590717 us-gaap:CommonStockMember 2019-12-31 0001590717 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001590717 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2019-12-31 0001590717 2019-12-31 0001590717 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001590717 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001590717 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2020-01-01 2020-03-31 0001590717 us-gaap:CommonStockMember 2020-03-31 0001590717 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001590717 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2020-03-31 0001590717 2020-03-31 0001590717 ctre:SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMember 2021-03-31 0001590717 ctre:SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMember 2021-01-01 2021-03-31 0001590717 ctre:AssistedLivingFacilityMember ctre:PropertiesWithPurchaseOptionLeaseExpirationOctober2034FirstOption2021Member 2021-03-31 0001590717 ctre:SkilledNursingFacilityMember ctre:PropertiesWithPurchaseOptionLeaseExpirationNovember2030FirstOption2022Member 2021-03-31 0001590717 ctre:SkilledNursingFacilityMember ctre:PropertiesWithPurchaseOptionLeaseExpirationMarch2029FirstOption2022Member 2021-03-31 0001590717 ctre:SkilledNursingAndCampusFacilitiesMember ctre:PropertiesWithPurchaseOptionLeaseExpirationOctober2032FirstOption2023Member 2021-03-31 0001590717 ctre:SkilledNursingFacilityMember ctre:PropertiesWithPurchaseOptionLeaseExpirationNovember2034FirstOption2024Member 2021-03-31 0001590717 ctre:AssistedLivingFacilityMember ctre:PropertiesWithPurchaseOptionLeaseExpirationOctober2034FirstOption2026Member 2021-03-31 0001590717 ctre:MetronIntegratedHealthSystemsAffiliatesMember 2021-01-01 2021-03-31 0001590717 ctre:SkilledNursingPropertiesMember 2021-01-01 2021-03-31 0001590717 ctre:MultiServiceCampusPropertiesMember 2021-01-01 2021-03-31 0001590717 ctre:MultiServiceCampusPropertiesMember srt:ScenarioForecastMember 2022-01-01 2022-12-31 0001590717 us-gaap:DiscontinuedOperationsHeldforsaleMember ctre:FiveOaksHealthcareLLCMember 2020-12-31 0001590717 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember ctre:FiveOaksHealthcareLLCMember 2021-02-01 2021-02-01 0001590717 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember ctre:FiveOaksHealthcareLLCMember 2021-02-01 0001590717 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember ctre:OwnedAndOperatedLivingFacilitiesMember 2020-11-01 0001590717 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember ctre:OwnedAndOperatedLivingFacilitiesMember 2020-11-01 2020-11-01 0001590717 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember ctre:OwnedAndOperatedLivingFacilitiesMember 2020-10-01 2020-12-31 0001590717 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember ctre:MetronSkilledNursingFacilitiesMember 2020-02-14 0001590717 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember ctre:MetronSkilledNursingFacilitiesMember 2020-02-14 2020-02-14 0001590717 ctre:CascadeCapitalGroupLLCMember us-gaap:MortgageReceivablesMember 2020-02-14 0001590717 ctre:CascadeCapitalGroupLLCMember us-gaap:MortgageReceivablesMember 2020-04-01 2020-04-30 0001590717 ctre:CascadeCapitalGroupLLCMember us-gaap:MortgageReceivablesMember 2020-04-30 0001590717 ctre:CascadeCapitalGroupLLCMember us-gaap:MortgageReceivablesMember 2020-07-01 2020-07-31 0001590717 ctre:NobleVAHoldingsLLCMember ctre:AssistedLivingFacilityMember 2020-12-01 0001590717 ctre:NobleTripleNetMasterLeaseMember 2020-12-01 0001590717 ctre:NobleVAHoldingsLLCMember 2020-12-01 2020-12-01 0001590717 ctre:NextVAStarRealtyHoldingsLLCMember ctre:MezzanineLoanMember 2020-11-30 0001590717 ctre:NextVAStarRealtyHoldingsLLCMember srt:MinimumMember ctre:MezzanineLoanMember 2020-11-30 0001590717 ctre:NextVAStarRealtyHoldingsLLCMember srt:MaximumMember ctre:MezzanineLoanMember 2020-11-30 0001590717 ctre:NextVAStarRealtyHoldingsLLCMember ctre:MezzanineLoanMember 2020-11-01 2020-11-30 0001590717 ctre:MezzanineLoanMember 2021-01-01 2021-03-31 0001590717 ctre:MantecaValleyPostAcuteMember us-gaap:MortgageReceivablesMember 2019-07-01 2019-07-31 0001590717 ctre:MantecaValleyPostAcuteMember us-gaap:MortgageReceivablesMember 2019-07-31 0001590717 ctre:MantecaValleyPostAcuteMember 2019-07-01 2019-07-31 0001590717 ctre:CommuniCareMember us-gaap:MortgageReceivablesMember 2019-09-30 0001590717 ctre:CascadeCapitalGroupLLCMember us-gaap:MortgageReceivablesMember 2020-02-29 0001590717 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember ctre:MetronSkilledNursingFacilitiesMember 2020-02-29 0001590717 ctre:CascadeCapitalGroupLLCMember 2020-04-30 0001590717 ctre:CascadeCapitalGroupLLCMember us-gaap:MortgageReceivablesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-04-30 0001590717 us-gaap:MortgageReceivablesMember 2021-03-31 0001590717 us-gaap:MortgageReceivablesMember 2021-01-01 2021-03-31 0001590717 us-gaap:MortgageReceivablesMember 2020-01-01 2020-03-31 0001590717 us-gaap:LoansReceivableMember 2021-01-01 2021-03-31 0001590717 ctre:PreferredEquityInvestmentCascadiaDevelopmentBoiseIDMember 2016-09-30 0001590717 ctre:PreferredEquityInvestmentCascadiaDevelopmentBoiseIDMember us-gaap:PrimeRateMember 2016-09-01 2016-09-30 0001590717 ctre:PreferredEquityInvestmentCascadiaDevelopmentBoiseIDMember 2016-09-01 2016-09-30 0001590717 ctre:SkilledNursingPropertiesMember 2020-01-01 2020-01-31 0001590717 ctre:PreferredEquityInvestmentCascadiaDevelopmentBoiseIDMember 2020-01-01 2020-01-31 0001590717 ctre:PreferredEquityInvestmentCascadiaDevelopmentBoiseIDMember 2020-01-01 2020-03-31 0001590717 ctre:MezzanineLoanMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001590717 ctre:MezzanineLoanMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001590717 ctre:MezzanineLoanMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001590717 ctre:MezzanineLoanMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001590717 ctre:MezzanineLoanMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001590717 ctre:MezzanineLoanMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001590717 ctre:MezzanineLoanMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001590717 ctre:MezzanineLoanMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001590717 us-gaap:FinancingReceivablesEqualToGreaterThan90DaysPastDueMember 2021-03-31 0001590717 ctre:SeniorUnsecuredNotesMember 2021-03-31 0001590717 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember ctre:SeniorUnsecuredNotesMember 2021-03-31 0001590717 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember ctre:SeniorUnsecuredNotesMember 2021-03-31 0001590717 ctre:SeniorUnsecuredNotesMember 2020-12-31 0001590717 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember ctre:SeniorUnsecuredNotesMember 2020-12-31 0001590717 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember ctre:SeniorUnsecuredNotesMember 2020-12-31 0001590717 us-gaap:SeniorNotesMember 2021-03-31 0001590717 us-gaap:SeniorNotesMember 2020-12-31 0001590717 ctre:SeniorUnsecuredTermLoanMember 2021-03-31 0001590717 ctre:SeniorUnsecuredTermLoanMember 2020-12-31 0001590717 us-gaap:LineOfCreditMember 2021-03-31 0001590717 us-gaap:LineOfCreditMember 2020-12-31 0001590717 ctre:FivePointTwoFiveSeniorNotesDue2025Member ctre:SeniorUnsecuredNotesMember 2017-05-10 0001590717 ctre:FivePointTwoFiveSeniorNotesDue2025Member ctre:SeniorUnsecuredNotesMember 2017-05-10 2017-05-10 0001590717 ctre:FivePointTwoFiveSeniorNotesDue2025Member ctre:SeniorUnsecuredNotesMember 2020-06-01 2020-06-01 0001590717 us-gaap:RevolvingCreditFacilityMember ctre:NewRevolvingFacilityMember 2019-02-08 0001590717 us-gaap:LetterOfCreditMember 2019-02-08 0001590717 ctre:SwinglineLoanMember 2019-02-08 0001590717 ctre:NewTermLoanFeb2019Member ctre:SeniorUnsecuredTermLoanMember 2019-02-08 0001590717 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember ctre:NewRevolvingFacilityMember us-gaap:BaseRateMember 2019-02-08 2019-02-08 0001590717 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ctre:NewRevolvingFacilityMember us-gaap:BaseRateMember 2019-02-08 2019-02-08 0001590717 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember ctre:NewRevolvingFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-02-08 2019-02-08 0001590717 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ctre:NewRevolvingFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-02-08 2019-02-08 0001590717 srt:MinimumMember ctre:NewTermLoanFeb2019Member ctre:SeniorUnsecuredTermLoanMember us-gaap:BaseRateMember 2019-02-08 2019-02-08 0001590717 srt:MaximumMember ctre:NewTermLoanFeb2019Member ctre:SeniorUnsecuredTermLoanMember us-gaap:BaseRateMember 2019-02-08 2019-02-08 0001590717 srt:MinimumMember ctre:NewTermLoanFeb2019Member ctre:SeniorUnsecuredTermLoanMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-02-08 2019-02-08 0001590717 srt:MaximumMember ctre:NewTermLoanFeb2019Member ctre:SeniorUnsecuredTermLoanMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-02-08 2019-02-08 0001590717 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember ctre:NewRevolvingFacilityMember 2019-02-08 2019-02-08 0001590717 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ctre:NewRevolvingFacilityMember 2019-02-08 2019-02-08 0001590717 us-gaap:RevolvingCreditFacilityMember ctre:NewRevolvingFacilityMember 2019-02-08 2019-02-08 0001590717 srt:MaximumMember ctre:AtTheMarketOfferingProgramMember 2020-03-10 0001590717 ctre:AtTheMarketOfferingProgramMember 2020-01-01 2020-03-31 0001590717 ctre:AtTheMarketOfferingProgramMember 2021-01-01 2021-03-31 0001590717 ctre:AtTheMarketOfferingProgramMember 2021-03-31 0001590717 2020-03-20 0001590717 ctre:EnsignEmployeesMember us-gaap:RestrictedStockMember 2014-06-01 2014-06-01 0001590717 ctre:EnsignEmployeesMember us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001590717 ctre:EnsignEmployeesMember us-gaap:RestrictedStockMember 2021-03-31 0001590717 ctre:OfficerAndEmployeeMember us-gaap:RestrictedStockMember 2021-01-01 2021-01-31 0001590717 ctre:OfficerAndEmployeeMember us-gaap:RestrictedStockMember 2021-02-01 2021-02-28 0001590717 ctre:OfficerAndEmployeeMember us-gaap:RestrictedStockMember 2021-02-28 0001590717 ctre:OfficerAndEmployeeMember us-gaap:RestrictedStockMember 2021-01-31 0001590717 srt:OfficerMember us-gaap:PerformanceSharesMember 2021-01-01 2021-01-31 0001590717 srt:MinimumMember srt:OfficerMember us-gaap:PerformanceSharesMember 2021-01-01 2021-01-31 0001590717 srt:MaximumMember srt:OfficerMember us-gaap:PerformanceSharesMember 2021-01-01 2021-01-31 0001590717 srt:OfficerMember us-gaap:PerformanceSharesMember 2021-02-01 2021-02-28 0001590717 srt:MinimumMember srt:OfficerMember us-gaap:PerformanceSharesMember 2021-02-01 2021-02-28 0001590717 srt:MaximumMember srt:OfficerMember us-gaap:PerformanceSharesMember 2021-02-01 2021-02-28 0001590717 us-gaap:PerformanceSharesMember 2021-01-01 2021-03-31 0001590717 ctre:EnsignAndPennantMember 2021-03-31 0001590717 ctre:CapitalImprovementsAtTripleNetLeasedFacilitiesMember 2021-03-31 0001590717 ctre:EnsignMember ctre:SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMember 2021-03-31 0001590717 ctre:EnsignMember 2021-01-01 2021-03-31 0001590717 ctre:EnsignMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001590717 ctre:EnsignMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0001590717 ctre:PriorityManagementGroupLLCMember ctre:SkilledNursingAndCampusFacilitiesMember 2021-03-31 0001590717 ctre:PriorityManagementGroupLLCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0001590717 ctre:PriorityManagementGroupLLCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001590717 ctre:SkilledNursingPropertiesMember us-gaap:SubsequentEventMember 2021-04-01 2021-04-30 0001590717 ctre:BayshireLLCMember us-gaap:SubsequentEventMember 2021-04-30 0001590717 ctre:BayshireLLCMember ctre:SkilledNursingPropertiesMember us-gaap:SubsequentEventMember 2021-04-01 2021-04-30 shares iso4217:USD iso4217:USD shares ctre:facility ctre:bed ctre:state ctre:property ctre:unit pure ctre:extension_option ctre:installment ctre:company ctre:unit_bed 0001590717 --12-31 2021 Q1 false us-gaap:HealthCareResidentServiceMember us-gaap:HealthCareResidentServiceMember us-gaap:HealthCareResidentServiceMember us-gaap:HealthCareResidentServiceMember P5D P1Y 10-Q true 2021-03-31 false 001-36181 CareTrust REIT, Inc. MD 46-3999490 905 Calle Amanecer Suite 300 San Clemente CA 92673 949 542-3130 Common Stock, par value $0.01 per share CTRE NASDAQ Yes Yes Large Accelerated Filer false false false 96785096 1577450000 1448099000 15155000 15000000 0 7226000 30469000 18919000 1780000 1823000 7448000 10450000 1797000 2042000 1634099000 1503559000 296858000 296669000 198978000 198925000 170000000 50000000 16898000 19572000 25924000 24251000 708658000 589417000 0.01 0.01 100000000 100000000 0 0 0 0 0 0 0.01 0.01 500000000 500000000 95981062 95981062 95215797 95215797 960000 952000 1180840000 1164402000 256359000 251212000 925441000 914142000 1634099000 1503559000 45246000 42464000 0 625000 505000 1251000 45751000 44340000 13473000 13160000 5762000 6714000 696000 485000 0 546000 5142000 4054000 25073000 24959000 -192000 -56000 20486000 19325000 0.21 0.20 0.21 0.20 95378000 95161000 95385000 95161000 95215797 952000 1164402000 -251212000 914142000 702000 7000 16184000 16191000 63265 1000 -1331000 -1330000 1585000 1585000 0.265 25633000 25633000 20486000 20486000 95981062 960000 1180840000 -256359000 925441000 95103270 951000 1162990000 -236350000 927591000 90000 90000 93061 1000 -1987000 -1986000 884000 884000 0.25 23931000 23931000 19325000 19325000 95196331 952000 1161797000 -240956000 921793000 20486000 19325000 13486000 13175000 487000 487000 1585000 884000 12000 26000 -192000 -56000 0 1346000 100000 -335000 -278000 -454000 -2453000 482000 33949000 36518000 138151000 25905000 1319000 2418000 700000 100000 56000 662000 0 2327000 0 1000000 6814000 2134000 -133300000 -24300000 16191000 90000 120000000 15000000 1330000 1986000 23960000 21532000 110901000 -8608000 11550000 3610000 18919000 20327000 30469000 23937000 1325000 2289000 1673000 2399000 358000 167000 0 32400000 ORGANIZATION<div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of Business—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CareTrust REIT, Inc.’s (“CareTrust REIT” or the “Company”) primary business consists of acquiring, financing, developing and owning real property to be leased to third-party tenants in the healthcare sector. As of March 31, 2021, the Company owned and leased to independent operators, 222 skilled nursing, multi-service campuses, assisted living and independent living facilities consisting of 23,222 operational beds and units located in 28 states with the highest concentration of properties by rental revenues located in California, Texas, Louisiana, Idaho and Arizona. As of March 31, 2021, we also had other real estate investments consisting of one mezzanine loan receivable with a carrying value of $15.2 million.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has led governments and other authorities around the world, including federal, state and local authorities in the United States, to impose measures intended to reduce its spread, including restrictions on freedom of movement and business operations such as travel bans, border closings, business limitations and closures (subject to exceptions for essential operations and businesses), quarantines and shelter-in-place orders. Although most of these governmental restrictions have since been lifted or scaled back, resurgences of COVID-19 and the emergence of new variants thereof have resulted in the reimposition of certain restrictions and may lead to other restrictions being reimplemented in response to efforts to reduce the spread of COVID-19. Given the dynamic nature of these circumstances and the related adverse impact these restrictions have had, and may continue to have, on the economy generally, the Company’s business, results of operations and financial condition may be adversely impacted by the COVID-19 pandemic. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The duration and extent of the COVID-19 pandemic’s effect on the Company’s operational and financial performance, and the operational and financial performance of the Company’s tenants, will depend on future developments, which are highly uncertain and cannot be predicted at this time, including new information which may emerge concerning the timing of vaccine rollouts, public acceptance and usage of vaccines and the effectiveness of vaccines in limiting the spread of COVID-19 and its variants that may continue to occur, and how quickly and to what extent normal economic and operating conditions can resume. The adverse impact of the COVID-19 pandemic on the Company’s business, results of operations and financial condition could be material.</span></div> 222 23222 28 15200000 BASIS OF PRESENTATION<div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The accompanying condensed consolidated financial statements of the Company were prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and Article 10 of Regulation S-X. Accordingly, the condensed consolidated financial statements do not include all of the disclosures required by GAAP for a complete set of annual audited financial statements. The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020. In the opinion of management, all adjustments which are of a normal and recurring nature and considered necessary for a fair presentation of the results of the interim periods presented have been included. The results of operations for the interim periods are not necessarily indicative of results for the full year. All intercompany transactions and account balances within the Company have been eliminated.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-04, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASU 2020-04”), that provides optional relief to applying reference rate reform to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”), which will be discontinued by the end of 2021. The amendments in this update are effective immediately and may be applied through December 31, 2022. The Company is still evaluating the impact of ASU 2020-04 and expects to take full advantage of the offered optional expedients and exceptions, but does not expect the adoption of the standard to have a material impact on the Company’s consolidated financial statements.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The accompanying condensed consolidated financial statements of the Company were prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and Article 10 of Regulation S-X. Accordingly, the condensed consolidated financial statements do not include all of the disclosures required by GAAP for a complete set of annual audited financial statements. The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020. In the opinion of management, all adjustments which are of a normal and recurring nature and considered necessary for a fair presentation of the results of the interim periods presented have been included. The results of operations for the interim periods are not necessarily indicative of results for the full year. All intercompany transactions and account balances within the Company have been eliminated.</span> <span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-04, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASU 2020-04”), that provides optional relief to applying reference rate reform to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”), which will be discontinued by the end of 2021. The amendments in this update are effective immediately and may be applied through December 31, 2022. The Company is still evaluating the impact of ASU 2020-04 and expects to take full advantage of the offered optional expedients and exceptions, but does not expect the adoption of the standard to have a material impact on the Company’s consolidated financial statements.</span> REAL ESTATE INVESTMENTS, NET<div style="margin-bottom:9pt;margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s investment in owned properties as of March 31, 2021 and December 31, 2020 (dollars in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,457 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,356 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,578,754 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,477,849 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integral equipment, furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,131 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,836 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identified intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,658 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,926,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,783,393 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(348,550)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(335,294)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate investments, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,577,450 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,448,099 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, all 222 of the Company’s facilities wer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e leased to various operators under triple-net leases. All of these leases contain annual escalators based on the percentage change in the Consumer Price Index (but not less than zero), some of which are subject to a cap, or fixed rent escalators.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company’s total future contractual minimum rental income for all of its tenants, excluding operating expense reimbursements, were (dollars in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (nine months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,001 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,082 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,777 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,488 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860,010 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,864,266 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tenant Purchase Options</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company’s operators hold purchase options allowing them to acquire properties they currently lease from the Company. A summary of these purchase options is presented below (dollars in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset Type</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Properties</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Expiration</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1st Option Open Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option Type</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current Cash Rent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ALF</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2034</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/1/2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,207 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/1/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/1/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B / C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF / Campus</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2032</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/1/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2034</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/1/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,789 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ALF</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2034</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/1/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,559 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Option type includes:</span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A - Fixed base price plus a specified share on any appreciation.</span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B - Fixed base price.</span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C - Fixed capitalization rate on lease revenue.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Based on annualized cash revenue for contracts in place at March 31, 2021.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Purchase option reflects two option types.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rental Income</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes components of the Company’s rental income (dollars in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.960%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rental Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual rent due</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,171 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,438 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line rent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease termination revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,246 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,464 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Includes initial cash rent and tenant operating expense reimbursements, as adjusted for applicable rental escalators and rent increases due to capital expenditures funded by the Company. For tenants on a cash basis, this represents the lesser of the amount that would be recognized on a straight-line basis or cash that has been received. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) During the three months ended March 31, 2021, in connection with the agreement to terminate its lease agreements with affiliates of Metron Integrated Health Systems (“Metron”) and to sell the facilities to a third-party, the Company received $0.1 million from Metron affiliates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Real Estate Acquisitions</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s acquisitions for the three months ended March 31, 2021 (dollars in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.349%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type of Property</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchase Price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Initial Annual Cash Rent</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Properties</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Beds/Units</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skilled nursing</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,492 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multi-service campuses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,708 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,508 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,096 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Purchase price includes capitalized acquisition costs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The number of beds/units includes operating beds at the acquisition date. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Initial annual cash rent represents the first twelve months of rent upon commencement of the Company’s long-term net leases, which is scheduled to occur upon the tenants’ receipt of licensing approval and increases to $9.4 million in the second year with Consumer Price Index (“CPI”) based annual escalators thereafter. The facilities are currently being leased back to the seller under a short-term lease with a term of less than one year. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Sales and Assets Held for Sale</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, there were no assets classified as held for sale. During the fourth quarter of 2020, the Company met the criteria to classify one skilled nursing facility operated by affiliates of Five Oaks Healthcare, LLC as held for sale. Assets held for sale include the net book value of property the Company plans to sell within the next year. If the determination is made that the Company no longer expects to sell an asset within the next year, the asset is reclassified out of assets held for sale. On February 1, 2021, the Company closed on the sale of the one skilled nursing facility consisting of 90 beds located in Washington with a carrying value of $7.2 million, for net sales proceeds of $7.0 million. The Company recorded a loss of $0.2 million in connection with the sale.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2020, the Company sold the one remaining owned and operated independent living facility consisting of 168 units located in Texas with an aggregate carrying value of $4.2 million for gross proceeds of $4.5 million. In connection with the sale, the Company recognized a gain of $20,000 during the three months ended December 31, 2020. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 14, 2020, the Company closed on the sale of six skilled nursing facilities formerly operated by affiliates of Metron. In connection with the sale for $36.0 million, the Company received $3.5 million in cash and provided subsidiaries of Cascade Capital Group, LLC (“Cascade”), the purchaser of the properties, with a short-term mortgage loan secured by these properties for $32.4 million. The mortgage loan bore interest at 7.5% and initially had a maturity date of March 31, 2020. In connection with the sale, the Company recognized a loss of approximately $0.1 million. In April 2020, the mortgage loan was settled with $18.9 million in cash and a new mortgage loan for $13.9 million. In July 2020, the Company received prepayment in full, including accrued interest, for the new $13.9 million mortgage loan. See Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Real Estate Investments, Net,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further detail on the new mortgage loan. </span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Amendments</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Twenty/20 Lease Termination and New Noble Master Lease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On December 1, 2020, five assisted living facilities in Virginia operated by Twenty/20 Management, Inc. (“Twenty/20”) were transferred to affiliates of Noble VA Holdings, LLC (“Noble”). In connection with the transfer, the Company entered into a new triple-net master lease with Noble. The new lease has a remaining initial term of approximately 14 years, with two five-year renewal options and CPI-based rent escalators. Initial annual cash rent under the new lease is approximately $3.2 million</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</span></div> <div style="margin-bottom:9pt;margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s investment in owned properties as of March 31, 2021 and December 31, 2020 (dollars in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,457 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,356 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,578,754 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,477,849 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integral equipment, furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,131 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,836 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identified intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,658 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,926,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,783,393 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(348,550)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(335,294)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate investments, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,577,450 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,448,099 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 243457000 205356000 1578754000 1477849000 101131000 97836000 2658000 2352000 1926000000 1783393000 348550000 335294000 1577450000 1448099000 222 <div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company’s total future contractual minimum rental income for all of its tenants, excluding operating expense reimbursements, were (dollars in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (nine months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,001 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,082 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,777 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,488 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860,010 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,864,266 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 132001000 176082000 175777000 174467000 174441000 171488000 860010000 1864266000 <div style="margin-bottom:6pt;margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company’s operators hold purchase options allowing them to acquire properties they currently lease from the Company. A summary of these purchase options is presented below (dollars in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset Type</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Properties</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Expiration</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1st Option Open Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option Type</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current Cash Rent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ALF</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2034</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/1/2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,207 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/1/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/1/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B / C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF / Campus</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2032</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/1/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2034</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/1/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,789 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ALF</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2034</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/1/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,559 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Option type includes:</span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A - Fixed base price plus a specified share on any appreciation.</span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B - Fixed base price.</span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C - Fixed capitalization rate on lease revenue.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Based on annualized cash revenue for contracts in place at March 31, 2021.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Purchase option reflects two option types.</span></div> 7 3207000 11 4800000 1 766000 2 959000 4 3789000 2 1559000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes components of the Company’s rental income (dollars in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.960%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rental Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual rent due</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,171 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,438 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line rent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease termination revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,246 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,464 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Includes initial cash rent and tenant operating expense reimbursements, as adjusted for applicable rental escalators and rent increases due to capital expenditures funded by the Company. For tenants on a cash basis, this represents the lesser of the amount that would be recognized on a straight-line basis or cash that has been received. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) During the three months ended March 31, 2021, in connection with the agreement to terminate its lease agreements with affiliates of Metron Integrated Health Systems (“Metron”) and to sell the facilities to a third-party, the Company received $0.1 million from Metron affiliates.</span></div> 45171000 42438000 12000 26000 63000 0 45246000 42464000 100000 <div style="margin-bottom:6pt;margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s acquisitions for the three months ended March 31, 2021 (dollars in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.349%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type of Property</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchase Price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Initial Annual Cash Rent</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Properties</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Beds/Units</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skilled nursing</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,492 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multi-service campuses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,708 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,508 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,096 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Purchase price includes capitalized acquisition costs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The number of beds/units includes operating beds at the acquisition date. </span></div>(3) Initial annual cash rent represents the first twelve months of rent upon commencement of the Company’s long-term net leases, which is scheduled to occur upon the tenants’ receipt of licensing approval and increases to $9.4 million in the second year with Consumer Price Index (“CPI”) based annual escalators thereafter. The facilities are currently being leased back to the seller under a short-term lease with a term of less than one year. 15800000 1492000 1 145 125708000 8604000 4 640 141508000 10096000 5 785 9400000 0 1 90 7200000 7000000.0 -200000 1 168 4200000 4500000 20000 6 36000000.0 3500000 32400000 0.075 100000 18900000 13900000 13900000 5 P14Y 2 P5Y 3200000 OTHER REAL ESTATE INVESTMENTS, NET<div style="margin-bottom:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mezzanine Loan Receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—In November 2020, the Company provided Next VA Star Realty Holdings, LLC a mezzanine loan for nine skilled nursing facilities secured by membership interests in affiliates of Next VA Star Realty Holdings, LLC for approximately $15.0 million, at an annual interest rate of 12%. The loan requires monthly interest payments, is set to mature on November 30, 2025, and may (subject to certain restrictions) be prepaid before the maturity date if paid in full and for an exit fee ranging from 1% to 3% of the loan plus unpaid interest payments equal to 24 months (less the amount of monthly interest payments made by the borrower through the date of prepayment). During the three months ended March 31, 2021, the Company recognized $0.5 million of interest income related to its mezzanine loan. </span></div><div style="margin-bottom:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mortgage Loans Receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—In July 2019, the Company provided MCRC, LLC a real estate loan secured by a 176-bed skilled nursing facility in Manteca, California for $3.0 million, which bore a fixed interest rate of 8% and required monthly interest payments. Concurrently, the Company entered into a purchase and sale agreement to purchase the Manteca facility from MCRC, LLC for approximately $16.4 million subject to normal diligence and other contingencies. The loan documents provided for a maturity date of the earlier to occur of the closing date of the acquisition, or <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE3MjBhYWNiODBjZTRlYzlhZWMxNzlhZGYzYTNlMGEyL3NlYzphNzIwYWFjYjgwY2U0ZWM5YWVjMTc5YWRmM2EzZTBhMl80MC9mcmFnOmM5NzJjZWExMjQyOTRkYjY4M2I1NjUyZDIzMjI4NGJlL3RleHRyZWdpb246Yzk3MmNlYTEyNDI5NGRiNjgzYjU2NTJkMjMyMjg0YmVfMTg5Mg_67059004-dead-4a5d-b7d7-b7af9fff3877">five</span> business days following the termination of the purchase and sale agreement.  MCRC, LLC breached its obligation to sell the Manteca facility to the Company on the terms outlined in the purchase and sale agreement and to repay the real estate loan upon its stated maturity. As a result, the Company commenced non-judicial foreclosure proceedings with respect to the Manteca facility. In January 2020, the borrower further collateralized the loan by causing one of its affiliates to grant the Company a deed of trust in the real estate and improvements that constitute Palm Gardens Assisted Living Facility in Yolo County, California. During the three months ended June 30, 2020, payment for the loan principal and accrued interest, including default interest, as well as reimbursement for attorney’s fees and certain other costs of suit, were received in full by the Company and, as a result, the Company withdrew all foreclosure-related proceedings related to the Manteca facility loan. </span></div><div style="margin-bottom:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company provided affiliates of CommuniCare a $26.5 million loan secured by mortgages on the three skilled nursing facilities sold to CommuniCare</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which bore a fixed interest rate of 10%. The mortgage loan, which required CommuniCare to make monthly interest payments, was set to mature on February 29, 2020 and included an option to be prepaid before the maturity date. In January 2020, the Company amended the mortgage loan’s maturity date to April 30, 2020. In April 2020, the Company amended the mortgage loan’s maturity date to May 29, 2020. During the three months ended June 30, 2020, payment for the mortgage loan and accrued interest was received in full by the Company.</span></div><div style="margin-bottom:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the Company provided subsidiaries of Cascade a $32.4 million loan secured by mortgages on the six skilled nursing facilities formerly operated by affiliates of Metron sold to Cascade in February 2020, as discussed in Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Real Estate Investments, Net. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The mortgage loan bore interest at 7.5% and initially had a maturity date of March 31, 2020. In April 2020, the mortgage loan was settled in connection with a new mortgage loan transaction between the Company and a third-party institutional lender as co-lenders, pursuant to which the Company received $18.9 million in cash and a new mortgage loan for $13.9 million. The new mortgage loan with Cascade was secured by the same six skilled nursing facilities purchased by Cascade and was for a combined principal amount of $33.9 million, with the Company’s $13.9 million portion of the indebtedness initially bearing interest at a variable rate equal to LIBOR plus 4.00%, subject to a LIBOR floor of 1.75%. The new mortgage loan had a maturity date of April 29, 2022 and included two six-month extension options. In July 2020, prepayment for the mortgage loan of $13.9 million and accrued interest was received in full by the Company. </span></div><div style="margin-bottom:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company had no remaining mortgage loan receivables.</span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021 and 2020, the Company recognized no interest income and $1.1 million of interest income, respectively, related to its mortgage loans. During both the three months ended March 31, 2021 and 2020, the Company recognized $0.1 million of interest income related to its other loans receivable.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Equity Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—In September 2016, the Company completed a $2.3 million preferred equity investment with an affiliate of Cascadia Development, LLC. The preferred equity investment yielded a return equal to prime plus 9.5% but in no event less than 12.0% calculated on a quarterly basis on the outstanding carrying value of the investment. The investment was used to develop a 99-bed skilled nursing facility in Boise, Idaho. In connection with its investment, the Company obtained an option to purchase the development at a fixed-formula price upon stabilization, with an initial lease yield of at least 9.0%. The project was completed in the first quarter of 2018 and began lease-up during the second quarter of 2018. In January 2020, the Company purchased the skilled nursing facility for approximately $18.7 million, inclusive of transaction costs. The Company paid $15.0 million after receiving back its initial investment of $2.3 million and cumulative contractual preferred return through January 17, 2020, the acquisition date, of $1.4 million, of which less than $0.1 million was recognized as interest income during the three months ended March 31, 2020. The Company did not recognize any interest income during the three months ended March 31, 2021 related to preferred equity investments. As of March 31, 2021, the Company had no remaining preferred equity investments.</span></div> 9 15000000.0 0.12 0.01 0.03 P24M 500000 176 3000000.0 0.08 16400000 26500000 3 0.10 32400000 6 0.075 18900000 13900000 6 33900000 13900000 0.0400 0.0175 2 P6M 13900000 0 0 1100000 100000 2300000 0.095 0.120 99 0.090 18700000 15000000.0 2300000 1400000 100000 0 FAIR VALUE MEASUREMENTS<div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines fair value based on quoted prices when available or through the use of alternative approaches, such as discounting the expected cash flows using market interest rates commensurate with the credit quality and duration of the investment. GAAP guidance defines three levels of inputs that may be used to measure fair value:</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 – Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability or can be corroborated with observable market data for substantially the entire contractual term of the asset or liability.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 – Unobservable inputs reflect the entity’s own assumptions about the assumptions that market participants would use in the pricing of the asset or liability and are consequently not based on market activity, but rather through particular valuation techniques.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of where an asset or liability falls in the hierarchy requires significant judgment and considers factors specific to the asset or liability. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company evaluates its hierarchy disclosures each quarter and, depending on various factors, it is possible that an asset or liability may be classified differently from quarter to quarter. Changes in the type of inputs may result in a reclassification for certain assets. The Company does not expect that changes in classifications between levels will be frequent.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Items Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020, aggregated by the level in the fair value hierarchy within which those instruments fall (dollars in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine loan receivable</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,155 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine loan receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mezzanine loan receivable:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair value of the mezzanine loan receivable was estimated using an internal valuation model that considered the expected future cash flows of the investment, the underlying collateral value, market interest rates and other credit enhancements. As such, the Company classifies the instrument as Level 3 due to the significant unobservable inputs used in determin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ing market interest rates for investments with similar terms. Future changes in market interest rates could materially impact the estimated discounted cash flows. A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s of March 31, 2021 and December 31, 2020, the Company did not have any loans that were 90 days or more past due.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, there were no changes in assets and liabilities with Level 3 inputs in the fair value hierarchy.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Items Disclosed at Fair Value</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Considerable judgment is necessary to estimate the fair value disclosure of financial instruments. The estimates of fair value presented herein are not necessarily indicative of the amounts that could be realized upon disposition of the financial instruments. A summary of the face values, carrying amounts and fair values of the Company’s financial instruments as of March 31, 2021 and December 31, 2020 using Level 2 inputs for the Notes (as defined in Note 6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below), is as follows (dollars in thousands): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.581%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Face<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Face<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior unsecured notes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296,858 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">309,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311,430 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents, accounts and other receivables, other loans receivable, and accounts payable and accrued liabilities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These balances approximate their fair values due to the short-term nature of these instruments.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unsecured revolving credit facility and senior unsecured term loan:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair values approximate their carrying values as the interest rates are variable and approximate prevailing market interest rates for similar debt arrangements.</span></div> <div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines fair value based on quoted prices when available or through the use of alternative approaches, such as discounting the expected cash flows using market interest rates commensurate with the credit quality and duration of the investment. GAAP guidance defines three levels of inputs that may be used to measure fair value:</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 – Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability or can be corroborated with observable market data for substantially the entire contractual term of the asset or liability.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 – Unobservable inputs reflect the entity’s own assumptions about the assumptions that market participants would use in the pricing of the asset or liability and are consequently not based on market activity, but rather through particular valuation techniques.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of where an asset or liability falls in the hierarchy requires significant judgment and considers factors specific to the asset or liability. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company evaluates its hierarchy disclosures each quarter and, depending on various factors, it is possible that an asset or liability may be classified differently from quarter to quarter. Changes in the type of inputs may result in a reclassification for certain assets. The Company does not expect that changes in classifications between levels will be frequent.</span></div> <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020, aggregated by the level in the fair value hierarchy within which those instruments fall (dollars in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine loan receivable</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,155 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine loan receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 0 15155000 15155000 0 0 15000000 15000000 0 A summary of the face values, carrying amounts and fair values of the Company’s financial instruments as of March 31, 2021 and December 31, 2020 using Level 2 inputs for the Notes (as defined in Note 6, <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below), is as follows (dollars in thousands): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.581%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Face<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Face<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior unsecured notes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296,858 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">309,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311,430 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 300000000 296858000 309000000 300000000 296669000 311430000 DEBT<div style="margin-top:6pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balance of the Company’s indebtedness as of March 31, 2021 and December 31, 2020 (dollars in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:29.985%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.192%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Loan Fees</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Loan Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior unsecured notes payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,142)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,858 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,331)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,669 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior unsecured term loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,022)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,075)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,925 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unsecured revolving credit facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,164)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665,836 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,406)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545,594 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Unsecured Notes Payable</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2017, the Company’s wholly owned subsidiary, CTR Partnership, L.P. (the “Operating Partnership”), and its wholly owned subsidiary, CareTrust Capital Corp. (together with the Operating Partnership, the “Issuers”), completed an underwritten public offering of $300.0 million aggregate principal amount of 5.25% Senior Notes due 2025 (the “Notes”). The Notes were issued at par, resulting in gross proceeds of $300.0 million and net proceeds of approximately $294.0 million after deducting underwriting fees and other offering expenses. The Notes mature on June 1, 2025 and bear interest at a rate of 5.25% per year. Interest on the Notes is payable on June 1 and December 1 of each year.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 1, 2020, the Issuers may redeem the Notes any time at the redemption prices set forth in the indenture. As of March 31, 2021, the Issuers have not elected to redeem any of the Notes. If certain changes of control of the Company occur, holders of the Notes will have the right to require the Issuers to repurchase their Notes at 101% of the principal amount plus accrued and unpaid interest, if any, to, but not including, the repurchase date.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The obligations under the Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by the Company and certain of the Company’s wholly owned existing and, subject to certain exceptions, future material subsidiaries (other than the Issuers); provided, however, that such guarantees are subject to automatic release under certain customary circumstances.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indenture contains customary covenants such as limiting the ability of the Company and its restricted subsidiaries to: incur or guarantee additional indebtedness; incur or guarantee secured indebtedness; pay dividends or distributions on, or redeem or repurchase, capital stock; make certain investments or other restricted payments; sell assets; enter into transactions with affiliates; merge or consolidate or sell all or substantially all of their assets; and create restrictions on the ability of the Issuers and their restricted subsidiaries to pay dividends or other amounts to the Issuers. The indenture also requires the Company and its restricted subsidiaries to maintain a specified ratio of unencumbered assets to unsecured indebtedness. These covenants are subject to a number of important and significant limitations, qualifications and exceptions. The indenture also contains customary events of default.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company was in compliance with all applicable financial covenants under the indenture.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unsecured Revolving Credit Facility and Term Loan</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2019, the Operating Partnership, as the borrower, the Company, as guarantor, CareTrust GP, LLC, and certain of the Operating Partnership’s wholly owned subsidiaries entered into an amended and restated credit and guaranty agreement with KeyBank National Association, as administrative agent, an issuing bank and swingline lender, and the lenders party thereto (the “Amended Credit Agreement”). The Amended Credit Agreement provides for: (i) an unsecured revolving credit facility (the “Revolving Facility”) with revolving commitments in an aggregate principal amount of $600.0 million, including a letter of credit subfacility for 10% of the then available revolving commitments and a swingline loan subfacility for 10% of the then available revolving commitments and (ii) an unsecured term loan credit facility (the “Term Loan” and, together with the Revolving Facility, the “Amended Credit Facility”) in an aggregate principal amount of $200.0 million. Borrowing availability under the Revolving Facility is subject to no default or event of default under the Amended Credit Agreement having occurred at the time of borrowing. The proceeds of the Term Loan were used, in part, to repay in full all outstanding borrowings under the Company’s prior term loan and revolving facility under its prior credit agreement. Future borrowings under the Amended Credit Facility will be used for working capital purposes, for capital expenditures, to fund acquisitions and for general corporate purposes. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rates applicable to loans under the Revolving Facility are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.10% to 0.55% per annum or LIBOR plus a margin ranging from 1.10% to 1.55% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). The interest rates applicable to loans under the Term Loan are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.50% to 1.20% per annum or LIBOR plus a margin ranging from 1.50% to 2.20% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). In addition, the Operating Partnership will pay a facility fee on the revolving commitments under the Revolving Facility ranging from 0.15% to 0.35% per annum, based on the debt to asset value ratio of the Company and its consolidated subsidiaries (unless the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt and the Operating Partnership elects to decrease the applicable margin as described above, in which case the Operating Partnership will pay a facility fee on the revolving commitments ranging from 0.125% to 0.30% per annum based on the credit ratings of the Company’s senior long-term unsecured debt). As of March 31, 2021, the Operating Partnership had </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$200.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> outstanding under the Term Loan and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$170.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of borrowings outstanding under the Revolving Facility. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Facility has a maturity date of February 8, 2023, and includes, at the sole discretion of the Operating Partnership, two, six-month extension options. The Term Loan has a maturity date of February 8, 2026.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Facility is guaranteed, jointly and severally, by the Company and its wholly owned subsidiaries that are party to the Amended Credit Agreement (other than the Operating Partnership). The Amended Credit Agreement contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend organizational documents and pay certain dividends and other restricted </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payments. The Amended Credit Agreement requires the Company to comply with financial maintenance covenants to be tested quarterly, consisting of a maximum debt to asset value ratio, a minimum fixed charge coverage ratio, a minimum tangible net worth, a maximum cash distributions to operating income ratio, a maximum secured debt to asset value ratio, a maximum secured recourse debt to asset value ratio, a maximum unsecured debt to unencumbered properties asset value ratio, a minimum unsecured interest coverage ratio and a minimum rent coverage ratio. The Amended Credit Agreement also contains certain customary events of default, including the failure to make timely payments under the Amended Credit Facility or other material indebtedness, the failure to satisfy certain covenants (including the financial maintenance covenants), the occurrence of change of control and specified events of bankruptcy and insolvency.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company was in compliance with all applicable financial covenants under the Amended Credit Agreement.</span></div> <div style="margin-top:6pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balance of the Company’s indebtedness as of March 31, 2021 and December 31, 2020 (dollars in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:29.985%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.192%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Loan Fees</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Loan Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior unsecured notes payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,142)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,858 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,331)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,669 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior unsecured term loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,022)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,075)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,925 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unsecured revolving credit facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,164)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665,836 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,406)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545,594 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 300000000 3142000 296858000 300000000 3331000 296669000 200000000 1022000 198978000 200000000 1075000 198925000 170000000 0 170000000 50000000 0 50000000 670000000 4164000 665836000 550000000 4406000 545594000 300000000.0 0.0525 300000000.0 294000000.0 0.0525 1.01 600000000.0 0.10 0.10 200000000.0 0.0010 0.0055 0.0110 0.0155 0.0050 0.0120 0.0150 0.0220 0.0015 0.0035 0.00125 0.0030 200000000.0 170000000.0 2 P6M EQUITY<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">At-The-Market Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—On March 10, 2020, the Company entered into a new equity distribution agreement to issue and sell, from time to time, up to $500.0 million in aggregate offering price of its common stock through an “at-the-market” equity offering program (the “New ATM Program”). In connection with the entry into the equity distribution agreement and the commencement of the New ATM Program, the Company’s “at-the-market” equity offering program pursuant to the Company’s prior equity distribution agreement, dated as of March 4, 2019, was terminated (the “Prior ATM Program”).</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no Prior ATM Program or New ATM Program activity for the three months ended March 31, 2020. The following table summarizes the New ATM Program activity for the three months ended March 31, 2021 (in thousands, except per share amounts).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.854%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average sales price per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross proceeds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,579 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Total gross proceeds is before $0.2 million of commissions paid to the sales agents during the three months ended March 31, 2021 under the New ATM Program. </span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company had $483.4 million available for future issuances under the New ATM Program. </span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Share Repurchase Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">—On March 20, 2020, the Company’s Board of Directors authorized a share repurchase program to repurchase up to $150.0 million of outstanding shares of the Company’s common stock (the “Repurchase Program”). </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Repurchases under the Repurchase Program, which expires on March 31, 2023, may be made through open market purchases, privately negotiated transactions, structured or derivative transactions, including accelerated share repurchase transactions, or other methods of acquiring shares, in each case subject to market conditions and at such times as shall be permitted by applicable securities laws and determined by management. Repurchases under the Repurchase Program may also be made pursuant to a plan adopted under Rule 10b5-1 promulgated under the Exchange Act. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company expects to finance any share repurchases under the Repurchase Program using available cash and may also use short-term borrowings under the Revolving Facility. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company did not repurchase any shares of common stock under the Repurchase Program during the three months ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 31, 2021 and 2020</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Repurchase Program may be modified, discontinued or suspended at any time.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends on Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The following table summarizes the cash dividends on the Company’s common stock declared by the Company’s Board of Directors for the first three months of 2021 (dollars in thousands, except per share amounts):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.608%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared per share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.265 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payment date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 15, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable as of record date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,633 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends record date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 500000000.0 0 The following table summarizes the New ATM Program activity for the three months ended March 31, 2021 (in thousands, except per share amounts).<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.854%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average sales price per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross proceeds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,579 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table>(1) Total gross proceeds is before $0.2 million of commissions paid to the sales agents during the three months ended March 31, 2021 under the New ATM Program. 702000 23.62 16579000 200000 483400000 150000000.0 0 0 The following table summarizes the cash dividends on the Company’s common stock declared by the Company’s Board of Directors for the first three months of 2021 (dollars in thousands, except per share amounts):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.608%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared per share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.265 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payment date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 15, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable as of record date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,633 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends record date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 0.265 2021-04-15 25633000 2021-03-31 STOCK-BASED COMPENSATION<div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All stock-based awards are subject to the terms of the CareTrust REIT, Inc. and CTR Partnership, L.P. Incentive Award Plan (the “Plan”). The Plan provides for the granting of stock-based compensation, including stock options, restricted stock, performance awards, restricted stock units and other incentive awards to officers, employees and directors in connection with their employment with or services provided to the Company.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Awards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—In connection with the separation of the healthcare business and real estate business of the Ensign Group, Inc. (“Ensign”) into two separate and independently publicly traded companies (the “Spin-Off”) on June 1, 2014, employees of Ensign who had unvested shares of restricted stock were given one share of CareTrust REIT unvested restricted stock totaling 207,580 shares at the Spin-Off. These restricted shares were subject to a time vesting provision only and the Company did not recognize any stock compensation expense associated with these awards. During the year ended December 31, 2020, 1,760 shares were forfeited. At March 31, 2021, there were no unvested restricted stock awards outstanding.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021 and February 2021, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted 140,514 and 99,189 shares of restricted stock, respectively, to officers and employees. Each share had a fair market value on the date of grant of $22.48 and $22.18 per share, respectively, based on the closing market price of the Company’s common stock on that date, and the shares vest in three equal annual installments beginning on the first anniversary of the grant date. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Compensation Committee granted 108,414 performance stock awards to officers. Each share had a fair market value on the date of grant of $22.48 per share, based on the closing market price of the Company’s common stock on that date. Performance stock awards are subject to both time and performance based conditions and vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE3MjBhYWNiODBjZTRlYzlhZWMxNzlhZGYzYTNlMGEyL3NlYzphNzIwYWFjYjgwY2U0ZWM5YWVjMTc5YWRmM2EzZTBhMl81Mi9mcmFnOjg2NThhYTU4M2NhZjRkZWZhOGVlYzA0ZjE0NmZjMzlhL3RleHRyZWdpb246ODY1OGFhNTgzY2FmNGRlZmE4ZWVjMDRmMTQ2ZmMzOWFfMTA5OTUxMTY0MzE1OQ_6c9b1e21-3921-4eca-99f9-c04351b30c9c">one</span>-to three-year period. The amount of such performance awards that will ultimately vest is dependent on the Company’s Normalized Funds from Operations (“NFFO”) per share, as defined by the Compensation Committee, meeting or exceeding a specified per share amount for the applicable vesting period. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in February 2021, the Compensation Committee granted 99,189 performance stock awards to officers. Each share had an estimated fair market value on the date of grant of $27.98 per share. Performance stock awards are subject to both time and performance based conditions and cliff vest over a three-year period. The amount of such performance awards that will ultimately vest is dependent on the Company’s total shareholder return (“TSR”) performance relative to a custom TSR peer group consisting of 16 other publicly traded healthcare REITs and will range from 0% to 200% of the TSR awards initially granted. Compensation expense for awards with performance-based vesting conditions is recognized based upon the grant date fair value per share for each component multiplied by the estimated number of performance stock awards to be earned after considering the Company’s expectation of future performance and is recognized provided that the requisite service is rendered, regardless of when, if ever, the market condition is satisfied. Forfeitures of stock-based awards are recognized as they occur.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the TSR-based performance stock awards is estimated on the date of the grant using a Monte Carlo valuation model. The risk-free rate is based on the U.S. Treasury yield curve in effect at the grant date for the expected performance period. Expected volatility is based on historical volatility for the most recent 2.84 year period ending on the grant date for the Company and the selected TSR peer group, and is calculated on a daily basis. The following are the key assumptions used in this valuation:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.298%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected service period</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.84 years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield (assuming full reinvestment)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock-based compensation expense recognized (dollars in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.300%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,585 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, there was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$14.5 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of unamortized stock-based compensation expense related to unvested awards and the weighted-average remaining vesting period of such awards was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.5 years</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span> 207580 1760 0 140514 99189 22.48 22.18 3 3 108414 22.48 P3Y 99189 27.98 P3Y 16 0 2 P2Y10M2D The following are the key assumptions used in this valuation:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.298%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected service period</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.84 years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield (assuming full reinvestment)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 0.0027 0.5293 P2Y10M2D 0 <div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock-based compensation expense recognized (dollars in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.300%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,585 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 1585000 884000 14500000 P2Y6M EARNINGS PER COMMON SHARE<div style="margin-top:6pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted earnings per common share (“EPS”) for the Company’s common stock for the three months ended March 31, 2021 and 2020, and reconciles the weighted-average common shares outstanding used in the calculation of basic EPS to the weighted-average common shares outstanding used in the calculation of diluted EPS (amounts in thousands, except per share amounts):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.861%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,486 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income allocated to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for basic and diluted earnings available to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,367 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,250 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,161 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average diluted common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,385 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,161 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per common share, basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per common share, diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s unvest</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ed restricted shares associated with its incentive award plan and unvested restricted shares issued to employees of Ensign at the Spin-Off ha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ve been excluded from the above calculation of earnings per diluted share for the three months ended March 31, 2021 and 2020, when their inclusion would have been anti-dilutive.</span></div> <div style="margin-top:6pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted earnings per common share (“EPS”) for the Company’s common stock for the three months ended March 31, 2021 and 2020, and reconciles the weighted-average common shares outstanding used in the calculation of basic EPS to the weighted-average common shares outstanding used in the calculation of diluted EPS (amounts in thousands, except per share amounts):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.861%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,486 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income allocated to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for basic and diluted earnings available to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,367 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,250 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,161 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average diluted common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,385 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,161 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per common share, basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per common share, diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 20486000 19325000 119000 75000 20367000 19250000 95378000 95161000 95385000 95161000 0.21 0.20 0.21 0.20 COMMITMENTS AND CONTINGENCIESThe Company and its subsidiaries are and may become from time to time a party to various claims and lawsuits arising in the ordinary course of business, which are not individually or in the aggregate anticipated to have a material adverse effect on the Company’s results of operations, financial condition or cash flows. Claims and lawsuits may include matters involving general or professional liability asserted against the Company’s tenants, which are the responsibility of the <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company’s tenants and for which the Company is entitled to be indemnified by its tenants under the insurance and indemnification provisions in the applicable leases.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures for each property leased under the Company’s triple-net leases are generally the responsibility of the tenant, except that, for the facilities leased to subsidiaries of Ensign and The Pennant Group, Inc. (“Pennant”), the tenant will have an option to require the Company to finance certain capital expenditures up to an aggregate of 20% of the Company’s initial investment in such property, subject to a corresponding rent increase at the time of funding. For the Company’s other triple-net master leases, subject to approval by the Company, the tenants may request capital expenditure funding that would generally be subject to a corresponding rent increase at the time of funding and which are subject to tenant compliance with the conditions to the Company’s approval and funding of their requests. As of March 31, 2021, the Company had committed to fund certain capital improvements at certain triple-net leased facilities totaling $14.1 million, of which $13.1 million is subject to rent increase at the time of funding.</span></div> 0.20 14100000 13100000 CONCENTRATION OF RISK<div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Major operator concentrations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> – As of March 31, 2021, Ensign leased </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> skilled nursing, multi-service campuses, assisted living and independent living facilities which had</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a total of 9,551 beds and units and are located in Arizona, California, Colorado, Idaho, Iowa, Nebraska, Nevada, Texas, Utah and Washington</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The four states in w</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hich Ensign leases the highest concentration of properties by rental revenues as of March 31, 2021 are Texas, California, Arizona and Utah. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During both the three months ended March 31, 2021 and 2020, Ensign represented </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Company’s rental income, exclusive of operating expense reimbursements.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensign is subject to the registration and reporting requirements of the SEC and is required to file with the SEC annual reports containing audited financial information and quarterly reports containing unaudited financial information. Ensign’s financial statements, as filed with the SEC, can be found at http://www.sec.gov. The Company has not verified this information through an independent investigation or otherwise. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Priority Management Group (“PMG”) leased 15 skilled nursing and campus facilities which had a total of 2,144 beds </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and units, and are located in Louisiana and Texas. During both the three months ended March 31, 2021 and 2020, PMG represented </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Company’s rental income, exclusive of operating expense reimbursements.</span></div> 89 9551 4 0.32 0.32 15 2144 0.16 0.16 SUBSEQUENT EVENTS<div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates subsequent events in accordance with ASC 855, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subsequent Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company evaluates subsequent events up until the date the condensed consolidated financial statements are issued.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Recent Acquisition</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company acquired one skilled nursing facility with the Company’s existing tenant Bayshire, LLC (“Bayshire”). The amended lease with Bayshire has a remaining term of approximately 13 years. The purchase price for the facility was approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$9.7 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which includes an estimated purchase price and capitalized acquisition costs. The estimated contractual initial annual cash rent from the acquisition is approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.8 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and increases to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.9 million</span> in the second year with CPI-based annual escalators thereafter. The acquisition was funded using cash on hand. 1 P13Y 9700000 800000 900000 XML 11 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Cover - shares
3 Months Ended
Mar. 31, 2021
May 05, 2021
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2021  
Document Transition Report false  
Entity File Number 001-36181  
Entity Registrant Name CareTrust REIT, Inc.  
Entity Central Index Key 0001590717  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q1  
Amendment Flag false  
Entity Incorporation, State or Country Code MD  
Entity Tax Identification Number 46-3999490  
Entity Address, Address Line One 905 Calle Amanecer  
Entity Address, Address Line Two Suite 300  
Entity Address, City or Town San Clemente  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 92673  
City Area Code 949  
Local Phone Number 542-3130  
Title of 12(b) Security Common Stock, par value $0.01 per share  
Trading Symbol CTRE  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   96,785,096
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Assets:    
Real estate investments, net $ 1,577,450 $ 1,448,099
Other real estate investments, net 15,155 15,000
Assets held for sale, net 0 7,226
Cash and cash equivalents 30,469 18,919
Accounts and other receivables, net 1,780 1,823
Prepaid expenses and other assets, net 7,448 10,450
Deferred financing costs, net 1,797 2,042
Total assets 1,634,099 1,503,559
Liabilities and Equity:    
Senior unsecured notes payable, net 296,858 296,669
Senior unsecured term loan, net 198,978 198,925
Unsecured revolving credit facility 170,000 50,000
Accounts payable and accrued liabilities 16,898 19,572
Dividends payable 25,924 24,251
Total liabilities 708,658 589,417
Commitments and contingencies
Equity:    
Preferred stock, $0.01 par value; 100,000,000 shares authorized, no shares issued and outstanding as of March 31, 2021 and December 31, 2020 0 0
Common stock, $0.01 par value; 500,000,000 shares authorized, 95,981,062 and 95,215,797 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively 960 952
Additional paid-in capital 1,180,840 1,164,402
Cumulative distributions in excess of earnings (256,359) (251,212)
Total equity 925,441 914,142
Total liabilities and equity $ 1,634,099 $ 1,503,559
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Preferred stock, par value (in usd per share) $ 0.01 $ 0.01
Preferred stock, authorized (shares) 100,000,000 100,000,000
Preferred stock, issued (shares) 0 0
Preferred stock, outstanding (shares) 0 0
Common stock, par value (in usd per share) $ 0.01 $ 0.01
Common stock, authorized (shares) 500,000,000 500,000,000
Common stock, issued (shares) 95,981,062 95,215,797
Common stock, outstanding (shares) 95,981,062 95,215,797
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Income Statements - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Revenues:    
Rental income $ 45,246 $ 42,464
Independent living facilities 0 625
Interest and other income 505 1,251
Total revenues 45,751 44,340
Expenses:    
Depreciation and amortization 13,473 13,160
Interest expense 5,762 6,714
Property taxes 696 485
Independent living facilities 0 546
General and administrative 5,142 4,054
Total expenses 25,073 24,959
Other loss:    
Loss on sale of real estate (192) (56)
Net income $ 20,486 $ 19,325
Earnings Per Share [Abstract]    
Basic (in usd per share) $ 0.21 $ 0.20
Diluted (in usd per share) $ 0.21 $ 0.20
Weighted-average number of common shares:    
Basic (in shares) 95,378 95,161
Diluted (in shares) 95,385 95,161
Independent living facilities, revenue services us-gaap:HealthCareResidentServiceMember us-gaap:HealthCareResidentServiceMember
Independent living facilities, cost of services us-gaap:HealthCareResidentServiceMember us-gaap:HealthCareResidentServiceMember
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Cumulative Distributions in Excess of Earnings
Beginning balance at Dec. 31, 2019 $ 927,591 $ 951 $ 1,162,990 $ (236,350)
Beginning balance (in shares) at Dec. 31, 2019   95,103,270    
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of common stock, net (90)   (90)  
Vesting of restricted common stock, net of shares withheld for employee taxes (1,986) $ 1 (1,987)  
Vesting of restricted common stock, net of shares withheld for employee taxes (in shares)   93,061    
Amortization of stock-based compensation 884   884  
Common dividends (23,931)     (23,931)
Net income 19,325     19,325
Ending balance at Mar. 31, 2020 921,793 $ 952 1,161,797 (240,956)
Ending balance (in shares) at Mar. 31, 2020   95,196,331    
Beginning balance at Dec. 31, 2020 914,142 $ 952 1,164,402 (251,212)
Beginning balance (in shares) at Dec. 31, 2020   95,215,797    
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of common stock, net 16,191 $ 7 16,184  
Issuance of common stock, net, (in shares)   702,000    
Vesting of restricted common stock, net of shares withheld for employee taxes (1,330) $ 1 (1,331)  
Vesting of restricted common stock, net of shares withheld for employee taxes (in shares)   63,265    
Amortization of stock-based compensation 1,585   1,585  
Common dividends (25,633)     (25,633)
Net income 20,486     20,486
Ending balance at Mar. 31, 2021 $ 925,441 $ 960 $ 1,180,840 $ (256,359)
Ending balance (in shares) at Mar. 31, 2021   95,981,062    
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Equity (Parenthetical) - $ / shares
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Statement of Stockholders' Equity [Abstract]    
Common dividends (in usd per share) $ 0.265 $ 0.25
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Cash flows from operating activities:    
Net income $ 20,486 $ 19,325
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization (including below-market ground leases) 13,486 13,175
Amortization of deferred financing costs 487 487
Amortization of stock-based compensation 1,585 884
Straight-line rental income (12) (26)
Loss on sale of real estate 192 56
Interest income distribution from other real estate investment 0 1,346
Change in operating assets and liabilities:    
Accounts and other receivables, net (100) 335
Prepaid expenses and other assets, net 278 454
Accounts payable and accrued liabilities (2,453) 482
Net cash provided by operating activities 33,949 36,518
Cash flows from investing activities:    
Acquisitions of real estate, net of deposits applied (138,151) (25,905)
Purchases of equipment, furniture and fixtures and improvements to real estate (1,319) (2,418)
Investment in real estate mortgage and other loans receivable (700) (100)
Principal payments received on real estate mortgage and other loans receivable 56 662
Repayment of other real estate investment 0 2,327
Escrow deposits for potential acquisitions of real estate 0 (1,000)
Net proceeds from sales of real estate 6,814 2,134
Net cash used in investing activities (133,300) (24,300)
Cash flows from financing activities:    
Proceeds from (costs paid for) the issuance of common stock, net 16,191  
Proceeds from (costs paid for) the issuance of common stock, net   (90)
Borrowings under unsecured revolving credit facility 120,000 15,000
Net-settle adjustment on restricted stock (1,330) (1,986)
Dividends paid on common stock (23,960) (21,532)
Net cash provided by (used in) financing activities 110,901 (8,608)
Net increase in cash and cash equivalents 11,550 3,610
Cash and cash equivalents, beginning of period 18,919 20,327
Cash and cash equivalents, end of period 30,469 23,937
Supplemental disclosures of cash flow information:    
Interest paid 1,325 2,289
Supplemental schedule of noncash investing and financing activities:    
Increase in dividends payable 1,673 2,399
Transfer of pre-acquisition costs to acquired assets 358 167
Sale of real estate settled with note receivable $ 0 $ 32,400
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.21.1
Organization
3 Months Ended
Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization ORGANIZATION
Description of Business—CareTrust REIT, Inc.’s (“CareTrust REIT” or the “Company”) primary business consists of acquiring, financing, developing and owning real property to be leased to third-party tenants in the healthcare sector. As of March 31, 2021, the Company owned and leased to independent operators, 222 skilled nursing, multi-service campuses, assisted living and independent living facilities consisting of 23,222 operational beds and units located in 28 states with the highest concentration of properties by rental revenues located in California, Texas, Louisiana, Idaho and Arizona. As of March 31, 2021, we also had other real estate investments consisting of one mezzanine loan receivable with a carrying value of $15.2 million.
The COVID-19 pandemic has led governments and other authorities around the world, including federal, state and local authorities in the United States, to impose measures intended to reduce its spread, including restrictions on freedom of movement and business operations such as travel bans, border closings, business limitations and closures (subject to exceptions for essential operations and businesses), quarantines and shelter-in-place orders. Although most of these governmental restrictions have since been lifted or scaled back, resurgences of COVID-19 and the emergence of new variants thereof have resulted in the reimposition of certain restrictions and may lead to other restrictions being reimplemented in response to efforts to reduce the spread of COVID-19. Given the dynamic nature of these circumstances and the related adverse impact these restrictions have had, and may continue to have, on the economy generally, the Company’s business, results of operations and financial condition may be adversely impacted by the COVID-19 pandemic.
The duration and extent of the COVID-19 pandemic’s effect on the Company’s operational and financial performance, and the operational and financial performance of the Company’s tenants, will depend on future developments, which are highly uncertain and cannot be predicted at this time, including new information which may emerge concerning the timing of vaccine rollouts, public acceptance and usage of vaccines and the effectiveness of vaccines in limiting the spread of COVID-19 and its variants that may continue to occur, and how quickly and to what extent normal economic and operating conditions can resume. The adverse impact of the COVID-19 pandemic on the Company’s business, results of operations and financial condition could be material.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.21.1
Basis of Presentation
3 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
Basis of Presentation BASIS OF PRESENTATION
Basis of Presentation—The accompanying condensed consolidated financial statements of the Company were prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and Article 10 of Regulation S-X. Accordingly, the condensed consolidated financial statements do not include all of the disclosures required by GAAP for a complete set of annual audited financial statements. The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020. In the opinion of management, all adjustments which are of a normal and recurring nature and considered necessary for a fair presentation of the results of the interim periods presented have been included. The results of operations for the interim periods are not necessarily indicative of results for the full year. All intercompany transactions and account balances within the Company have been eliminated.
 Recent Accounting Pronouncements— In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-04, Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”), that provides optional relief to applying reference rate reform to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”), which will be discontinued by the end of 2021. The amendments in this update are effective immediately and may be applied through December 31, 2022. The Company is still evaluating the impact of ASU 2020-04 and expects to take full advantage of the offered optional expedients and exceptions, but does not expect the adoption of the standard to have a material impact on the Company’s consolidated financial statements.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.21.1
Real Estate Investments, Net
3 Months Ended
Mar. 31, 2021
Real Estate [Abstract]  
Real Estate Investments, Net REAL ESTATE INVESTMENTS, NET
The following table summarizes the Company’s investment in owned properties as of March 31, 2021 and December 31, 2020 (dollars in thousands):
March 31, 2021December 31, 2020
Land$243,457 $205,356 
Buildings and improvements1,578,754 1,477,849 
Integral equipment, furniture and fixtures101,131 97,836 
Identified intangible assets2,658 2,352 
Real estate investments1,926,000 1,783,393 
Accumulated depreciation and amortization(348,550)(335,294)
Real estate investments, net$1,577,450 $1,448,099 
As of March 31, 2021, all 222 of the Company’s facilities were leased to various operators under triple-net leases. All of these leases contain annual escalators based on the percentage change in the Consumer Price Index (but not less than zero), some of which are subject to a cap, or fixed rent escalators.
As of March 31, 2021, the Company’s total future contractual minimum rental income for all of its tenants, excluding operating expense reimbursements, were (dollars in thousands): 
YearAmount
2021 (nine months)$132,001 
2022176,082 
2023175,777 
2024174,467 
2025174,441 
2026171,488 
Thereafter860,010 
Total$1,864,266 
Tenant Purchase Options
Certain of the Company’s operators hold purchase options allowing them to acquire properties they currently lease from the Company. A summary of these purchase options is presented below (dollars in thousands):
Asset TypePropertiesLease Expiration1st Option Open Date
Option Type(1)
Current Cash Rent(2)
ALF7October 20341/1/2021A$3,207 
SNF11November 20301/1/2022C4,800 
SNF1March 20294/1/2022
B / C(3)
766 
SNF / Campus2October 20321/1/2023B959 
SNF4November 203412/1/2024B3,789 
ALF2October 20341/1/2026A1,559 
(1) Option type includes:
A - Fixed base price plus a specified share on any appreciation.
B - Fixed base price.
C - Fixed capitalization rate on lease revenue.
(2) Based on annualized cash revenue for contracts in place at March 31, 2021.
(3) Purchase option reflects two option types.
Rental Income
The following table summarizes components of the Company’s rental income (dollars in thousands):
For the Three Months Ended March 31,
Rental Income20212020
Contractual rent due(1)
$45,171 $42,438 
Straight-line rent12 26 
Lease termination revenue(2)
63 — 
Total$45,246 $42,464 
(1) Includes initial cash rent and tenant operating expense reimbursements, as adjusted for applicable rental escalators and rent increases due to capital expenditures funded by the Company. For tenants on a cash basis, this represents the lesser of the amount that would be recognized on a straight-line basis or cash that has been received.
(2) During the three months ended March 31, 2021, in connection with the agreement to terminate its lease agreements with affiliates of Metron Integrated Health Systems (“Metron”) and to sell the facilities to a third-party, the Company received $0.1 million from Metron affiliates.
Recent Real Estate Acquisitions
The following table summarizes the Company’s acquisitions for the three months ended March 31, 2021 (dollars in thousands):
Type of Property
Purchase Price(1)
Initial Annual Cash RentNumber of Properties
Number of Beds/Units(2)
Skilled nursing$15,800 $1,492 145 
Multi-service campuses(3)
125,708 8,604 640 
Total$141,508 $10,096 785 
(1) Purchase price includes capitalized acquisition costs.
(2) The number of beds/units includes operating beds at the acquisition date.
(3) Initial annual cash rent represents the first twelve months of rent upon commencement of the Company’s long-term net leases, which is scheduled to occur upon the tenants’ receipt of licensing approval and increases to $9.4 million in the second year with Consumer Price Index (“CPI”) based annual escalators thereafter. The facilities are currently being leased back to the seller under a short-term lease with a term of less than one year.

Asset Sales and Assets Held for Sale
As of March 31, 2021, there were no assets classified as held for sale. During the fourth quarter of 2020, the Company met the criteria to classify one skilled nursing facility operated by affiliates of Five Oaks Healthcare, LLC as held for sale. Assets held for sale include the net book value of property the Company plans to sell within the next year. If the determination is made that the Company no longer expects to sell an asset within the next year, the asset is reclassified out of assets held for sale. On February 1, 2021, the Company closed on the sale of the one skilled nursing facility consisting of 90 beds located in Washington with a carrying value of $7.2 million, for net sales proceeds of $7.0 million. The Company recorded a loss of $0.2 million in connection with the sale.
On November 1, 2020, the Company sold the one remaining owned and operated independent living facility consisting of 168 units located in Texas with an aggregate carrying value of $4.2 million for gross proceeds of $4.5 million. In connection with the sale, the Company recognized a gain of $20,000 during the three months ended December 31, 2020.
On February 14, 2020, the Company closed on the sale of six skilled nursing facilities formerly operated by affiliates of Metron. In connection with the sale for $36.0 million, the Company received $3.5 million in cash and provided subsidiaries of Cascade Capital Group, LLC (“Cascade”), the purchaser of the properties, with a short-term mortgage loan secured by these properties for $32.4 million. The mortgage loan bore interest at 7.5% and initially had a maturity date of March 31, 2020. In connection with the sale, the Company recognized a loss of approximately $0.1 million. In April 2020, the mortgage loan was settled with $18.9 million in cash and a new mortgage loan for $13.9 million. In July 2020, the Company received prepayment in full, including accrued interest, for the new $13.9 million mortgage loan. See Note 4, Other Real Estate Investments, Net, for further detail on the new mortgage loan.

Lease Amendments
Twenty/20 Lease Termination and New Noble Master Lease. On December 1, 2020, five assisted living facilities in Virginia operated by Twenty/20 Management, Inc. (“Twenty/20”) were transferred to affiliates of Noble VA Holdings, LLC (“Noble”). In connection with the transfer, the Company entered into a new triple-net master lease with Noble. The new lease has a remaining initial term of approximately 14 years, with two five-year renewal options and CPI-based rent escalators. Initial annual cash rent under the new lease is approximately $3.2 million.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.21.1
Other Real Estate Investments, Net
3 Months Ended
Mar. 31, 2021
Real Estate [Abstract]  
Other Real Estate Investments, Net OTHER REAL ESTATE INVESTMENTS, NET
Mezzanine Loan Receivable—In November 2020, the Company provided Next VA Star Realty Holdings, LLC a mezzanine loan for nine skilled nursing facilities secured by membership interests in affiliates of Next VA Star Realty Holdings, LLC for approximately $15.0 million, at an annual interest rate of 12%. The loan requires monthly interest payments, is set to mature on November 30, 2025, and may (subject to certain restrictions) be prepaid before the maturity date if paid in full and for an exit fee ranging from 1% to 3% of the loan plus unpaid interest payments equal to 24 months (less the amount of monthly interest payments made by the borrower through the date of prepayment). During the three months ended March 31, 2021, the Company recognized $0.5 million of interest income related to its mezzanine loan.
Mortgage Loans Receivable—In July 2019, the Company provided MCRC, LLC a real estate loan secured by a 176-bed skilled nursing facility in Manteca, California for $3.0 million, which bore a fixed interest rate of 8% and required monthly interest payments. Concurrently, the Company entered into a purchase and sale agreement to purchase the Manteca facility from MCRC, LLC for approximately $16.4 million subject to normal diligence and other contingencies. The loan documents provided for a maturity date of the earlier to occur of the closing date of the acquisition, or five business days following the termination of the purchase and sale agreement.  MCRC, LLC breached its obligation to sell the Manteca facility to the Company on the terms outlined in the purchase and sale agreement and to repay the real estate loan upon its stated maturity. As a result, the Company commenced non-judicial foreclosure proceedings with respect to the Manteca facility. In January 2020, the borrower further collateralized the loan by causing one of its affiliates to grant the Company a deed of trust in the real estate and improvements that constitute Palm Gardens Assisted Living Facility in Yolo County, California. During the three months ended June 30, 2020, payment for the loan principal and accrued interest, including default interest, as well as reimbursement for attorney’s fees and certain other costs of suit, were received in full by the Company and, as a result, the Company withdrew all foreclosure-related proceedings related to the Manteca facility loan.
In September 2019, the Company provided affiliates of CommuniCare a $26.5 million loan secured by mortgages on the three skilled nursing facilities sold to CommuniCare, which bore a fixed interest rate of 10%. The mortgage loan, which required CommuniCare to make monthly interest payments, was set to mature on February 29, 2020 and included an option to be prepaid before the maturity date. In January 2020, the Company amended the mortgage loan’s maturity date to April 30, 2020. In April 2020, the Company amended the mortgage loan’s maturity date to May 29, 2020. During the three months ended June 30, 2020, payment for the mortgage loan and accrued interest was received in full by the Company.
In February 2020, the Company provided subsidiaries of Cascade a $32.4 million loan secured by mortgages on the six skilled nursing facilities formerly operated by affiliates of Metron sold to Cascade in February 2020, as discussed in Note 3, Real Estate Investments, Net. The mortgage loan bore interest at 7.5% and initially had a maturity date of March 31, 2020. In April 2020, the mortgage loan was settled in connection with a new mortgage loan transaction between the Company and a third-party institutional lender as co-lenders, pursuant to which the Company received $18.9 million in cash and a new mortgage loan for $13.9 million. The new mortgage loan with Cascade was secured by the same six skilled nursing facilities purchased by Cascade and was for a combined principal amount of $33.9 million, with the Company’s $13.9 million portion of the indebtedness initially bearing interest at a variable rate equal to LIBOR plus 4.00%, subject to a LIBOR floor of 1.75%. The new mortgage loan had a maturity date of April 29, 2022 and included two six-month extension options. In July 2020, prepayment for the mortgage loan of $13.9 million and accrued interest was received in full by the Company.
As of March 31, 2021, the Company had no remaining mortgage loan receivables.
During the three months ended March 31, 2021 and 2020, the Company recognized no interest income and $1.1 million of interest income, respectively, related to its mortgage loans. During both the three months ended March 31, 2021 and 2020, the Company recognized $0.1 million of interest income related to its other loans receivable.
Preferred Equity Investments—In September 2016, the Company completed a $2.3 million preferred equity investment with an affiliate of Cascadia Development, LLC. The preferred equity investment yielded a return equal to prime plus 9.5% but in no event less than 12.0% calculated on a quarterly basis on the outstanding carrying value of the investment. The investment was used to develop a 99-bed skilled nursing facility in Boise, Idaho. In connection with its investment, the Company obtained an option to purchase the development at a fixed-formula price upon stabilization, with an initial lease yield of at least 9.0%. The project was completed in the first quarter of 2018 and began lease-up during the second quarter of 2018. In January 2020, the Company purchased the skilled nursing facility for approximately $18.7 million, inclusive of transaction costs. The Company paid $15.0 million after receiving back its initial investment of $2.3 million and cumulative contractual preferred return through January 17, 2020, the acquisition date, of $1.4 million, of which less than $0.1 million was recognized as interest income during the three months ended March 31, 2020. The Company did not recognize any interest income during the three months ended March 31, 2021 related to preferred equity investments. As of March 31, 2021, the Company had no remaining preferred equity investments.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements
3 Months Ended
Mar. 31, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements FAIR VALUE MEASUREMENTS
The Company determines fair value based on quoted prices when available or through the use of alternative approaches, such as discounting the expected cash flows using market interest rates commensurate with the credit quality and duration of the investment. GAAP guidance defines three levels of inputs that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability or can be corroborated with observable market data for substantially the entire contractual term of the asset or liability.

Level 3 – Unobservable inputs reflect the entity’s own assumptions about the assumptions that market participants would use in the pricing of the asset or liability and are consequently not based on market activity, but rather through particular valuation techniques.

The determination of where an asset or liability falls in the hierarchy requires significant judgment and considers factors specific to the asset or liability. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company evaluates its hierarchy disclosures each quarter and, depending on various factors, it is possible that an asset or liability may be classified differently from quarter to quarter. Changes in the type of inputs may result in a reclassification for certain assets. The Company does not expect that changes in classifications between levels will be frequent.
Items Measured at Fair Value on a Recurring Basis
The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020, aggregated by the level in the fair value hierarchy within which those instruments fall (dollars in thousands):
Level 1Level 2Level 3
Balance as of March 31, 2021
Assets:
Mezzanine loan receivable$— $— $15,155 $15,155 

Level 1Level 2Level 3
Balance as of December 31, 2020
Assets:
Mezzanine loan receivable$— $— $15,000 $15,000 
Mezzanine loan receivable: The fair value of the mezzanine loan receivable was estimated using an internal valuation model that considered the expected future cash flows of the investment, the underlying collateral value, market interest rates and other credit enhancements. As such, the Company classifies the instrument as Level 3 due to the significant unobservable inputs used in determining market interest rates for investments with similar terms. Future changes in market interest rates could materially impact the estimated discounted cash flows. As of March 31, 2021 and December 31, 2020, the Company did not have any loans that were 90 days or more past due.
For the three months ended March 31, 2021, there were no changes in assets and liabilities with Level 3 inputs in the fair value hierarchy.

Items Disclosed at Fair Value

Considerable judgment is necessary to estimate the fair value disclosure of financial instruments. The estimates of fair value presented herein are not necessarily indicative of the amounts that could be realized upon disposition of the financial instruments. A summary of the face values, carrying amounts and fair values of the Company’s financial instruments as of March 31, 2021 and December 31, 2020 using Level 2 inputs for the Notes (as defined in Note 6, Debt, below), is as follows (dollars in thousands):  

 March 31, 2021December 31, 2020
 LevelFace
Value
Carrying
Amount
Fair
Value
Face
Value
Carrying
Amount
Fair
Value
Financial liabilities:
Senior unsecured notes payable2$300,000 $296,858 $309,000 $300,000 $296,669 $311,430 

Cash and cash equivalents, accounts and other receivables, other loans receivable, and accounts payable and accrued liabilities: These balances approximate their fair values due to the short-term nature of these instruments.

Unsecured revolving credit facility and senior unsecured term loan: The fair values approximate their carrying values as the interest rates are variable and approximate prevailing market interest rates for similar debt arrangements.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.21.1
Debt
3 Months Ended
Mar. 31, 2021
Debt Disclosure [Abstract]  
Debt DEBT
The following table summarizes the balance of the Company’s indebtedness as of March 31, 2021 and December 31, 2020 (dollars in thousands):
March 31, 2021December 31, 2020
Principal AmountDeferred Loan FeesCarrying ValuePrincipal AmountDeferred Loan FeesCarrying Value
Senior unsecured notes payable$300,000 $(3,142)$296,858 $300,000 $(3,331)$296,669 
Senior unsecured term loan200,000 (1,022)198,978 200,000 (1,075)198,925 
Unsecured revolving credit facility170,000 — 170,000 50,000 — 50,000 
$670,000 $(4,164)$665,836 $550,000 $(4,406)$545,594 
Senior Unsecured Notes Payable
On May 10, 2017, the Company’s wholly owned subsidiary, CTR Partnership, L.P. (the “Operating Partnership”), and its wholly owned subsidiary, CareTrust Capital Corp. (together with the Operating Partnership, the “Issuers”), completed an underwritten public offering of $300.0 million aggregate principal amount of 5.25% Senior Notes due 2025 (the “Notes”). The Notes were issued at par, resulting in gross proceeds of $300.0 million and net proceeds of approximately $294.0 million after deducting underwriting fees and other offering expenses. The Notes mature on June 1, 2025 and bear interest at a rate of 5.25% per year. Interest on the Notes is payable on June 1 and December 1 of each year.
As of June 1, 2020, the Issuers may redeem the Notes any time at the redemption prices set forth in the indenture. As of March 31, 2021, the Issuers have not elected to redeem any of the Notes. If certain changes of control of the Company occur, holders of the Notes will have the right to require the Issuers to repurchase their Notes at 101% of the principal amount plus accrued and unpaid interest, if any, to, but not including, the repurchase date.
The obligations under the Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by the Company and certain of the Company’s wholly owned existing and, subject to certain exceptions, future material subsidiaries (other than the Issuers); provided, however, that such guarantees are subject to automatic release under certain customary circumstances.
The indenture contains customary covenants such as limiting the ability of the Company and its restricted subsidiaries to: incur or guarantee additional indebtedness; incur or guarantee secured indebtedness; pay dividends or distributions on, or redeem or repurchase, capital stock; make certain investments or other restricted payments; sell assets; enter into transactions with affiliates; merge or consolidate or sell all or substantially all of their assets; and create restrictions on the ability of the Issuers and their restricted subsidiaries to pay dividends or other amounts to the Issuers. The indenture also requires the Company and its restricted subsidiaries to maintain a specified ratio of unencumbered assets to unsecured indebtedness. These covenants are subject to a number of important and significant limitations, qualifications and exceptions. The indenture also contains customary events of default.
As of March 31, 2021, the Company was in compliance with all applicable financial covenants under the indenture.

Unsecured Revolving Credit Facility and Term Loan
On February 8, 2019, the Operating Partnership, as the borrower, the Company, as guarantor, CareTrust GP, LLC, and certain of the Operating Partnership’s wholly owned subsidiaries entered into an amended and restated credit and guaranty agreement with KeyBank National Association, as administrative agent, an issuing bank and swingline lender, and the lenders party thereto (the “Amended Credit Agreement”). The Amended Credit Agreement provides for: (i) an unsecured revolving credit facility (the “Revolving Facility”) with revolving commitments in an aggregate principal amount of $600.0 million, including a letter of credit subfacility for 10% of the then available revolving commitments and a swingline loan subfacility for 10% of the then available revolving commitments and (ii) an unsecured term loan credit facility (the “Term Loan” and, together with the Revolving Facility, the “Amended Credit Facility”) in an aggregate principal amount of $200.0 million. Borrowing availability under the Revolving Facility is subject to no default or event of default under the Amended Credit Agreement having occurred at the time of borrowing. The proceeds of the Term Loan were used, in part, to repay in full all outstanding borrowings under the Company’s prior term loan and revolving facility under its prior credit agreement. Future borrowings under the Amended Credit Facility will be used for working capital purposes, for capital expenditures, to fund acquisitions and for general corporate purposes.
The interest rates applicable to loans under the Revolving Facility are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.10% to 0.55% per annum or LIBOR plus a margin ranging from 1.10% to 1.55% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). The interest rates applicable to loans under the Term Loan are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.50% to 1.20% per annum or LIBOR plus a margin ranging from 1.50% to 2.20% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). In addition, the Operating Partnership will pay a facility fee on the revolving commitments under the Revolving Facility ranging from 0.15% to 0.35% per annum, based on the debt to asset value ratio of the Company and its consolidated subsidiaries (unless the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt and the Operating Partnership elects to decrease the applicable margin as described above, in which case the Operating Partnership will pay a facility fee on the revolving commitments ranging from 0.125% to 0.30% per annum based on the credit ratings of the Company’s senior long-term unsecured debt). As of March 31, 2021, the Operating Partnership had $200.0 million outstanding under the Term Loan and $170.0 million of borrowings outstanding under the Revolving Facility.
The Revolving Facility has a maturity date of February 8, 2023, and includes, at the sole discretion of the Operating Partnership, two, six-month extension options. The Term Loan has a maturity date of February 8, 2026.
The Amended Credit Facility is guaranteed, jointly and severally, by the Company and its wholly owned subsidiaries that are party to the Amended Credit Agreement (other than the Operating Partnership). The Amended Credit Agreement contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend organizational documents and pay certain dividends and other restricted
payments. The Amended Credit Agreement requires the Company to comply with financial maintenance covenants to be tested quarterly, consisting of a maximum debt to asset value ratio, a minimum fixed charge coverage ratio, a minimum tangible net worth, a maximum cash distributions to operating income ratio, a maximum secured debt to asset value ratio, a maximum secured recourse debt to asset value ratio, a maximum unsecured debt to unencumbered properties asset value ratio, a minimum unsecured interest coverage ratio and a minimum rent coverage ratio. The Amended Credit Agreement also contains certain customary events of default, including the failure to make timely payments under the Amended Credit Facility or other material indebtedness, the failure to satisfy certain covenants (including the financial maintenance covenants), the occurrence of change of control and specified events of bankruptcy and insolvency.
As of March 31, 2021, the Company was in compliance with all applicable financial covenants under the Amended Credit Agreement.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.21.1
Equity
3 Months Ended
Mar. 31, 2021
Equity [Abstract]  
Equity EQUITY
Common Stock
At-The-Market Offering—On March 10, 2020, the Company entered into a new equity distribution agreement to issue and sell, from time to time, up to $500.0 million in aggregate offering price of its common stock through an “at-the-market” equity offering program (the “New ATM Program”). In connection with the entry into the equity distribution agreement and the commencement of the New ATM Program, the Company’s “at-the-market” equity offering program pursuant to the Company’s prior equity distribution agreement, dated as of March 4, 2019, was terminated (the “Prior ATM Program”).
There was no Prior ATM Program or New ATM Program activity for the three months ended March 31, 2020. The following table summarizes the New ATM Program activity for the three months ended March 31, 2021 (in thousands, except per share amounts).
For the Three Months Ended
March 31, 2021
Number of shares702 
Average sales price per share$23.62 
Gross proceeds(1)
$16,579 
(1) Total gross proceeds is before $0.2 million of commissions paid to the sales agents during the three months ended March 31, 2021 under the New ATM Program.
As of March 31, 2021, the Company had $483.4 million available for future issuances under the New ATM Program.
Share Repurchase Program—On March 20, 2020, the Company’s Board of Directors authorized a share repurchase program to repurchase up to $150.0 million of outstanding shares of the Company’s common stock (the “Repurchase Program”). Repurchases under the Repurchase Program, which expires on March 31, 2023, may be made through open market purchases, privately negotiated transactions, structured or derivative transactions, including accelerated share repurchase transactions, or other methods of acquiring shares, in each case subject to market conditions and at such times as shall be permitted by applicable securities laws and determined by management. Repurchases under the Repurchase Program may also be made pursuant to a plan adopted under Rule 10b5-1 promulgated under the Exchange Act. The Company expects to finance any share repurchases under the Repurchase Program using available cash and may also use short-term borrowings under the Revolving Facility. The Company did not repurchase any shares of common stock under the Repurchase Program during the three months ended March 31, 2021 and 2020. The Repurchase Program may be modified, discontinued or suspended at any time.
Dividends on Common Stock—The following table summarizes the cash dividends on the Company’s common stock declared by the Company’s Board of Directors for the first three months of 2021 (dollars in thousands, except per share amounts):
For the Three Months Ended
March 31, 2021
Dividends declared per share$0.265 
Dividends payment dateApril 15, 2021
Dividends payable as of record date$25,633 
Dividends record dateMarch 31, 2021
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-Based Compensation
3 Months Ended
Mar. 31, 2021
Share-based Payment Arrangement [Abstract]  
Stock-Based Compensation STOCK-BASED COMPENSATION
All stock-based awards are subject to the terms of the CareTrust REIT, Inc. and CTR Partnership, L.P. Incentive Award Plan (the “Plan”). The Plan provides for the granting of stock-based compensation, including stock options, restricted stock, performance awards, restricted stock units and other incentive awards to officers, employees and directors in connection with their employment with or services provided to the Company.
Restricted Stock Awards—In connection with the separation of the healthcare business and real estate business of the Ensign Group, Inc. (“Ensign”) into two separate and independently publicly traded companies (the “Spin-Off”) on June 1, 2014, employees of Ensign who had unvested shares of restricted stock were given one share of CareTrust REIT unvested restricted stock totaling 207,580 shares at the Spin-Off. These restricted shares were subject to a time vesting provision only and the Company did not recognize any stock compensation expense associated with these awards. During the year ended December 31, 2020, 1,760 shares were forfeited. At March 31, 2021, there were no unvested restricted stock awards outstanding.
In January 2021 and February 2021, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted 140,514 and 99,189 shares of restricted stock, respectively, to officers and employees. Each share had a fair market value on the date of grant of $22.48 and $22.18 per share, respectively, based on the closing market price of the Company’s common stock on that date, and the shares vest in three equal annual installments beginning on the first anniversary of the grant date.
In January 2021, the Compensation Committee granted 108,414 performance stock awards to officers. Each share had a fair market value on the date of grant of $22.48 per share, based on the closing market price of the Company’s common stock on that date. Performance stock awards are subject to both time and performance based conditions and vest over a one-to three-year period. The amount of such performance awards that will ultimately vest is dependent on the Company’s Normalized Funds from Operations (“NFFO”) per share, as defined by the Compensation Committee, meeting or exceeding a specified per share amount for the applicable vesting period.
Additionally, in February 2021, the Compensation Committee granted 99,189 performance stock awards to officers. Each share had an estimated fair market value on the date of grant of $27.98 per share. Performance stock awards are subject to both time and performance based conditions and cliff vest over a three-year period. The amount of such performance awards that will ultimately vest is dependent on the Company’s total shareholder return (“TSR”) performance relative to a custom TSR peer group consisting of 16 other publicly traded healthcare REITs and will range from 0% to 200% of the TSR awards initially granted. Compensation expense for awards with performance-based vesting conditions is recognized based upon the grant date fair value per share for each component multiplied by the estimated number of performance stock awards to be earned after considering the Company’s expectation of future performance and is recognized provided that the requisite service is rendered, regardless of when, if ever, the market condition is satisfied. Forfeitures of stock-based awards are recognized as they occur.
The fair value of the TSR-based performance stock awards is estimated on the date of the grant using a Monte Carlo valuation model. The risk-free rate is based on the U.S. Treasury yield curve in effect at the grant date for the expected performance period. Expected volatility is based on historical volatility for the most recent 2.84 year period ending on the grant date for the Company and the selected TSR peer group, and is calculated on a daily basis. The following are the key assumptions used in this valuation:
For the Three Months Ended March 31, 2021
Risk free interest rate0.27 %
Expected stock price volatility52.93 %
Expected service period2.84 years
Expected dividend yield (assuming full reinvestment)— %
The following table summarizes the stock-based compensation expense recognized (dollars in thousands):
 For the Three Months Ended March 31,
 20212020
Stock-based compensation expense$1,585 $884 
As of March 31, 2021, there was $14.5 million of unamortized stock-based compensation expense related to unvested awards and the weighted-average remaining vesting period of such awards was 2.5 years.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.21.1
Earnings Per Common Share
3 Months Ended
Mar. 31, 2021
Earnings Per Share [Abstract]  
Earnings Per Common Share EARNINGS PER COMMON SHARE
The following table presents the calculation of basic and diluted earnings per common share (“EPS”) for the Company’s common stock for the three months ended March 31, 2021 and 2020, and reconciles the weighted-average common shares outstanding used in the calculation of basic EPS to the weighted-average common shares outstanding used in the calculation of diluted EPS (amounts in thousands, except per share amounts):
 
 For the Three Months Ended March 31,
 20212020
Numerator:
Net income$20,486 $19,325 
Less: Net income allocated to participating securities(119)(75)
Numerator for basic and diluted earnings available to common stockholders$20,367 $19,250 
Denominator:
Weighted-average basic common shares outstanding95,378 95,161 
Weighted-average diluted common shares outstanding95,385 95,161 
Earnings per common share, basic$0.21 $0.20 
Earnings per common share, diluted$0.21 $0.20 
The Company’s unvested restricted shares associated with its incentive award plan and unvested restricted shares issued to employees of Ensign at the Spin-Off have been excluded from the above calculation of earnings per diluted share for the three months ended March 31, 2021 and 2020, when their inclusion would have been anti-dilutive.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies COMMITMENTS AND CONTINGENCIESThe Company and its subsidiaries are and may become from time to time a party to various claims and lawsuits arising in the ordinary course of business, which are not individually or in the aggregate anticipated to have a material adverse effect on the Company’s results of operations, financial condition or cash flows. Claims and lawsuits may include matters involving general or professional liability asserted against the Company’s tenants, which are the responsibility of the
Company’s tenants and for which the Company is entitled to be indemnified by its tenants under the insurance and indemnification provisions in the applicable leases.
Capital expenditures for each property leased under the Company’s triple-net leases are generally the responsibility of the tenant, except that, for the facilities leased to subsidiaries of Ensign and The Pennant Group, Inc. (“Pennant”), the tenant will have an option to require the Company to finance certain capital expenditures up to an aggregate of 20% of the Company’s initial investment in such property, subject to a corresponding rent increase at the time of funding. For the Company’s other triple-net master leases, subject to approval by the Company, the tenants may request capital expenditure funding that would generally be subject to a corresponding rent increase at the time of funding and which are subject to tenant compliance with the conditions to the Company’s approval and funding of their requests. As of March 31, 2021, the Company had committed to fund certain capital improvements at certain triple-net leased facilities totaling $14.1 million, of which $13.1 million is subject to rent increase at the time of funding.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.21.1
Concentration of Risk
3 Months Ended
Mar. 31, 2021
Risks and Uncertainties [Abstract]  
Concentration of Risk CONCENTRATION OF RISK
Major operator concentrations – As of March 31, 2021, Ensign leased 89 skilled nursing, multi-service campuses, assisted living and independent living facilities which had a total of 9,551 beds and units and are located in Arizona, California, Colorado, Idaho, Iowa, Nebraska, Nevada, Texas, Utah and Washington. The four states in which Ensign leases the highest concentration of properties by rental revenues as of March 31, 2021 are Texas, California, Arizona and Utah. During both the three months ended March 31, 2021 and 2020, Ensign represented 32% of the Company’s rental income, exclusive of operating expense reimbursements.
Ensign is subject to the registration and reporting requirements of the SEC and is required to file with the SEC annual reports containing audited financial information and quarterly reports containing unaudited financial information. Ensign’s financial statements, as filed with the SEC, can be found at http://www.sec.gov. The Company has not verified this information through an independent investigation or otherwise.
As of March 31, 2021, Priority Management Group (“PMG”) leased 15 skilled nursing and campus facilities which had a total of 2,144 beds and units, and are located in Louisiana and Texas. During both the three months ended March 31, 2021 and 2020, PMG represented 16% of the Company’s rental income, exclusive of operating expense reimbursements.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.21.1
Subsequent Events
3 Months Ended
Mar. 31, 2021
Subsequent Events [Abstract]  
Subsequent Events SUBSEQUENT EVENTS
The Company evaluates subsequent events in accordance with ASC 855, Subsequent Events. The Company evaluates subsequent events up until the date the condensed consolidated financial statements are issued.
Recent Acquisition
In April 2021, the Company acquired one skilled nursing facility with the Company’s existing tenant Bayshire, LLC (“Bayshire”). The amended lease with Bayshire has a remaining term of approximately 13 years. The purchase price for the facility was approximately $9.7 million, which includes an estimated purchase price and capitalized acquisition costs. The estimated contractual initial annual cash rent from the acquisition is approximately $0.8 million and increases to $0.9 million in the second year with CPI-based annual escalators thereafter. The acquisition was funded using cash on hand.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.21.1
Basis of Presentation (Policies)
3 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
Basis of Presentation Basis of Presentation—The accompanying condensed consolidated financial statements of the Company were prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and Article 10 of Regulation S-X. Accordingly, the condensed consolidated financial statements do not include all of the disclosures required by GAAP for a complete set of annual audited financial statements. The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020. In the opinion of management, all adjustments which are of a normal and recurring nature and considered necessary for a fair presentation of the results of the interim periods presented have been included. The results of operations for the interim periods are not necessarily indicative of results for the full year. All intercompany transactions and account balances within the Company have been eliminated.
Recent Accounting Pronouncements Recent Accounting Pronouncements— In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-04, Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”), that provides optional relief to applying reference rate reform to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”), which will be discontinued by the end of 2021. The amendments in this update are effective immediately and may be applied through December 31, 2022. The Company is still evaluating the impact of ASU 2020-04 and expects to take full advantage of the offered optional expedients and exceptions, but does not expect the adoption of the standard to have a material impact on the Company’s consolidated financial statements.
Fair Value Measurements
The Company determines fair value based on quoted prices when available or through the use of alternative approaches, such as discounting the expected cash flows using market interest rates commensurate with the credit quality and duration of the investment. GAAP guidance defines three levels of inputs that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability or can be corroborated with observable market data for substantially the entire contractual term of the asset or liability.

Level 3 – Unobservable inputs reflect the entity’s own assumptions about the assumptions that market participants would use in the pricing of the asset or liability and are consequently not based on market activity, but rather through particular valuation techniques.

The determination of where an asset or liability falls in the hierarchy requires significant judgment and considers factors specific to the asset or liability. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company evaluates its hierarchy disclosures each quarter and, depending on various factors, it is possible that an asset or liability may be classified differently from quarter to quarter. Changes in the type of inputs may result in a reclassification for certain assets. The Company does not expect that changes in classifications between levels will be frequent.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.21.1
Real Estate Investments, Net (Tables)
3 Months Ended
Mar. 31, 2021
Real Estate [Abstract]  
Summary of Investment in Owned Properties
The following table summarizes the Company’s investment in owned properties as of March 31, 2021 and December 31, 2020 (dollars in thousands):
March 31, 2021December 31, 2020
Land$243,457 $205,356 
Buildings and improvements1,578,754 1,477,849 
Integral equipment, furniture and fixtures101,131 97,836 
Identified intangible assets2,658 2,352 
Real estate investments1,926,000 1,783,393 
Accumulated depreciation and amortization(348,550)(335,294)
Real estate investments, net$1,577,450 $1,448,099 
Schedule of Total Future Contractual Minimum Rental Income
As of March 31, 2021, the Company’s total future contractual minimum rental income for all of its tenants, excluding operating expense reimbursements, were (dollars in thousands): 
YearAmount
2021 (nine months)$132,001 
2022176,082 
2023175,777 
2024174,467 
2025174,441 
2026171,488 
Thereafter860,010 
Total$1,864,266 
Schedule Of Tenant Purchase Options
Certain of the Company’s operators hold purchase options allowing them to acquire properties they currently lease from the Company. A summary of these purchase options is presented below (dollars in thousands):
Asset TypePropertiesLease Expiration1st Option Open Date
Option Type(1)
Current Cash Rent(2)
ALF7October 20341/1/2021A$3,207 
SNF11November 20301/1/2022C4,800 
SNF1March 20294/1/2022
B / C(3)
766 
SNF / Campus2October 20321/1/2023B959 
SNF4November 203412/1/2024B3,789 
ALF2October 20341/1/2026A1,559 
(1) Option type includes:
A - Fixed base price plus a specified share on any appreciation.
B - Fixed base price.
C - Fixed capitalization rate on lease revenue.
(2) Based on annualized cash revenue for contracts in place at March 31, 2021.
(3) Purchase option reflects two option types.
Schedule of Rental Income
The following table summarizes components of the Company’s rental income (dollars in thousands):
For the Three Months Ended March 31,
Rental Income20212020
Contractual rent due(1)
$45,171 $42,438 
Straight-line rent12 26 
Lease termination revenue(2)
63 — 
Total$45,246 $42,464 
(1) Includes initial cash rent and tenant operating expense reimbursements, as adjusted for applicable rental escalators and rent increases due to capital expenditures funded by the Company. For tenants on a cash basis, this represents the lesser of the amount that would be recognized on a straight-line basis or cash that has been received.
(2) During the three months ended March 31, 2021, in connection with the agreement to terminate its lease agreements with affiliates of Metron Integrated Health Systems (“Metron”) and to sell the facilities to a third-party, the Company received $0.1 million from Metron affiliates.
Schedule of Real Estate Acquisitions
The following table summarizes the Company’s acquisitions for the three months ended March 31, 2021 (dollars in thousands):
Type of Property
Purchase Price(1)
Initial Annual Cash RentNumber of Properties
Number of Beds/Units(2)
Skilled nursing$15,800 $1,492 145 
Multi-service campuses(3)
125,708 8,604 640 
Total$141,508 $10,096 785 
(1) Purchase price includes capitalized acquisition costs.
(2) The number of beds/units includes operating beds at the acquisition date.
(3) Initial annual cash rent represents the first twelve months of rent upon commencement of the Company’s long-term net leases, which is scheduled to occur upon the tenants’ receipt of licensing approval and increases to $9.4 million in the second year with Consumer Price Index (“CPI”) based annual escalators thereafter. The facilities are currently being leased back to the seller under a short-term lease with a term of less than one year.
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements (Tables)
3 Months Ended
Mar. 31, 2021
Fair Value Disclosures [Abstract]  
Schedule of Items Measured at Fair Value on a Recurring Basis
The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020, aggregated by the level in the fair value hierarchy within which those instruments fall (dollars in thousands):
Level 1Level 2Level 3
Balance as of March 31, 2021
Assets:
Mezzanine loan receivable$— $— $15,155 $15,155 

Level 1Level 2Level 3
Balance as of December 31, 2020
Assets:
Mezzanine loan receivable$— $— $15,000 $15,000 
Summary of Face Value, Carrying Amount and Fair Value of Financial Instruments A summary of the face values, carrying amounts and fair values of the Company’s financial instruments as of March 31, 2021 and December 31, 2020 using Level 2 inputs for the Notes (as defined in Note 6, Debt, below), is as follows (dollars in thousands):  
 March 31, 2021December 31, 2020
 LevelFace
Value
Carrying
Amount
Fair
Value
Face
Value
Carrying
Amount
Fair
Value
Financial liabilities:
Senior unsecured notes payable2$300,000 $296,858 $309,000 $300,000 $296,669 $311,430 
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.21.1
Debt (Tables)
3 Months Ended
Mar. 31, 2021
Debt Disclosure [Abstract]  
Schedule of Debt Instruments
The following table summarizes the balance of the Company’s indebtedness as of March 31, 2021 and December 31, 2020 (dollars in thousands):
March 31, 2021December 31, 2020
Principal AmountDeferred Loan FeesCarrying ValuePrincipal AmountDeferred Loan FeesCarrying Value
Senior unsecured notes payable$300,000 $(3,142)$296,858 $300,000 $(3,331)$296,669 
Senior unsecured term loan200,000 (1,022)198,978 200,000 (1,075)198,925 
Unsecured revolving credit facility170,000 — 170,000 50,000 — 50,000 
$670,000 $(4,164)$665,836 $550,000 $(4,406)$545,594 
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.21.1
Equity (Tables)
3 Months Ended
Mar. 31, 2021
Equity [Abstract]  
Summary of the At-The-Market Offering Program The following table summarizes the New ATM Program activity for the three months ended March 31, 2021 (in thousands, except per share amounts).
For the Three Months Ended
March 31, 2021
Number of shares702 
Average sales price per share$23.62 
Gross proceeds(1)
$16,579 
(1) Total gross proceeds is before $0.2 million of commissions paid to the sales agents during the three months ended March 31, 2021 under the New ATM Program.
Schedule of Dividends on Common Stock The following table summarizes the cash dividends on the Company’s common stock declared by the Company’s Board of Directors for the first three months of 2021 (dollars in thousands, except per share amounts):
For the Three Months Ended
March 31, 2021
Dividends declared per share$0.265 
Dividends payment dateApril 15, 2021
Dividends payable as of record date$25,633 
Dividends record dateMarch 31, 2021
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of Valuation Assumptions The following are the key assumptions used in this valuation:
For the Three Months Ended March 31, 2021
Risk free interest rate0.27 %
Expected stock price volatility52.93 %
Expected service period2.84 years
Expected dividend yield (assuming full reinvestment)— %
Schedule of Stock-Based Compensation Expense
The following table summarizes the stock-based compensation expense recognized (dollars in thousands):
 For the Three Months Ended March 31,
 20212020
Stock-based compensation expense$1,585 $884 
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.21.1
Earnings Per Common Share (Tables)
3 Months Ended
Mar. 31, 2021
Earnings Per Share [Abstract]  
Reconciliation of Weighted-Average Common Shares Outstanding Used in Calculation of Basic EPS to Diluted EPS
The following table presents the calculation of basic and diluted earnings per common share (“EPS”) for the Company’s common stock for the three months ended March 31, 2021 and 2020, and reconciles the weighted-average common shares outstanding used in the calculation of basic EPS to the weighted-average common shares outstanding used in the calculation of diluted EPS (amounts in thousands, except per share amounts):
 
 For the Three Months Ended March 31,
 20212020
Numerator:
Net income$20,486 $19,325 
Less: Net income allocated to participating securities(119)(75)
Numerator for basic and diluted earnings available to common stockholders$20,367 $19,250 
Denominator:
Weighted-average basic common shares outstanding95,378 95,161 
Weighted-average diluted common shares outstanding95,385 95,161 
Earnings per common share, basic$0.21 $0.20 
Earnings per common share, diluted$0.21 $0.20 
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.21.1
Organization (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2021
USD ($)
state
bed
facility
Dec. 31, 2020
USD ($)
Real Estate Properties [Line Items]    
Number of states with properties | state 28  
Other real estate investments, net | $ $ 15,155 $ 15,000
Skilled nursing, multi-service campuses, assisted living and independent living facilities    
Real Estate Properties [Line Items]    
Number of facilities | facility 222  
Number of operational beds and units in facilities | bed 23,222  
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.21.1
Real Estate Investments, Net - Narrative (Details)
Mar. 31, 2021
facility
Skilled nursing, multi-service campuses, assisted living and independent living facilities  
Real Estate [Line Items]  
Number of facilities 222
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.21.1
Real Estate Investments, Net - Investment in Owned Properties (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Real Estate [Abstract]    
Land $ 243,457 $ 205,356
Buildings and improvements 1,578,754 1,477,849
Integral equipment, furniture and fixtures 101,131 97,836
Identified intangible assets 2,658 2,352
Real estate investments 1,926,000 1,783,393
Accumulated depreciation and amortization (348,550) (335,294)
Real estate investments, net $ 1,577,450 $ 1,448,099
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.21.1
Real Estate Investments, Net - Future Contractual Minimum Rental Income (Details)
$ in Thousands
Mar. 31, 2021
USD ($)
Future Contractual Minimum Rental Income  
2021 (nine months) $ 132,001
2022 176,082
2023 175,777
2024 174,467
2025 174,441
2026 171,488
Thereafter 860,010
Total $ 1,864,266
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.21.1
Real Estate Investments, Net - Tenant Purchase Options (Details)
$ in Thousands
Mar. 31, 2021
USD ($)
property
ALF | Lease Expiration October 2034, First option 2021  
Lessor, Lease, Description [Line Items]  
Properties | property 7
Current Cash Rent | $ $ 3,207
ALF | Lease Expiration October 2034, First option 2026  
Lessor, Lease, Description [Line Items]  
Properties | property 2
Current Cash Rent | $ $ 1,559
SNF | Lease Expiration November 2030, First option 2022  
Lessor, Lease, Description [Line Items]  
Properties | property 11
Current Cash Rent | $ $ 4,800
SNF | Lease Expiration March 2029, First option 2022  
Lessor, Lease, Description [Line Items]  
Properties | property 1
Current Cash Rent | $ $ 766
SNF | Lease Expiration November 2034, First option 2024  
Lessor, Lease, Description [Line Items]  
Properties | property 4
Current Cash Rent | $ $ 3,789
SNF / Campus | Lease Expiration October 2032, First option 2023  
Lessor, Lease, Description [Line Items]  
Properties | property 2
Current Cash Rent | $ $ 959
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.21.1
Real Estate Investments, Net - Rental Income (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Lessor, Lease, Description [Line Items]    
Contractual rent due $ 45,171 $ 42,438
Straight-line rent 12 26
Lease termination revenue 63 0
Total rental income 45,246 $ 42,464
Metron affiliates    
Lessor, Lease, Description [Line Items]    
Lease termination revenue $ 100  
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.21.1
Real Estate Investments, Net - Recent Real Estate Acquisitions (Details)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2020
USD ($)
Mar. 31, 2021
USD ($)
property
unit
Dec. 31, 2022
USD ($)
Business Acquisition [Line Items]      
Purchase Price   $ 141,508  
Initial Annual Cash Rent   $ 10,096  
Number of Properties | property   5  
Number of Beds/Units | unit   785  
Skilled nursing      
Business Acquisition [Line Items]      
Purchase Price $ 18,700 $ 15,800  
Initial Annual Cash Rent   $ 1,492  
Number of Properties | property   1  
Number of Beds/Units | unit   145  
Multi-service campuses      
Business Acquisition [Line Items]      
Purchase Price   $ 125,708  
Initial Annual Cash Rent   $ 8,604  
Number of Properties | property   4  
Number of Beds/Units | unit   640  
Multi-service campuses | Forecast      
Business Acquisition [Line Items]      
Initial Annual Cash Rent     $ 9,400
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.21.1
Real Estate Investments, Net - Asset Sales and Assets Held for Sale Narrative (Details)
1 Months Ended 3 Months Ended
Feb. 01, 2021
USD ($)
bed
Nov. 01, 2020
USD ($)
facility
unit
Feb. 14, 2020
USD ($)
facility
Jul. 31, 2020
USD ($)
Apr. 30, 2020
USD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
property
Mar. 31, 2020
USD ($)
Feb. 29, 2020
USD ($)
facility
Real Estate [Line Items]                  
Assets held for sale, net           $ 0 $ 7,226,000    
Real estate investments, net           1,577,450,000 $ 1,448,099,000    
Proceeds from sale           6,814,000   $ 2,134,000  
Gain (loss) on sale of real estate           (192,000)   $ (56,000)  
Mortgage loan receivable                  
Real Estate [Line Items]                  
Loan receivable           $ 0      
Mortgage loan receivable | Cascade Capital Group, LLC                  
Real Estate [Line Items]                  
Loan receivable     $ 32,400,000           $ 32,400,000
Loan receivable interest rate (percent)     7.50%           7.50%
Proceeds from settlement of loan       $ 13,900,000 $ 18,900,000        
Loan receivable         $ 13,900,000        
Held for sale | Five Oaks Healthcare LLC                  
Real Estate [Line Items]                  
Number of properties held for sale | property             1    
Disposed of by sale | Five Oaks Healthcare LLC                  
Real Estate [Line Items]                  
Number of operational beds | bed 90                
Real estate investments, net $ 7,200,000                
Proceeds from sale 7,000,000.0                
Gain (loss) on sale of real estate $ (200,000)                
Disposed of by sale | Owned and operated living facility                  
Real Estate [Line Items]                  
Number of properties sold | facility   1              
Number of units in property sold | unit   168              
Real estate investments, net   $ 4,200,000              
Proceeds from sale   $ 4,500,000              
Gain (loss) on sale of real estate             $ 20,000    
Disposed of by sale | Metron skilled nursing facilities                  
Real Estate [Line Items]                  
Number of properties sold | facility     6           6
Proceeds from sale     $ 3,500,000            
Gain (loss) on sale of real estate     100,000            
Contract purchase price     $ 36,000,000.0            
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.21.1
Real Estate Investments, Net - Lease Amendments Narrative (Details)
$ in Thousands
3 Months Ended
Dec. 01, 2020
USD ($)
facility
extension_option
Mar. 31, 2021
USD ($)
Real Estate [Line Items]    
Initial annual cash rents   $ 10,096
Noble triple-net master lease    
Real Estate [Line Items]    
Initial lease term (in years) 14 years  
Number of renewal options | extension_option 2  
Lease renewal term (in years) 5 years  
Noble    
Real Estate [Line Items]    
Initial annual cash rents $ 3,200  
Noble | Assisted living    
Real Estate [Line Items]    
Number of properties transferred | facility 5  
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.21.1
Other Real Estate Investments, Net (Details)
1 Months Ended 3 Months Ended
Nov. 30, 2020
USD ($)
facility
Jul. 31, 2020
USD ($)
Apr. 30, 2020
USD ($)
extension_option
property
Jan. 31, 2020
USD ($)
Jul. 31, 2019
USD ($)
bed
Sep. 30, 2016
USD ($)
bed
Mar. 31, 2021
USD ($)
Mar. 31, 2020
USD ($)
Feb. 29, 2020
USD ($)
facility
Feb. 14, 2020
USD ($)
facility
Sep. 30, 2019
USD ($)
facility
Real Estate Properties [Line Items]                      
Preferred equity investment             $ 0        
Aggregate purchase price             141,508,000        
Payment to acquire facility             138,151,000 $ 25,905,000      
Return of initial investment             0 2,327,000      
Metron skilled nursing facilities | Disposed of by sale                      
Real Estate Properties [Line Items]                      
Number of properties sold | facility                 6 6  
Mezzanine loan receivable                      
Real Estate Properties [Line Items]                      
Interest income             500,000        
Mortgage loan receivable                      
Real Estate Properties [Line Items]                      
Loan receivable             0        
Interest income             0 1,100,000      
Other loans receivable                      
Real Estate Properties [Line Items]                      
Interest income             100,000        
Next VA Star Realty Holdings LLC | Mezzanine loan receivable                      
Real Estate Properties [Line Items]                      
Number of facilities in agreement secured by membership interests | facility 9                    
Loan receivable $ 15,000,000.0                    
Loan receivable interest rate (percent) 12.00%                    
Period of unpaid interest payments due upon prepayment 24 months                    
Next VA Star Realty Holdings LLC | Mezzanine loan receivable | Minimum                      
Real Estate Properties [Line Items]                      
Loans receivable exit fee (percent) 1.00%                    
Next VA Star Realty Holdings LLC | Mezzanine loan receivable | Maximum                      
Real Estate Properties [Line Items]                      
Loans receivable exit fee (percent) 3.00%                    
MCRC, LLC                      
Real Estate Properties [Line Items]                      
Purchase and sale agreement amount         $ 16,400,000            
Number of days after termination of purchase and sale agreement for maturity         5 days            
MCRC, LLC | Mortgage loan receivable                      
Real Estate Properties [Line Items]                      
Loan receivable         $ 3,000,000.0            
Loan receivable interest rate (percent)         8.00%            
Number of beds in facility used to secure loan | bed         176            
CommuniCare | Mortgage loan receivable                      
Real Estate Properties [Line Items]                      
Loan receivable                     $ 26,500,000
Loan receivable interest rate (percent)                     10.00%
Facilities utilized to secure mortgage loan | facility                     3
Cascade Capital Group, LLC                      
Real Estate Properties [Line Items]                      
Combined principal amount of loan     $ 33,900,000                
Cascade Capital Group, LLC | Mortgage loan receivable                      
Real Estate Properties [Line Items]                      
Loan receivable                 $ 32,400,000 $ 32,400,000  
Loan receivable interest rate (percent)                 7.50% 7.50%  
Facilities utilized to secure mortgage loan | property     6                
Proceeds from settlement of loan   $ 13,900,000 $ 18,900,000                
Loan receivable     $ 13,900,000                
LIBOR floor for loan (percent)     1.75%                
Number of extension options | extension_option     2                
Extension option term (in months)     6 months                
Cascade Capital Group, LLC | Mortgage loan receivable | LIBOR                      
Real Estate Properties [Line Items]                      
Basis spread on variable rate for loan (percent)     4.00%                
Cascadia Development, Boise ID                      
Real Estate Properties [Line Items]                      
Preferred equity investment           $ 2,300,000          
Preferred equity investment minimum yield           12.00%          
Number of beds planned for construction | bed           99          
Initial lease yield (percent)           9.00%          
Return of initial investment       $ 2,300,000              
Cumulative contractual preferred return through acquisition date       1,400,000              
Interest income related to preferred equity investments               $ 100,000      
Cascadia Development, Boise ID | Prime Rate                      
Real Estate Properties [Line Items]                      
Basis spread of preferred equity investment yield           9.50%          
Skilled nursing properties                      
Real Estate Properties [Line Items]                      
Aggregate purchase price       18,700,000     $ 15,800,000        
Payment to acquire facility       $ 15,000,000.0              
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements - Items Measured at Fair Value on Recurring Basis (Details) - Recurring - Mezzanine loan receivable - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Assets:    
Mezzanine loan receivable $ 15,155 $ 15,000
Level 1    
Assets:    
Mezzanine loan receivable 0 0
Level 2    
Assets:    
Mezzanine loan receivable 0 0
Level 3    
Assets:    
Mezzanine loan receivable $ 15,155 $ 15,000
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements - Narrative (Details)
Mar. 31, 2021
USD ($)
Greater than 90 days past due  
Financing Receivable, Past Due [Line Items]  
Mortgage loan receivable $ 0
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements - Face Value, Carrying Amount and Fair Value of Financial Instruments (Details) - Senior unsecured notes payable - USD ($)
Mar. 31, 2021
Dec. 31, 2020
Financial liabilities:    
Senior unsecured notes payable - face value $ 300,000,000 $ 300,000,000
Carrying Amount | Level 2    
Financial liabilities:    
Senior unsecured notes payable 296,858,000 296,669,000
Fair Value | Level 2    
Financial liabilities:    
Senior unsecured notes payable $ 309,000,000 $ 311,430,000
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.21.1
Debt - Schedule of Debt (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Debt Instrument [Line Items]    
Principal Amount $ 670,000 $ 550,000
Deferred Loan Fees (4,164) (4,406)
Carrying Value 665,836 545,594
Senior unsecured notes payable    
Debt Instrument [Line Items]    
Principal Amount 300,000 300,000
Deferred Loan Fees (3,142) (3,331)
Carrying Value 296,858 296,669
Senior unsecured term loan    
Debt Instrument [Line Items]    
Principal Amount 200,000 200,000
Deferred Loan Fees (1,022) (1,075)
Carrying Value 198,978 198,925
Unsecured revolving credit facility    
Debt Instrument [Line Items]    
Principal Amount 170,000 50,000
Deferred Loan Fees 0 0
Carrying Value $ 170,000 $ 50,000
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.21.1
Debt - Senior Unsecured Notes Payable Narrative (Details) - Senior unsecured notes payable - USD ($)
Jun. 01, 2020
May 10, 2017
Mar. 31, 2021
Dec. 31, 2020
Debt Instrument [Line Items]        
Debt instrument face amount     $ 300,000,000 $ 300,000,000
5.25% Senior Notes due 2025        
Debt Instrument [Line Items]        
Debt instrument face amount   $ 300,000,000.0    
Interest rate (percent)   5.25%    
Gross proceeds from issuance of senior notes   $ 300,000,000.0    
Net proceeds from issuance of senior notes   $ 294,000,000.0    
Redemption price, percentage upon change of control (percent) 101.00%      
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.21.1
Debt - Unsecured Revolving Credit Facility and Term Loan Narrative (Details)
Feb. 08, 2019
USD ($)
extension_option
Mar. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Line of Credit Facility [Line Items]      
Outstanding amounts   $ 670,000,000 $ 550,000,000
Outstanding borrowings   665,836,000 545,594,000
Revolving credit facility | New Revolving Facility      
Line of Credit Facility [Line Items]      
Credit facility borrowing capacity $ 600,000,000.0    
Number of extension options | extension_option 2    
Extension option term (in months) 6 months    
Revolving credit facility | New Revolving Facility | Minimum      
Line of Credit Facility [Line Items]      
Facility fee on revolving commitment fees (percent) 0.15%    
Facility fee on revolving commitment fee based on investment grade ratings (percent) 0.125%    
Revolving credit facility | New Revolving Facility | Minimum | Base Rate      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (percent) 0.10%    
Revolving credit facility | New Revolving Facility | Minimum | LIBOR      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (percent) 1.10%    
Revolving credit facility | New Revolving Facility | Maximum      
Line of Credit Facility [Line Items]      
Facility fee on revolving commitment fees (percent) 0.35%    
Facility fee on revolving commitment fee based on investment grade ratings (percent) 0.30%    
Revolving credit facility | New Revolving Facility | Maximum | Base Rate      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (percent) 0.55%    
Revolving credit facility | New Revolving Facility | Maximum | LIBOR      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (percent) 1.55%    
Letter of credit      
Line of Credit Facility [Line Items]      
Subfacility capacity as percentage of available revolving commitments (percent) 10.00%    
Swingline loan      
Line of Credit Facility [Line Items]      
Subfacility capacity as percentage of available revolving commitments (percent) 10.00%    
Revolving Facility      
Line of Credit Facility [Line Items]      
Outstanding amounts   170,000,000 50,000,000
Outstanding borrowings   170,000,000 50,000,000
New Term Loan      
Line of Credit Facility [Line Items]      
Outstanding amounts   200,000,000 200,000,000
Outstanding borrowings   $ 198,978,000 $ 198,925,000
New Term Loan | Term Loan      
Line of Credit Facility [Line Items]      
Debt instrument face amount $ 200,000,000.0    
New Term Loan | Term Loan | Minimum | Base Rate      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (percent) 0.50%    
New Term Loan | Term Loan | Minimum | LIBOR      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (percent) 1.50%    
New Term Loan | Term Loan | Maximum | Base Rate      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (percent) 1.20%    
New Term Loan | Term Loan | Maximum | LIBOR      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (percent) 2.20%    
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.21.1
Equity - Narrative (Details) - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Mar. 20, 2020
Mar. 10, 2020
Class of Stock [Line Items]        
Share repurchase program authorization     $ 150,000,000.0  
Shares repurchased (in shares) 0 0    
ATM Program        
Class of Stock [Line Items]        
Issuance of common stock, net, (in shares) 702,000 0    
Remaining offering amount available $ 483,400,000      
ATM Program | Maximum        
Class of Stock [Line Items]        
Authorized aggregate offering price of common stock       $ 500,000,000.0
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.21.1
Equity - At-The-Market Offering (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Class of Stock [Line Items]    
Gross proceeds $ 16,191  
Commissions paid on stock issuance   $ 90
ATM Program    
Class of Stock [Line Items]    
Number of shares (in shares) 702,000 0
Average sales price per share (usd per share) $ 23.62  
Gross proceeds $ 16,579  
Commissions paid on stock issuance $ 200  
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.21.1
Equity - Dividends on Common Stock (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dividends on common stock    
Dividends declared per share $ 0.265 $ 0.25
Dividends payment date Apr. 15, 2021  
Dividends payable as of record date $ 25,633 $ 23,931
Dividends record date Mar. 31, 2021  
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-Based Compensation - Narrative (Details)
$ / shares in Units, $ in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Jun. 01, 2014
shares
Feb. 28, 2021
installment
company
$ / shares
shares
Jan. 31, 2021
installment
$ / shares
shares
Mar. 31, 2021
USD ($)
shares
Dec. 31, 2020
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Unamortized stock-based compensation expense related to unvested awards | $       $ 14.5  
Weighted average remaining vesting period related to expense recognition       2 years 6 months  
Restricted stock award | Ensign Employees          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock awards unvested during spin-off (in shares) 207,580        
Shares forfeited (shares)         1,760
Unvested stock awards outstanding (in shares)       0  
Restricted stock award | Officers and employees          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of awards granted (in shares)   99,189 140,514    
Award grant date fair value (in usd per share) | $ / shares   $ 22.18 $ 22.48    
Number of equal annual vesting installments | installment   3 3    
Performance stock award          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Historical volatility term basis for expected volatility assumption       2 years 10 months 2 days  
Performance stock award | Officers          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of awards granted (in shares)   99,189 108,414    
Award grant date fair value (in usd per share) | $ / shares   $ 27.98 $ 22.48    
Vesting period (in years)   3 years      
Number of publicly traded healthcare REITs in peer group | company   16      
Performance stock award | Minimum | Officers          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting period (in years)     1 year    
Percentage of awards to vest relative To initial grant based on TSR performance   0.00%      
Performance stock award | Maximum | Officers          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting period (in years)     3 years    
Percentage of awards to vest relative To initial grant based on TSR performance   200.00%      
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-Based Compensation - Valuation Assumptions (Details) - Performance stock award
3 Months Ended
Mar. 31, 2021
Valuation Assumptions  
Risk free interest rate 0.27%
Expected stock price volatility 52.93%
Expected service period 2 years 10 months 2 days
Expected dividend yield (assuming full reinvestment) 0.00%
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Share-based Payment Arrangement [Abstract]    
Stock-based compensation expense $ 1,585 $ 884
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.21.1
Earnings Per Common Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Numerator:    
Net income (loss) $ 20,486 $ 19,325
Less: Net income allocated to participating securities (119) (75)
Numerator for basic and diluted earnings available to common stockholders $ 20,367 $ 19,250
Denominator:    
Weighted-average basic common shares outstanding (in shares) 95,378 95,161
Weighted-average diluted common shares outstanding (in shares) 95,385 95,161
Earnings (loss) per common share, basic (in usd per share) $ 0.21 $ 0.20
Earnings (loss) per common share, diluted (in usd per share) $ 0.21 $ 0.20
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies (Details)
$ in Millions
Mar. 31, 2021
USD ($)
Ensign and Pennant  
Other Commitments [Line Items]  
Aggregate required financing of capital expenditures as percentage of initial investment in property (percent) 20.00%
Certain capital improvements at triple-net leased facilities  
Other Commitments [Line Items]  
Funding commitment $ 14.1
Portion of funding commitment subject to rent increase at time of funding $ 13.1
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.21.1
Concentration of Risk (Details)
3 Months Ended
Mar. 31, 2021
state
facility
unit_bed
Mar. 31, 2020
Skilled nursing, multi-service campuses, assisted living and independent living facilities    
Concentration Risk [Line Items]    
Number of facilities 222  
Ensign    
Concentration Risk [Line Items]    
Number of states where Ensign leases the highest concentration of properties | state 4  
Ensign | Customer concentration risk | Rental income, exclusive of operating expense reimbursements    
Concentration Risk [Line Items]    
Concentration risk (percent) 32.00% 32.00%
PMG | Customer concentration risk | Rental income, exclusive of operating expense reimbursements    
Concentration Risk [Line Items]    
Concentration risk (percent) 16.00% 16.00%
Ensign | Skilled nursing, multi-service campuses, assisted living and independent living facilities    
Concentration Risk [Line Items]    
Number of facilities 89  
Number of beds and units in facilities | unit_bed 9,551  
PMG | Skilled nursing and campus facilities    
Concentration Risk [Line Items]    
Number of facilities 15  
Number of beds and units in facilities 2,144  
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.21.1
Subsequent Events (Details)
$ in Thousands
1 Months Ended 3 Months Ended
Apr. 30, 2021
USD ($)
property
Jan. 31, 2020
USD ($)
Mar. 31, 2021
USD ($)
property
Subsequent Event [Line Items]      
Number of properties acquired | property     5
Aggregate purchase price     $ 141,508
Initial annual cash rents     $ 10,096
Skilled nursing      
Subsequent Event [Line Items]      
Number of properties acquired | property     1
Aggregate purchase price   $ 18,700 $ 15,800
Initial annual cash rents     $ 1,492
Subsequent event | Skilled nursing      
Subsequent Event [Line Items]      
Number of properties acquired | property 1    
Aggregate purchase price $ 9,700    
Subsequent event | Bayshire, LLC      
Subsequent Event [Line Items]      
Amended lease term (in years) 13 years    
Subsequent event | Bayshire, LLC | Skilled nursing      
Subsequent Event [Line Items]      
Initial annual cash rents $ 800    
Anticipated annual cash rent in second year after acquisition $ 900    
EXCEL 63 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 65 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 66 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 145 317 1 false 70 0 false 13 false false R1.htm 0001001 - Document - Cover Sheet http://www.caretrustreit.com/role/Cover Cover Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Income Statements Sheet http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements Condensed Consolidated Income Statements Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Equity Sheet http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity Condensed Consolidated Statements of Equity Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statements of Equity (Parenthetical) Sheet http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquityParenthetical Condensed Consolidated Statements of Equity (Parenthetical) Statements 6 false false R7.htm 1006007 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 2101101 - Disclosure - Organization Sheet http://www.caretrustreit.com/role/Organization Organization Notes 8 false false R9.htm 2103102 - Disclosure - Basis of Presentation Sheet http://www.caretrustreit.com/role/BasisofPresentation Basis of Presentation Notes 9 false false R10.htm 2105103 - Disclosure - Real Estate Investments, Net Sheet http://www.caretrustreit.com/role/RealEstateInvestmentsNet Real Estate Investments, Net Notes 10 false false R11.htm 2115104 - Disclosure - Other Real Estate Investments, Net Sheet http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNet Other Real Estate Investments, Net Notes 11 false false R12.htm 2117105 - Disclosure - Fair Value Measurements Sheet http://www.caretrustreit.com/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 2122106 - Disclosure - Debt Sheet http://www.caretrustreit.com/role/Debt Debt Notes 13 false false R14.htm 2127107 - Disclosure - Equity Sheet http://www.caretrustreit.com/role/Equity Equity Notes 14 false false R15.htm 2132108 - Disclosure - Stock-Based Compensation Sheet http://www.caretrustreit.com/role/StockBasedCompensation Stock-Based Compensation Notes 15 false false R16.htm 2137109 - Disclosure - Earnings Per Common Share Sheet http://www.caretrustreit.com/role/EarningsPerCommonShare Earnings Per Common Share Notes 16 false false R17.htm 2140110 - Disclosure - Commitments and Contingencies Sheet http://www.caretrustreit.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 17 false false R18.htm 2142111 - Disclosure - Concentration of Risk Sheet http://www.caretrustreit.com/role/ConcentrationofRisk Concentration of Risk Notes 18 false false R19.htm 2144112 - Disclosure - Subsequent Events Sheet http://www.caretrustreit.com/role/SubsequentEvents Subsequent Events Notes 19 false false R20.htm 2204201 - Disclosure - Basis of Presentation (Policies) Sheet http://www.caretrustreit.com/role/BasisofPresentationPolicies Basis of Presentation (Policies) Policies 20 false false R21.htm 2306301 - Disclosure - Real Estate Investments, Net (Tables) Sheet http://www.caretrustreit.com/role/RealEstateInvestmentsNetTables Real Estate Investments, Net (Tables) Tables http://www.caretrustreit.com/role/RealEstateInvestmentsNet 21 false false R22.htm 2318302 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.caretrustreit.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.caretrustreit.com/role/FairValueMeasurements 22 false false R23.htm 2323303 - Disclosure - Debt (Tables) Sheet http://www.caretrustreit.com/role/DebtTables Debt (Tables) Tables http://www.caretrustreit.com/role/Debt 23 false false R24.htm 2328304 - Disclosure - Equity (Tables) Sheet http://www.caretrustreit.com/role/EquityTables Equity (Tables) Tables http://www.caretrustreit.com/role/Equity 24 false false R25.htm 2333305 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.caretrustreit.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.caretrustreit.com/role/StockBasedCompensation 25 false false R26.htm 2338306 - Disclosure - Earnings Per Common Share (Tables) Sheet http://www.caretrustreit.com/role/EarningsPerCommonShareTables Earnings Per Common Share (Tables) Tables http://www.caretrustreit.com/role/EarningsPerCommonShare 26 false false R27.htm 2402401 - Disclosure - Organization (Details) Sheet http://www.caretrustreit.com/role/OrganizationDetails Organization (Details) Details http://www.caretrustreit.com/role/Organization 27 false false R28.htm 2407402 - Disclosure - Real Estate Investments, Net - Narrative (Details) Sheet http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails Real Estate Investments, Net - Narrative (Details) Details 28 false false R29.htm 2408403 - Disclosure - Real Estate Investments, Net - Investment in Owned Properties (Details) Sheet http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails Real Estate Investments, Net - Investment in Owned Properties (Details) Details 29 false false R30.htm 2409404 - Disclosure - Real Estate Investments, Net - Future Contractual Minimum Rental Income (Details) Sheet http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails Real Estate Investments, Net - Future Contractual Minimum Rental Income (Details) Details 30 false false R31.htm 2410405 - Disclosure - Real Estate Investments, Net - Tenant Purchase Options (Details) Sheet http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails Real Estate Investments, Net - Tenant Purchase Options (Details) Details 31 false false R32.htm 2411406 - Disclosure - Real Estate Investments, Net - Rental Income (Details) Sheet http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails Real Estate Investments, Net - Rental Income (Details) Details 32 false false R33.htm 2412407 - Disclosure - Real Estate Investments, Net - Recent Real Estate Acquisitions (Details) Sheet http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails Real Estate Investments, Net - Recent Real Estate Acquisitions (Details) Details 33 false false R34.htm 2413408 - Disclosure - Real Estate Investments, Net - Asset Sales and Assets Held for Sale Narrative (Details) Sheet http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails Real Estate Investments, Net - Asset Sales and Assets Held for Sale Narrative (Details) Details 34 false false R35.htm 2414409 - Disclosure - Real Estate Investments, Net - Lease Amendments Narrative (Details) Sheet http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails Real Estate Investments, Net - Lease Amendments Narrative (Details) Details 35 false false R36.htm 2416410 - Disclosure - Other Real Estate Investments, Net (Details) Sheet http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails Other Real Estate Investments, Net (Details) Details http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNet 36 false false R37.htm 2419411 - Disclosure - Fair Value Measurements - Items Measured at Fair Value on Recurring Basis (Details) Sheet http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails Fair Value Measurements - Items Measured at Fair Value on Recurring Basis (Details) Details 37 false false R38.htm 2420412 - Disclosure - Fair Value Measurements - Narrative (Details) Sheet http://www.caretrustreit.com/role/FairValueMeasurementsNarrativeDetails Fair Value Measurements - Narrative (Details) Details 38 false false R39.htm 2421413 - Disclosure - Fair Value Measurements - Face Value, Carrying Amount and Fair Value of Financial Instruments (Details) Sheet http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails Fair Value Measurements - Face Value, Carrying Amount and Fair Value of Financial Instruments (Details) Details 39 false false R40.htm 2424414 - Disclosure - Debt - Schedule of Debt (Details) Sheet http://www.caretrustreit.com/role/DebtScheduleofDebtDetails Debt - Schedule of Debt (Details) Details 40 false false R41.htm 2425415 - Disclosure - Debt - Senior Unsecured Notes Payable Narrative (Details) Notes http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails Debt - Senior Unsecured Notes Payable Narrative (Details) Details 41 false false R42.htm 2426416 - Disclosure - Debt - Unsecured Revolving Credit Facility and Term Loan Narrative (Details) Sheet http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails Debt - Unsecured Revolving Credit Facility and Term Loan Narrative (Details) Details 42 false false R43.htm 2429417 - Disclosure - Equity - Narrative (Details) Sheet http://www.caretrustreit.com/role/EquityNarrativeDetails Equity - Narrative (Details) Details 43 false false R44.htm 2430418 - Disclosure - Equity - At-The-Market Offering (Details) Sheet http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails Equity - At-The-Market Offering (Details) Details 44 false false R45.htm 2431419 - Disclosure - Equity - Dividends on Common Stock (Details) Sheet http://www.caretrustreit.com/role/EquityDividendsonCommonStockDetails Equity - Dividends on Common Stock (Details) Details 45 false false R46.htm 2434420 - Disclosure - Stock-Based Compensation - Narrative (Details) Sheet http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails Stock-Based Compensation - Narrative (Details) Details 46 false false R47.htm 2435421 - Disclosure - Stock-Based Compensation - Valuation Assumptions (Details) Sheet http://www.caretrustreit.com/role/StockBasedCompensationValuationAssumptionsDetails Stock-Based Compensation - Valuation Assumptions (Details) Details 47 false false R48.htm 2436422 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details) Sheet http://www.caretrustreit.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails Stock-Based Compensation - Stock-Based Compensation Expense (Details) Details 48 false false R49.htm 2439423 - Disclosure - Earnings Per Common Share (Details) Sheet http://www.caretrustreit.com/role/EarningsPerCommonShareDetails Earnings Per Common Share (Details) Details http://www.caretrustreit.com/role/EarningsPerCommonShareTables 49 false false R50.htm 2441424 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.caretrustreit.com/role/CommitmentsandContingencies 50 false false R51.htm 2443425 - Disclosure - Concentration of Risk (Details) Sheet http://www.caretrustreit.com/role/ConcentrationofRiskDetails Concentration of Risk (Details) Details http://www.caretrustreit.com/role/ConcentrationofRisk 51 false false R52.htm 2445426 - Disclosure - Subsequent Events (Details) Sheet http://www.caretrustreit.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.caretrustreit.com/role/SubsequentEvents 52 false false All Reports Book All Reports ctre-20210331.htm ctre-20210331.xsd ctre-20210331_cal.xml ctre-20210331_def.xml ctre-20210331_lab.xml ctre-20210331_pre.xml ctre20210331q1ex311.htm ctre20210331q1ex312.htm ctre20210331q1ex321.htm http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/srt/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true true JSON 69 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ctre-20210331.htm": { "axisCustom": 1, "axisStandard": 26, "contextCount": 145, "dts": { "calculationLink": { "local": [ "ctre-20210331_cal.xml" ] }, "definitionLink": { "local": [ "ctre-20210331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "ctre-20210331.htm" ] }, "labelLink": { "local": [ "ctre-20210331_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "ctre-20210331_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "ctre-20210331.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 441, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 5, "http://www.caretrustreit.com/20210331": 1, "http://xbrl.sec.gov/dei/2020-01-31": 5, "total": 11 }, "keyCustom": 58, "keyStandard": 259, "memberCustom": 38, "memberStandard": 30, "nsprefix": "ctre", "nsuri": "http://www.caretrustreit.com/20210331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.caretrustreit.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RealEstateDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105103 - Disclosure - Real Estate Investments, Net", "role": "http://www.caretrustreit.com/role/RealEstateInvestmentsNet", "shortName": "Real Estate Investments, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RealEstateDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "ctre:OtherRealEstateInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115104 - Disclosure - Other Real Estate Investments, Net", "role": "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNet", "shortName": "Other Real Estate Investments, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "ctre:OtherRealEstateInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117105 - Disclosure - Fair Value Measurements", "role": "http://www.caretrustreit.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2122106 - Disclosure - Debt", "role": "http://www.caretrustreit.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127107 - Disclosure - Equity", "role": "http://www.caretrustreit.com/role/Equity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2132108 - Disclosure - Stock-Based Compensation", "role": "http://www.caretrustreit.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2137109 - Disclosure - Earnings Per Common Share", "role": "http://www.caretrustreit.com/role/EarningsPerCommonShare", "shortName": "Earnings Per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2140110 - Disclosure - Commitments and Contingencies", "role": "http://www.caretrustreit.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2142111 - Disclosure - Concentration of Risk", "role": "http://www.caretrustreit.com/role/ConcentrationofRisk", "shortName": "Concentration of Risk", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2144112 - Disclosure - Subsequent Events", "role": "http://www.caretrustreit.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "iafc60f98e3dd4681a3371564f855c4a7_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RealEstateInvestmentPropertyNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "iafc60f98e3dd4681a3371564f855c4a7_I20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - Basis of Presentation (Policies)", "role": "http://www.caretrustreit.com/role/BasisofPresentationPolicies", "shortName": "Basis of Presentation (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - Real Estate Investments, Net (Tables)", "role": "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTables", "shortName": "Real Estate Investments, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318302 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.caretrustreit.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2323303 - Disclosure - Debt (Tables)", "role": "http://www.caretrustreit.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2328304 - Disclosure - Equity (Tables)", "role": "http://www.caretrustreit.com/role/EquityTables", "shortName": "Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "ctre:ScheduleOfShareBasedPaymentAwardPerformanceStockAwardValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2333305 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.caretrustreit.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "ctre:ScheduleOfShareBasedPaymentAwardPerformanceStockAwardValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2338306 - Disclosure - Earnings Per Common Share (Tables)", "role": "http://www.caretrustreit.com/role/EarningsPerCommonShareTables", "shortName": "Earnings Per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "iafc60f98e3dd4681a3371564f855c4a7_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfStatesInWhichEntityOperates", "reportCount": 1, "unique": true, "unitRef": "state", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Organization (Details)", "role": "http://www.caretrustreit.com/role/OrganizationDetails", "shortName": "Organization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "iafc60f98e3dd4681a3371564f855c4a7_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfStatesInWhichEntityOperates", "reportCount": 1, "unique": true, "unitRef": "state", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "i56d75a2f400c40f990e6d69b5cdac14a_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfRealEstateProperties", "reportCount": 1, "unitRef": "facility", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Real Estate Investments, Net - Narrative (Details)", "role": "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails", "shortName": "Real Estate Investments, Net - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "iafc60f98e3dd4681a3371564f855c4a7_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Land", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Real Estate Investments, Net - Investment in Owned Properties (Details)", "role": "http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails", "shortName": "Real Estate Investments, Net - Investment in Owned Properties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "iafc60f98e3dd4681a3371564f855c4a7_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Land", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "iafc60f98e3dd4681a3371564f855c4a7_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "iafc60f98e3dd4681a3371564f855c4a7_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "iafc60f98e3dd4681a3371564f855c4a7_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409404 - Disclosure - Real Estate Investments, Net - Future Contractual Minimum Rental Income (Details)", "role": "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails", "shortName": "Real Estate Investments, Net - Future Contractual Minimum Rental Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "iafc60f98e3dd4681a3371564f855c4a7_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ctre:ScheduleOfTenantPurchaseOptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ie843ed10ce10424aa8f08754bb995e23_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "ctre:NumberOfPropertiesWithTenantPurchaseOption", "reportCount": 1, "unique": true, "unitRef": "property", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410405 - Disclosure - Real Estate Investments, Net - Tenant Purchase Options (Details)", "role": "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails", "shortName": "Real Estate Investments, Net - Tenant Purchase Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ctre:ScheduleOfTenantPurchaseOptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ie843ed10ce10424aa8f08754bb995e23_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "ctre:NumberOfPropertiesWithTenantPurchaseOption", "reportCount": 1, "unique": true, "unitRef": "property", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLeaseIncomeLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411406 - Disclosure - Real Estate Investments, Net - Rental Income (Details)", "role": "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails", "shortName": "Real Estate Investments, Net - Rental Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLeaseIncomeLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ctre:ScheduleOfAssetsAcquisitionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "ctre:AssetAcquisitionConsiderationTransferred", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412407 - Disclosure - Real Estate Investments, Net - Recent Real Estate Acquisitions (Details)", "role": "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails", "shortName": "Real Estate Investments, Net - Recent Real Estate Acquisitions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ctre:ScheduleOfAssetsAcquisitionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": "INF", "lang": "en-US", "name": "ctre:NumberOfBedsOrUnitsInPropertiesAcquired", "reportCount": 1, "unique": true, "unitRef": "unit", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "iafc60f98e3dd4681a3371564f855c4a7_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413408 - Disclosure - Real Estate Investments, Net - Asset Sales and Assets Held for Sale Narrative (Details)", "role": "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails", "shortName": "Real Estate Investments, Net - Asset Sales and Assets Held for Sale Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "if04948522ea943e0892e4648286b24ef_I20201231", "decimals": "INF", "lang": "en-US", "name": "ctre:NumberOfPropertiesToBeSold", "reportCount": 1, "unique": true, "unitRef": "property", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ctre:ScheduleOfAssetsAcquisitionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "ctre:OperatingLeasesAnticipatedInitialAnnualLeaseRevenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414409 - Disclosure - Real Estate Investments, Net - Lease Amendments Narrative (Details)", "role": "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "shortName": "Real Estate Investments, Net - Lease Amendments Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "idfc611f01da94d0db373d9ad1d593350_I20201201", "decimals": null, "lang": "en-US", "name": "us-gaap:LessorOperatingLeaseTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "iafc60f98e3dd4681a3371564f855c4a7_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416410 - Disclosure - Other Real Estate Investments, Net (Details)", "role": "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "shortName": "Other Real Estate Investments, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "iafc60f98e3dd4681a3371564f855c4a7_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "if9b588a598d0415681dd7905ffb47368_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LoansReceivableFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419411 - Disclosure - Fair Value Measurements - Items Measured at Fair Value on Recurring Basis (Details)", "role": "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails", "shortName": "Fair Value Measurements - Items Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "if9b588a598d0415681dd7905ffb47368_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LoansReceivableFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "idbaa776c77ad4b47a75a3b777872acd4_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NotesReceivableGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420412 - Disclosure - Fair Value Measurements - Narrative (Details)", "role": "http://www.caretrustreit.com/role/FairValueMeasurementsNarrativeDetails", "shortName": "Fair Value Measurements - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "idbaa776c77ad4b47a75a3b777872acd4_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NotesReceivableGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "i784ad7daad604773b51865f044e6cb3e_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421413 - Disclosure - Fair Value Measurements - Face Value, Carrying Amount and Fair Value of Financial Instruments (Details)", "role": "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails", "shortName": "Fair Value Measurements - Face Value, Carrying Amount and Fair Value of Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "i1040d75ecb4e4777ab6b1cb837631b18_I20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:NotesPayableFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLeaseIncome", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Income Statements", "role": "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements", "shortName": "Condensed Consolidated Income Statements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "iafc60f98e3dd4681a3371564f855c4a7_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424414 - Disclosure - Debt - Schedule of Debt (Details)", "role": "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "shortName": "Debt - Schedule of Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "iafc60f98e3dd4681a3371564f855c4a7_I20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "i784ad7daad604773b51865f044e6cb3e_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425415 - Disclosure - Debt - Senior Unsecured Notes Payable Narrative (Details)", "role": "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "shortName": "Debt - Senior Unsecured Notes Payable Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "i1c63482d6ddb4f16b33c0bdc6b8c0e78_I20170510", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "iafc60f98e3dd4681a3371564f855c4a7_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426416 - Disclosure - Debt - Unsecured Revolving Credit Facility and Term Loan Narrative (Details)", "role": "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "shortName": "Debt - Unsecured Revolving Credit Facility and Term Loan Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "i1986925ddc9d4421b43e3069668f9a5d_I20190208", "decimals": "INF", "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "i5db9be295a0142698c65fceae1d5c7d4_I20200320", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429417 - Disclosure - Equity - Narrative (Details)", "role": "http://www.caretrustreit.com/role/EquityNarrativeDetails", "shortName": "Equity - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "i5db9be295a0142698c65fceae1d5c7d4_I20200320", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430418 - Disclosure - Equity - At-The-Market Offering (Details)", "role": "http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails", "shortName": "Equity - At-The-Market Offering (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "idb23a62bd5c5426faefdf7558320ec10_D20210101-20210331", "decimals": "2", "lang": "en-US", "name": "ctre:SharesIssuedDuringPeriodAveragePricePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431419 - Disclosure - Equity - Dividends on Common Stock (Details)", "role": "http://www.caretrustreit.com/role/EquityDividendsonCommonStockDetails", "shortName": "Equity - Dividends on Common Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "lang": "en-US", "name": "us-gaap:DividendPayableDateToBePaidDayMonthAndYear", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "iafc60f98e3dd4681a3371564f855c4a7_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434420 - Disclosure - Stock-Based Compensation - Narrative (Details)", "role": "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails", "shortName": "Stock-Based Compensation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "iafc60f98e3dd4681a3371564f855c4a7_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "i8869f2f390bf4bbda6e03461d3954b1b_D20210101-20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435421 - Disclosure - Stock-Based Compensation - Valuation Assumptions (Details)", "role": "http://www.caretrustreit.com/role/StockBasedCompensationValuationAssumptionsDetails", "shortName": "Stock-Based Compensation - Valuation Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "i8869f2f390bf4bbda6e03461d3954b1b_D20210101-20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436422 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)", "role": "http://www.caretrustreit.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails", "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439423 - Disclosure - Earnings Per Common Share (Details)", "role": "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails", "shortName": "Earnings Per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "ctre:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasicAndDiluted", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ia8c9e9c3ec2241cc935fce2f2efb5aaf_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Equity", "role": "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity", "shortName": "Condensed Consolidated Statements of Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ia8c9e9c3ec2241cc935fce2f2efb5aaf_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "i62e4ace732124bc8b2a51c81e6489bc0_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "ctre:AggregateRequiredFinancingOfCapitalExpendituresAsPercentageOfInitialInvestmentInProperty", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441424 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "i62e4ace732124bc8b2a51c81e6489bc0_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "ctre:AggregateRequiredFinancingOfCapitalExpendituresAsPercentageOfInitialInvestmentInProperty", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "i56d75a2f400c40f990e6d69b5cdac14a_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfRealEstateProperties", "reportCount": 1, "unitRef": "facility", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2443425 - Disclosure - Concentration of Risk (Details)", "role": "http://www.caretrustreit.com/role/ConcentrationofRiskDetails", "shortName": "Concentration of Risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "idd0324c995ca4443814641cfb9cbf185_D20210101-20210331", "decimals": "INF", "lang": "en-US", "name": "ctre:ConcentrationRiskNumberOfStates", "reportCount": 1, "unique": true, "unitRef": "state", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ctre:ScheduleOfAssetsAcquisitionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "ctre:NumberOfPropertiesAcquired", "reportCount": 1, "unitRef": "property", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445426 - Disclosure - Subsequent Events (Details)", "role": "http://www.caretrustreit.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "if99ed97e33d444ff81ebb9db8eb12165_D20210401-20210430", "decimals": "INF", "lang": "en-US", "name": "ctre:NumberOfPropertiesAcquired", "reportCount": 1, "unique": true, "unitRef": "property", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Equity (Parenthetical)", "role": "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquityParenthetical", "shortName": "Condensed Consolidated Statements of Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Organization", "role": "http://www.caretrustreit.com/role/Organization", "shortName": "Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Basis of Presentation", "role": "http://www.caretrustreit.com/role/BasisofPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20210331.htm", "contextRef": "ib19d505423774e86addaeb2ea8c6cc92_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 70, "tag": { "ctre_AggregateRequiredFinancingOfCapitalExpendituresAsPercentageOfInitialInvestmentInProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate Required Financing Of Capital Expenditures As Percentage Of Initial Investment In Property", "label": "Aggregate Required Financing Of Capital Expenditures As Percentage Of Initial Investment In Property", "terseLabel": "Aggregate required financing of capital expenditures as percentage of initial investment in property (percent)" } } }, "localname": "AggregateRequiredFinancingOfCapitalExpendituresAsPercentageOfInitialInvestmentInProperty", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "ctre_AssetAcquisitionConsiderationTransferred": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Consideration Transferred", "label": "Asset Acquisition, Consideration Transferred", "terseLabel": "Purchase Price", "verboseLabel": "Aggregate purchase price" } } }, "localname": "AssetAcquisitionConsiderationTransferred", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "ctre_AssistedLivingFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assisted Living Facility [Member]", "label": "Assisted Living Facility [Member]", "terseLabel": "Assisted living", "verboseLabel": "ALF" } } }, "localname": "AssistedLivingFacilityMember", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "domainItemType" }, "ctre_AtTheMarketOfferingProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "At-The-Market Offering Program [Member]", "label": "At-The-Market Offering Program [Member]", "terseLabel": "ATM Program" } } }, "localname": "AtTheMarketOfferingProgramMember", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails", "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_BayshireLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bayshire, LLC", "label": "Bayshire, LLC [Member]", "terseLabel": "Bayshire, LLC" } } }, "localname": "BayshireLLCMember", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "ctre_CapitalImprovementsAtTripleNetLeasedFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capital Improvements At Triple Net Leased Facilities", "label": "Capital Improvements At Triple Net Leased Facilities [Member]", "terseLabel": "Certain capital improvements at triple-net leased facilities" } } }, "localname": "CapitalImprovementsAtTripleNetLeasedFacilitiesMember", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "ctre_CascadeCapitalGroupLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cascade Capital Group LLC", "label": "Cascade Capital Group LLC [Member]", "terseLabel": "Cascade Capital Group, LLC" } } }, "localname": "CascadeCapitalGroupLLCMember", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_CommuniCareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CommuniCare [Member]", "label": "CommuniCare [Member]", "terseLabel": "CommuniCare" } } }, "localname": "CommuniCareMember", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "domainItemType" }, "ctre_ConcentrationRiskNumberOfStates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of states where the entity's major tenants lease the highest concentration of properties.", "label": "Concentration Risk, Number Of States", "terseLabel": "Number of states where Ensign leases the highest concentration of properties" } } }, "localname": "ConcentrationRiskNumberOfStates", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "integerItemType" }, "ctre_DebtInstrumentRedemptionPriceUponChangeOfControlAsPercentageOfPrincipalAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument redemption price upon change of control as percentage of principal amount.", "label": "Debt Instrument Redemption Price Upon Change Of Control As Percentage Of Principal Amount", "terseLabel": "Redemption price, percentage upon change of control (percent)" } } }, "localname": "DebtInstrumentRedemptionPriceUponChangeOfControlAsPercentageOfPrincipalAmount", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails" ], "xbrltype": "percentItemType" }, "ctre_DisposalGroupIncludingDiscontinuedOperationContractPurchasePrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Contract Purchase Price", "label": "Disposal Group, Including Discontinued Operation, Contract Purchase Price", "terseLabel": "Contract purchase price" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationContractPurchasePrice", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ctre_EnsignAndPennantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ensign And Pennant", "label": "Ensign And Pennant [Member]", "terseLabel": "Ensign and Pennant" } } }, "localname": "EnsignAndPennantMember", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "ctre_EnsignEmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ensign Employees [Member]", "label": "Ensign Employees [Member]", "terseLabel": "Ensign Employees" } } }, "localname": "EnsignEmployeesMember", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_EnsignMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ensign [Member]", "label": "Ensign [Member]", "terseLabel": "Ensign" } } }, "localname": "EnsignMember", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "domainItemType" }, "ctre_EquityMethodInvestmentCumulativeContractualPreferredReturn": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity Method Investment, Cumulative Contractual Preferred Return", "label": "Equity Method Investment, Cumulative Contractual Preferred Return", "terseLabel": "Cumulative contractual preferred return through acquisition date" } } }, "localname": "EquityMethodInvestmentCumulativeContractualPreferredReturn", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "monetaryItemType" }, "ctre_EquityMethodInvestmentRateOfReturnFloor": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Method Investment, Rate Of Return, Floor", "label": "Equity Method Investment, Rate Of Return, Floor", "terseLabel": "Preferred equity investment minimum yield" } } }, "localname": "EquityMethodInvestmentRateOfReturnFloor", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "percentItemType" }, "ctre_EquityMethodInvestmentsBasisSpreadOnVariableRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Method Investments, Basis Spread On Variable Rate", "label": "Equity Method Investments, Basis Spread On Variable Rate", "terseLabel": "Basis spread of preferred equity investment yield" } } }, "localname": "EquityMethodInvestmentsBasisSpreadOnVariableRate", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "percentItemType" }, "ctre_FiveOaksHealthcareLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Five Oaks Healthcare LLC", "label": "Five Oaks Healthcare LLC [Member]", "terseLabel": "Five Oaks Healthcare LLC" } } }, "localname": "FiveOaksHealthcareLLCMember", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_FivePointTwoFiveSeniorNotesDue2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Five Point Two Five Senior Notes Due 2025 [Member]", "label": "Five Point Two Five Senior Notes Due 2025 [Member]", "terseLabel": "5.25% Senior Notes due 2025" } } }, "localname": "FivePointTwoFiveSeniorNotesDue2025Member", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_IncreaseDecreaseInDividendsPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase Decrease In Dividends Payable", "label": "Increase Decrease In Dividends Payable", "terseLabel": "Increase in dividends payable" } } }, "localname": "IncreaseDecreaseInDividendsPayable", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ctre_InitialLeaseYield": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial Lease Yield", "label": "Initial Lease Yield", "terseLabel": "Initial lease yield (percent)" } } }, "localname": "InitialLeaseYield", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "percentItemType" }, "ctre_LeaseArrangementsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Arrangements", "label": "Lease Arrangements [Axis]", "terseLabel": "Lease Arrangements [Axis]" } } }, "localname": "LeaseArrangementsAxis", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "ctre_LeaseArrangementsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Arrangements", "label": "Lease Arrangements [Domain]", "terseLabel": "Lease Arrangements [Domain]" } } }, "localname": "LeaseArrangementsDomain", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_LessorAnnualizedCashRevenueForContractsInPlace": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessor, Annualized Cash Revenue For Contracts In Place", "label": "Lessor, Annualized Cash Revenue For Contracts In Place", "terseLabel": "Current Cash Rent" } } }, "localname": "LessorAnnualizedCashRevenueForContractsInPlace", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "monetaryItemType" }, "ctre_LessorOperatingLeaseNumberOfRenewalOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessor, Operating Lease, Number Of Renewal Options", "label": "Lessor, Operating Lease, Number Of Renewal Options", "terseLabel": "Number of renewal options" } } }, "localname": "LessorOperatingLeaseNumberOfRenewalOptions", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails" ], "xbrltype": "integerItemType" }, "ctre_LineOfCreditCommitmentFeeBasedOnInvestmentGradeRatingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line Of Credit, Commitment Fee Based On Investment Grade Rating, Percentage", "label": "Line Of Credit, Commitment Fee Based On Investment Grade Rating, Percentage", "terseLabel": "Facility fee on revolving commitment fee based on investment grade ratings (percent)" } } }, "localname": "LineOfCreditCommitmentFeeBasedOnInvestmentGradeRatingPercentage", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "percentItemType" }, "ctre_LineOfCreditFacilityExtensionOptionTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line of credit facility extension option term.", "label": "Line Of Credit Facility Extension Option Term", "terseLabel": "Extension option term (in months)" } } }, "localname": "LineOfCreditFacilityExtensionOptionTerm", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "durationItemType" }, "ctre_LineOfCreditFacilityNumberOfExtensionOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line Of Credit Facility, Number Of Extension Options", "label": "Line Of Credit Facility, Number Of Extension Options", "terseLabel": "Number of extension options" } } }, "localname": "LineOfCreditFacilityNumberOfExtensionOptions", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "integerItemType" }, "ctre_LineOfCreditSubfacilityCapacityAsPercentageOfAvailableRevolvingCommitments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line Of Credit, Subfacility, Capacity As Percentage Of Available Revolving Commitments", "label": "Line Of Credit, Subfacility, Capacity As Percentage Of Available Revolving Commitments", "terseLabel": "Subfacility capacity as percentage of available revolving commitments (percent)" } } }, "localname": "LineOfCreditSubfacilityCapacityAsPercentageOfAvailableRevolvingCommitments", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "percentItemType" }, "ctre_LoanReceivableExtensionOptionTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan Receivable, Extension Option, Term", "label": "Loan Receivable, Extension Option, Term", "terseLabel": "Extension option term (in months)" } } }, "localname": "LoanReceivableExtensionOptionTerm", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "durationItemType" }, "ctre_LoanReceivableNumberOfBedsInPropertyUtilizedToSecureLoan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan Receivable, Number Of Beds In Property Utilized To Secure Loan", "label": "Loan Receivable, Number Of Beds In Property Utilized To Secure Loan", "terseLabel": "Number of beds in facility used to secure loan" } } }, "localname": "LoanReceivableNumberOfBedsInPropertyUtilizedToSecureLoan", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "integerItemType" }, "ctre_LoanReceivableNumberOfExtensionOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan Receivable, Number Of Extension Options", "label": "Loan Receivable, Number Of Extension Options", "terseLabel": "Number of extension options" } } }, "localname": "LoanReceivableNumberOfExtensionOptions", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "integerItemType" }, "ctre_LoanReceivableNumberOfFacilitiesInAgreementSecuredByMembershipInterests": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan Receivable, Number Of Facilities In Agreement Secured By Membership Interests", "label": "Loan Receivable, Number Of Facilities In Agreement Secured By Membership Interests", "terseLabel": "Number of facilities in agreement secured by membership interests" } } }, "localname": "LoanReceivableNumberOfFacilitiesInAgreementSecuredByMembershipInterests", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "integerItemType" }, "ctre_LoanReceivableNumberOfFacilitiesUtilizedToSecureMortgageLoan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan Receivable Number Of Facilities Utilized To Secure Mortgage Loan", "label": "Loan Receivable, Number Of Facilities Utilized To Secure Mortgage Loan", "terseLabel": "Facilities utilized to secure mortgage loan" } } }, "localname": "LoanReceivableNumberOfFacilitiesUtilizedToSecureMortgageLoan", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "integerItemType" }, "ctre_LoanReceivablePeriodOfUnpaidInterestPaymentsDueUponPrepayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan Receivable, Period Of Unpaid Interest Payments Due Upon Prepayment", "label": "Loan Receivable, Period Of Unpaid Interest Payments Due Upon Prepayment", "terseLabel": "Period of unpaid interest payments due upon prepayment" } } }, "localname": "LoanReceivablePeriodOfUnpaidInterestPaymentsDueUponPrepayment", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "durationItemType" }, "ctre_LoansReceivableExitFeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loans Receivable, Exit Fee, Percent", "label": "Loans Receivable, Exit Fee, Percent", "terseLabel": "Loans receivable exit fee (percent)" } } }, "localname": "LoansReceivableExitFeePercent", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "percentItemType" }, "ctre_LoansReceivableFixedInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loans Receivable, Fixed Interest Rate", "label": "Loans Receivable, Fixed Interest Rate", "terseLabel": "Loan receivable interest rate (percent)" } } }, "localname": "LoansReceivableFixedInterestRate", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "percentItemType" }, "ctre_LoansReceivableLIBORFloorPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loans Receivable, LIBOR Floor, Percentage", "label": "Loans Receivable, LIBOR Floor, Percentage", "terseLabel": "LIBOR floor for loan (percent)" } } }, "localname": "LoansReceivableLIBORFloorPercentage", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "percentItemType" }, "ctre_MantecaValleyPostAcuteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Manteca Valley Post Acute [Member]", "label": "Manteca Valley Post Acute [Member]", "terseLabel": "MCRC, LLC" } } }, "localname": "MantecaValleyPostAcuteMember", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "domainItemType" }, "ctre_MetronIntegratedHealthSystemsAffiliatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Metron Integrated Health Systems Affiliates", "label": "Metron Integrated Health Systems Affiliates [Member]", "terseLabel": "Metron affiliates" } } }, "localname": "MetronIntegratedHealthSystemsAffiliatesMember", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails" ], "xbrltype": "domainItemType" }, "ctre_MetronSkilledNursingFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Metron Skilled Nursing Facilities [Member]", "label": "Metron Skilled Nursing Facilities [Member]", "terseLabel": "Metron skilled nursing facilities" } } }, "localname": "MetronSkilledNursingFacilitiesMember", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_MezzanineLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mezzanine Loan", "label": "Mezzanine Loan [Member]", "terseLabel": "Mezzanine loan receivable" } } }, "localname": "MezzanineLoanMember", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "domainItemType" }, "ctre_MortgageLoanCombinedPrincipal": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Mortgage Loan, Combined Principal", "label": "Mortgage Loan, Combined Principal", "terseLabel": "Combined principal amount of loan" } } }, "localname": "MortgageLoanCombinedPrincipal", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "monetaryItemType" }, "ctre_MultiServiceCampusPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Multi-Service Campus Properties [Member]", "label": "Multi-Service Campus Properties [Member]", "terseLabel": "Multi-service campuses" } } }, "localname": "MultiServiceCampusPropertiesMember", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "ctre_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted": { "auth_ref": [], "calculation": { "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net income (loss) available to common stockholders basic and diluted.", "label": "Net Income Loss Available To Common Stockholders Basic And Diluted", "totalLabel": "Numerator for basic and diluted earnings available to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "ctre_NewRevolvingFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Revolving Facility [Member]", "label": "New Revolving Facility [Member]", "terseLabel": "New Revolving Facility" } } }, "localname": "NewRevolvingFacilityMember", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_NewTermLoanFeb2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Term Loan Feb 2019 [Member]", "label": "New Term Loan Feb 2019 [Member]", "terseLabel": "Term Loan" } } }, "localname": "NewTermLoanFeb2019Member", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_NextVAStarRealtyHoldingsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Next VA Star Realty Holdings LLC", "label": "Next VA Star Realty Holdings LLC [Member]", "terseLabel": "Next VA Star Realty Holdings LLC" } } }, "localname": "NextVAStarRealtyHoldingsLLCMember", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "domainItemType" }, "ctre_NobleTripleNetMasterLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Noble Triple-Net Master Lease", "label": "Noble Triple-Net Master Lease [Member]", "terseLabel": "Noble triple-net master lease" } } }, "localname": "NobleTripleNetMasterLeaseMember", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_NobleVAHoldingsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Noble VA Holdings LLC", "label": "Noble VA Holdings LLC [Member]", "terseLabel": "Noble" } } }, "localname": "NobleVAHoldingsLLCMember", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_NumberOfBedsOrUnitsInPropertiesAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Beds Or Units In Properties Acquired", "label": "Number Of Beds Or Units In Properties Acquired", "terseLabel": "Number of Beds/Units" } } }, "localname": "NumberOfBedsOrUnitsInPropertiesAcquired", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails" ], "xbrltype": "integerItemType" }, "ctre_NumberOfBedsPlannedForConstruction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Beds Planned For Construction", "label": "Number Of Beds Planned For Construction", "terseLabel": "Number of beds planned for construction" } } }, "localname": "NumberOfBedsPlannedForConstruction", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "integerItemType" }, "ctre_NumberOfOperationalBeds": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Operational Beds", "label": "Number Of Operational Beds", "terseLabel": "Number of operational beds" } } }, "localname": "NumberOfOperationalBeds", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "integerItemType" }, "ctre_NumberOfOperationalBedsAndUnitsInFacilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Operational Beds And Units In Facilities", "label": "Number Of Operational Beds And Units In Facilities", "terseLabel": "Number of operational beds and units in facilities" } } }, "localname": "NumberOfOperationalBedsAndUnitsInFacilities", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/OrganizationDetails" ], "xbrltype": "integerItemType" }, "ctre_NumberOfPropertiesAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Properties Acquired", "label": "Number Of Properties Acquired", "terseLabel": "Number of Properties", "verboseLabel": "Number of properties acquired" } } }, "localname": "NumberOfPropertiesAcquired", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "integerItemType" }, "ctre_NumberOfPropertiesSold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Properties Sold", "label": "Number Of Properties Sold", "terseLabel": "Number of properties sold" } } }, "localname": "NumberOfPropertiesSold", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "integerItemType" }, "ctre_NumberOfPropertiesToBeSold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Properties To Be Sold", "label": "Number Of Properties To Be Sold", "terseLabel": "Number of properties held for sale" } } }, "localname": "NumberOfPropertiesToBeSold", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "integerItemType" }, "ctre_NumberOfPropertiesTransferred": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Properties Transferred", "label": "Number Of Properties Transferred", "terseLabel": "Number of properties transferred" } } }, "localname": "NumberOfPropertiesTransferred", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails" ], "xbrltype": "integerItemType" }, "ctre_NumberOfPropertiesWithTenantPurchaseOption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Properties With Tenant Purchase Option", "label": "Number Of Properties With Tenant Purchase Option", "terseLabel": "Properties" } } }, "localname": "NumberOfPropertiesWithTenantPurchaseOption", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "integerItemType" }, "ctre_NumberOfUnitsAndBedsInFacilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Units And Beds In Facilities", "label": "Number Of Units And Beds In Facilities", "terseLabel": "Number of beds and units in facilities" } } }, "localname": "NumberOfUnitsAndBedsInFacilities", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "integerItemType" }, "ctre_NumberOfUnitsInPropertySold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Units In Property Sold", "label": "Number Of Units In Property Sold", "terseLabel": "Number of units in property sold" } } }, "localname": "NumberOfUnitsInPropertySold", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "integerItemType" }, "ctre_OfficerAndEmployeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Officer And Employee", "label": "Officer And Employee [Member]", "terseLabel": "Officers and employees" } } }, "localname": "OfficerAndEmployeeMember", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_OperatingLeasesAnticipatedAnnualLeaseRevenuesInSecondYearAfterAcquisition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating Leases, Anticipated Annual Lease Revenues In Second Year After Acquisition", "label": "Operating Leases, Anticipated Annual Lease Revenues In Second Year After Acquisition", "terseLabel": "Anticipated annual cash rent in second year after acquisition" } } }, "localname": "OperatingLeasesAnticipatedAnnualLeaseRevenuesInSecondYearAfterAcquisition", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "ctre_OperatingLeasesAnticipatedInitialAnnualLeaseRevenues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating Leases, Anticipated Initial Annual Lease Revenues", "label": "Operating Leases, Anticipated Initial Annual Lease Revenues", "terseLabel": "Initial Annual Cash Rent", "verboseLabel": "Initial annual cash rents" } } }, "localname": "OperatingLeasesAnticipatedInitialAnnualLeaseRevenues", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "ctre_OtherRealEstateInvestmentsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Real Estate Investments", "label": "Other Real Estate Investments [Text Block]", "terseLabel": "Other Real Estate Investments, Net" } } }, "localname": "OtherRealEstateInvestmentsTextBlock", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNet" ], "xbrltype": "textBlockItemType" }, "ctre_OwnedAndOperatedLivingFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Owned And Operated Living Facilities [Member]", "label": "Owned And Operated Living Facilities [Member]", "terseLabel": "Owned and operated living facility" } } }, "localname": "OwnedAndOperatedLivingFacilitiesMember", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_PaymentsToAcquireEquipmentFurnitureAndFixturesAndDevelopRealEstateAssets": { "auth_ref": [], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Equipment, Furniture And Fixtures And Develop Real Estate Assets", "label": "Payments To Acquire Equipment, Furniture And Fixtures And Develop Real Estate Assets", "negatedTerseLabel": "Purchases of equipment, furniture and fixtures and improvements to real estate" } } }, "localname": "PaymentsToAcquireEquipmentFurnitureAndFixturesAndDevelopRealEstateAssets", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ctre_PortionOfCommitmentSubjectToRentIncreaseAtTimeOfFunding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Portion Of Commitment Subject To Rent Increase At Time Of Funding", "label": "Portion Of Commitment Subject To Rent Increase At Time Of Funding", "terseLabel": "Portion of funding commitment subject to rent increase at time of funding" } } }, "localname": "PortionOfCommitmentSubjectToRentIncreaseAtTimeOfFunding", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "ctre_PreferredEquityInvestmentCascadiaDevelopmentBoiseIDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Equity Investment Cascadia Development Boise ID", "label": "Preferred Equity Investment Cascadia Development Boise ID [Member]", "terseLabel": "Cascadia Development, Boise ID" } } }, "localname": "PreferredEquityInvestmentCascadiaDevelopmentBoiseIDMember", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "domainItemType" }, "ctre_PriorityManagementGroupLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Priority Management Group LLC", "label": "Priority Management Group LLC [Member]", "terseLabel": "PMG" } } }, "localname": "PriorityManagementGroupLLCMember", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "domainItemType" }, "ctre_PropertiesWithPurchaseOptionLeaseExpirationMarch2029FirstOption2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Properties With Purchase Option, Lease Expiration March 2029, First Option 2022", "label": "Properties With Purchase Option, Lease Expiration March 2029, First Option 2022 [Member]", "terseLabel": "Lease Expiration March 2029, First option 2022" } } }, "localname": "PropertiesWithPurchaseOptionLeaseExpirationMarch2029FirstOption2022Member", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "domainItemType" }, "ctre_PropertiesWithPurchaseOptionLeaseExpirationNovember2030FirstOption2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Properties With Purchase Option, Lease Expiration November 2030, First Option 2022", "label": "Properties With Purchase Option, Lease Expiration November 2030, First Option 2022 [Member]", "terseLabel": "Lease Expiration November 2030, First option 2022" } } }, "localname": "PropertiesWithPurchaseOptionLeaseExpirationNovember2030FirstOption2022Member", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "domainItemType" }, "ctre_PropertiesWithPurchaseOptionLeaseExpirationNovember2034FirstOption2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Properties With Purchase Option, Lease Expiration November 2034, First Option 2024", "label": "Properties With Purchase Option, Lease Expiration November 2034, First Option 2024 [Member]", "terseLabel": "Lease Expiration November 2034, First option 2024" } } }, "localname": "PropertiesWithPurchaseOptionLeaseExpirationNovember2034FirstOption2024Member", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "domainItemType" }, "ctre_PropertiesWithPurchaseOptionLeaseExpirationOctober2032FirstOption2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Properties With Purchase Option, Lease Expiration October 2032, First Option 2023", "label": "Properties With Purchase Option, Lease Expiration October 2032, First Option 2023 [Member]", "terseLabel": "Lease Expiration October 2032, First option 2023" } } }, "localname": "PropertiesWithPurchaseOptionLeaseExpirationOctober2032FirstOption2023Member", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "domainItemType" }, "ctre_PropertiesWithPurchaseOptionLeaseExpirationOctober2034FirstOption2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Properties With Purchase Option, Lease Expiration October 2034, First Option 2021", "label": "Properties With Purchase Option, Lease Expiration October 2034, First Option 2021 [Member]", "terseLabel": "Lease Expiration October 2034, First option 2021" } } }, "localname": "PropertiesWithPurchaseOptionLeaseExpirationOctober2034FirstOption2021Member", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "domainItemType" }, "ctre_PropertiesWithPurchaseOptionLeaseExpirationOctober2034FirstOption2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Properties With Purchase Option, Lease Expiration October 2034. First Option 2026", "label": "Properties With Purchase Option, Lease Expiration October 2034. First Option 2026 [Member]", "terseLabel": "Lease Expiration October 2034, First option 2026" } } }, "localname": "PropertiesWithPurchaseOptionLeaseExpirationOctober2034FirstOption2026Member", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "domainItemType" }, "ctre_PurchaseAndSaleAgreementAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchase And Sale Agreement, Amount", "label": "Purchase And Sale Agreement, Amount", "terseLabel": "Purchase and sale agreement amount" } } }, "localname": "PurchaseAndSaleAgreementAmount", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "monetaryItemType" }, "ctre_PurchaseAndSaleAgreementMaturityDateOptionNumberOfDaysAfterTermination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase And Sale Agreement, Maturity Date Option, Number Of Days After Termination", "label": "Purchase And Sale Agreement, Maturity Date Option, Number Of Days After Termination", "terseLabel": "Number of days after termination of purchase and sale agreement for maturity" } } }, "localname": "PurchaseAndSaleAgreementMaturityDateOptionNumberOfDaysAfterTermination", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "durationItemType" }, "ctre_ScheduleOfAssetsAcquisitionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Assets Acquisitions [Table Text Block]", "label": "Schedule Of Assets Acquisitions [Table Text Block]", "terseLabel": "Schedule of Real Estate Acquisitions" } } }, "localname": "ScheduleOfAssetsAcquisitionsTableTextBlock", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "ctre_ScheduleOfShareBasedPaymentAwardPerformanceStockAwardValuationAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Share-Based Payment Award, Performance Stock Award, Valuation Assumptions", "label": "Schedule Of Share-Based Payment Award, Performance Stock Award, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardPerformanceStockAwardValuationAssumptionsTableTextBlock", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "ctre_ScheduleOfTenantPurchaseOptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Tenant Purchase Options", "label": "Schedule Of Tenant Purchase Options [Table Text Block]", "terseLabel": "Schedule Of Tenant Purchase Options" } } }, "localname": "ScheduleOfTenantPurchaseOptionsTableTextBlock", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "ctre_SecuritiesOfferingAuthorizedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Securities Offering, Authorized Amount", "label": "Securities Offering, Authorized Amount", "terseLabel": "Authorized aggregate offering price of common stock" } } }, "localname": "SecuritiesOfferingAuthorizedAmount", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ctre_SecuritiesOfferingRemainingAuthorizedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Securities Offering, Remaining Authorized Amount", "label": "Securities Offering, Remaining Authorized Amount", "terseLabel": "Remaining offering amount available" } } }, "localname": "SecuritiesOfferingRemainingAuthorizedAmount", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ctre_SeniorUnsecuredNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Unsecured Notes [Member]", "label": "Senior Unsecured Notes [Member]", "terseLabel": "Senior unsecured notes payable" } } }, "localname": "SeniorUnsecuredNotesMember", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "ctre_SeniorUnsecuredTermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Unsecured Term Loan [Member]", "label": "Senior Unsecured Term Loan [Member]", "terseLabel": "Senior unsecured term loan", "verboseLabel": "New Term Loan" } } }, "localname": "SeniorUnsecuredTermLoanMember", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfEqualAnnualInstallments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting, Number of Equal Annual Installments", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting, Number Of Equal Annual Installments", "terseLabel": "Number of equal annual vesting installments" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfEqualAnnualInstallments", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "integerItemType" }, "ctre_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedSpinOffInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options nonvested spin off in period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Spin Off In Period", "terseLabel": "Stock awards unvested during spin-off (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedSpinOffInPeriod", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "ctre_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityTermForExpectedVolatility": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Historical Volatility Term For Expected Volatility", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Term For Expected Volatility", "terseLabel": "Historical volatility term basis for expected volatility assumption" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityTermForExpectedVolatility", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "ctre_ShareBasedCompensationArrangementByShareBasedPaymentAwardTSRPerformancePercentageToVestRelativeToInitialGrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, TSR Performance, Percentage To Vest Relative To Initial Grant", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, TSR Performance, Percentage To Vest Relative To Initial Grant", "terseLabel": "Percentage of awards to vest relative To initial grant based on TSR performance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTSRPerformancePercentageToVestRelativeToInitialGrant", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "ctre_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingMetricTSRPerformancePeerGroupNumberOfCompanies": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Vesting Metric, TSR Performance Peer Group Number Of Companies", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Vesting Metric, TSR Performance Peer Group Number Of Companies", "terseLabel": "Number of publicly traded healthcare REITs in peer group" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingMetricTSRPerformancePeerGroupNumberOfCompanies", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "integerItemType" }, "ctre_SharesIssuedDuringPeriodAveragePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares Issued During Period, Average Price Per Share", "label": "Shares Issued During Period, Average Price Per Share", "terseLabel": "Average sales price per share (usd per share)" } } }, "localname": "SharesIssuedDuringPeriodAveragePricePerShare", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails" ], "xbrltype": "perShareItemType" }, "ctre_SkilledNursingAndCampusFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Skilled Nursing And Campus Facilities", "label": "Skilled Nursing And Campus Facilities [Member]", "terseLabel": "Skilled nursing and campus facilities", "verboseLabel": "SNF / Campus" } } }, "localname": "SkilledNursingAndCampusFacilitiesMember", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "domainItemType" }, "ctre_SkilledNursingFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Skilled Nursing Facility [Member]", "label": "Skilled Nursing Facility [Member]", "verboseLabel": "SNF" } } }, "localname": "SkilledNursingFacilityMember", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "domainItemType" }, "ctre_SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Skilled Nursing, Multi Service Campuses, Assisted Living, and Independent Living Facilities", "label": "Skilled Nursing, Multi Service Campuses, Assisted Living, and Independent Living Facilities [Member]", "terseLabel": "Skilled nursing, multi-service campuses, assisted living and independent living facilities" } } }, "localname": "SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMember", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails", "http://www.caretrustreit.com/role/OrganizationDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_SkilledNursingPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Skilled Nursing Properties [Member]", "label": "Skilled Nursing Properties [Member]", "terseLabel": "Skilled nursing", "verboseLabel": "Skilled nursing properties" } } }, "localname": "SkilledNursingPropertiesMember", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "ctre_SwinglineLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Swingline Loan [Member]", "label": "Swingline Loan [Member]", "terseLabel": "Swingline loan" } } }, "localname": "SwinglineLoanMember", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_TransferOfPreacquisitionCostsToAcquiredAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Transfer Of Preacquisition Costs To Acquired Assets", "label": "Transfer Of Preacquisition Costs To Acquired Assets", "terseLabel": "Transfer of pre-acquisition costs to acquired assets" } } }, "localname": "TransferOfPreacquisitionCostsToAcquiredAssets", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ctre_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasicAndDiluted": { "auth_ref": [], "calculation": { "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails": { "order": 2.0, "parentTag": "ctre_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Undistributed earnings (loss) allocated to participating securities, basic and diluted.", "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic and Diluted", "negatedLabel": "Less: Net income allocated to participating securities" } } }, "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasicAndDiluted", "nsuri": "http://www.caretrustreit.com/20210331", "presentation": [ "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r34", "r74" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails", "http://www.caretrustreit.com/role/ConcentrationofRiskDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r131", "r173", "r175", "r313" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r186", "r189", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r312", "r314" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/EquityNarrativeDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r186", "r189", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r312", "r314" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r131", "r173", "r175", "r313" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "domainItemType" }, "srt_OfficerMember": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "label": "Officer [Member]", "terseLabel": "Officers" } } }, "localname": "OfficerMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r176", "r186", "r189", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r312", "r314" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/EquityNarrativeDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r176", "r186", "r189", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r312", "r314" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/EquityNarrativeDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "auth_ref": [ "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327" ], "lang": { "en-us": { "role": { "label": "Name of Property [Axis]", "terseLabel": "Name of Property [Axis]" } } }, "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails", "http://www.caretrustreit.com/role/OrganizationDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "auth_ref": [ "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327" ], "lang": { "en-us": { "role": { "label": "Name of Property [Domain]", "terseLabel": "Name of Property [Domain]" } } }, "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails", "http://www.caretrustreit.com/role/OrganizationDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails", "http://www.caretrustreit.com/role/ConcentrationofRiskDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r153", "r187", "r266" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r132", "r263" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Information by type of receivable.", "label": "Receivable Type [Axis]", "terseLabel": "Receivable Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilities": { "auth_ref": [], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.", "label": "Accounts Payable and Other Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNet": { "auth_ref": [ "r14", "r296" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts Receivable, after Allowance for Credit Loss", "terseLabel": "Accounts and other receivables, net" } } }, "localname": "AccountsReceivableNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDistributionsInExcessOfNetIncome": { "auth_ref": [ "r319" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount as of the balance sheet date by which cumulative distributions to shareholders (or partners) exceed retained earnings (or accumulated earnings).", "label": "Accumulated Distributions in Excess of Net Income", "negatedLabel": "Cumulative distributions in excess of earnings" } } }, "localname": "AccumulatedDistributionsInExcessOfNetIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDistributionsInExcessOfNetIncomeMember": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Cumulative distributions to shareholders (or partners) in excess of retained earnings (or accumulated earnings).", "label": "Accumulated Distributions in Excess of Net Income [Member]", "terseLabel": "Cumulative Distributions in Excess of Earnings" } } }, "localname": "AccumulatedDistributionsInExcessOfNetIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r15" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r77", "r78", "r79", "r207", "r208", "r209" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r190", "r192", "r212", "r213" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Amortization of stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r163", "r170" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "negatedTerseLabel": "Issuance of common stock, net" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r192", "r204", "r211" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Amortization of stock-based compensation", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.caretrustreit.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r63", "r253" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of deferred financing costs" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r73", "r117", "r121", "r127", "r138", "r220", "r222", "r241", "r280", "r297" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup": { "auth_ref": [ "r145" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets held-for-sale that are not part of a disposal group.", "label": "Assets Held-for-sale, Not Part of Disposal Group", "terseLabel": "Assets held for sale, net" } } }, "localname": "AssetsHeldForSaleNotPartOfDisposalGroup", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r193", "r206" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails", "http://www.caretrustreit.com/role/StockBasedCompensationValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/BasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r236", "r237" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Amount" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r5", "r20", "r65" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r58", "r65", "r70" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r58", "r242" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental schedule of noncash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails", "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r29", "r152", "r286", "r302" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r149", "r150", "r151", "r154" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Common dividends (in usd per share)", "verboseLabel": "Dividends declared per share" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquityParenthetical", "http://www.caretrustreit.com/role/EquityDividendsonCommonStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r77", "r78" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized (shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r13", "r163" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, outstanding (shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r13" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.01 par value; 500,000,000 shares authorized, 95,981,062 and 95,215,797 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r109", "r110", "r131", "r238", "r239" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r109", "r110", "r131", "r238", "r239", "r318" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r109", "r110", "r131", "r238", "r239", "r318" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]", "terseLabel": "Concentration of Risk" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRisk" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r109", "r110", "r131", "r238", "r239" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk (percent)" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r107", "r109", "r110", "r111", "r238", "r240" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r109", "r110", "r131", "r238", "r239" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r45", "r278" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Independent living facilities" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r44" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r108", "r131" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer concentration risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r7", "r8", "r9", "r281", "r283", "r295" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate (percent)" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r9", "r156", "r283", "r295" ], "calculation": { "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Principal Amount", "verboseLabel": "Outstanding amounts" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r252", "r254" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument face amount", "verboseLabel": "Senior unsecured notes payable - face value" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate (percent)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r28", "r75", "r164", "r167", "r168", "r169", "r251", "r252", "r254", "r294" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r253" ], "calculation": { "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "negatedTerseLabel": "Deferred Loan Fees" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r23", "r253" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Deferred financing costs, net" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r63", "r147" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r63", "r116" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization (including below-market ground leases)" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsHeldforsaleMember": { "auth_ref": [ "r0", "r1", "r2" ], "lang": { "en-us": { "role": { "documentation": "Component or group of components classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.", "label": "Discontinued Operations, Held-for-sale [Member]", "terseLabel": "Held for sale" } } }, "localname": "DiscontinuedOperationsHeldforsaleMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r146", "r148" ], "lang": { "en-us": { "role": { "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Disposed of by sale" } } }, "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r185", "r188" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DividendPayableDateToBePaidDayMonthAndYear": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Date the declared dividend will be paid, in CCYY-MM-DD format.", "label": "Dividends Payable, Date to be Paid", "terseLabel": "Dividends payment date" } } }, "localname": "DividendPayableDateToBePaidDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityDividendsonCommonStockDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DividendsCommonStock": { "auth_ref": [ "r170", "r293" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Common Stock", "negatedLabel": "Common dividends", "terseLabel": "Dividends payable as of record date" } } }, "localname": "DividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity", "http://www.caretrustreit.com/role/EquityDividendsonCommonStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsCommonStockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dividends, Common Stock [Abstract]", "terseLabel": "Dividends on common stock" } } }, "localname": "DividendsCommonStockAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityDividendsonCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsDeclaredTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.", "label": "Dividends Declared [Table Text Block]", "terseLabel": "Schedule of Dividends on Common Stock" } } }, "localname": "DividendsDeclaredTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "auth_ref": [ "r8", "r10", "r282", "r298" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.", "label": "Dividends Payable", "verboseLabel": "Dividends payable" } } }, "localname": "DividendsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableDateOfRecordDayMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date the holder must own the stock to be entitled to the dividend, in CCYY-MM-DD format.", "label": "Dividends Payable, Date of Record", "terseLabel": "Dividends record date" } } }, "localname": "DividendsPayableDateOfRecordDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityDividendsonCommonStockDetails" ], "xbrltype": "dateItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r41", "r82", "r83", "r84", "r85", "r86", "r90", "r92", "r94", "r95", "r96", "r100", "r101", "r289", "r307" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in usd per share)", "verboseLabel": "Earnings (loss) per common share, basic (in usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements", "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r41", "r82", "r83", "r84", "r85", "r86", "r92", "r94", "r95", "r96", "r100", "r101", "r289", "r307" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in usd per share)", "verboseLabel": "Earnings (loss) per common share, diluted (in usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements", "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r97", "r98", "r99", "r102" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Common Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/EarningsPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r205" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unamortized stock-based compensation expense related to unvested awards" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average remaining vesting period related to expense recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r77", "r78", "r79", "r81", "r87", "r89", "r104", "r139", "r163", "r170", "r207", "r208", "r209", "r216", "r217", "r243", "r244", "r245", "r246", "r247", "r248", "r315", "r316", "r317" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "auth_ref": [ "r39", "r57", "r63", "r305" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.", "label": "Proceeds from Equity Method Investment, Distribution", "terseLabel": "Interest income distribution from other real estate investment" } } }, "localname": "EquityMethodInvestmentDividendsOrDistributions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r21", "r118", "r136" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Preferred equity investment" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair Value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r225", "r226", "r227", "r231" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r225", "r226" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Items Measured at Fair Value on a Recurring Basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r225", "r236", "r237" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r225", "r236" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Summary of Face Value, Carrying Amount and Fair Value of Financial Instruments" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r226", "r268", "r269", "r270" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails", "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r225", "r232" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r225", "r226", "r228", "r229", "r233" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r177", "r178", "r183", "r184", "r226", "r268" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r177", "r178", "r183", "r184", "r226", "r269" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails", "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r226", "r270" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r268", "r269", "r270" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails", "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r230", "r233" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]", "terseLabel": "Financial liabilities:" } } }, "localname": "FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Financing Receivable, Past Due [Line Items]", "terseLabel": "Financing Receivable, Past Due [Line Items]" } } }, "localname": "FinancingReceivableRecordedInvestmentPastDueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivablesEqualToGreaterThan90DaysPastDueMember": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Financial asset equal to or greater than 90 days past due.", "label": "Financial Asset, Equal to or Greater than 90 Days Past Due [Member]", "terseLabel": "Greater than 90 days past due" } } }, "localname": "FinancingReceivablesEqualToGreaterThan90DaysPastDueMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancingReceivablesPeriodPastDueAxis": { "auth_ref": [ "r140", "r143" ], "lang": { "en-us": { "role": { "documentation": "Information by time period financial asset is past due.", "label": "Financial Asset, Period Past Due [Axis]", "terseLabel": "Financial Asset, Aging [Axis]" } } }, "localname": "FinancingReceivablesPeriodPastDueAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivablesPeriodPastDueDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period in which financial asset is past due. Element name and standard label in Financial Asset, [numeric lower end] to [numeric higher end] [date measure] Past Due [Member] or Financial Asset, Greater Than [low end numeric value] [date measure] Past Due [Member] or Financial Asset, Less Than [high end numeric value] [date measure] Past Due [Member] formats.", "label": "Financial Asset, Period Past Due [Domain]", "terseLabel": "Financial Asset, Aging [Domain]" } } }, "localname": "FinancingReceivablesPeriodPastDueDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r144", "r279" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails": { "order": 4.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Identified intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FixturesAndEquipmentGross": { "auth_ref": [], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails": { "order": 3.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of fixtures and equipment. Includes, but is not limited to, machinery, equipment, and engines.", "label": "Fixtures and Equipment, Gross", "terseLabel": "Integral equipment, furniture and fixtures" } } }, "localname": "FixturesAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnTerminationOfLease": { "auth_ref": [ "r255" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingLeaseLeaseIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.", "label": "Gain (Loss) on Termination of Lease", "terseLabel": "Lease termination revenue" } } }, "localname": "GainLossOnTerminationOfLease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnSalesOfInvestmentRealEstate": { "auth_ref": [ "r42", "r43", "r63", "r287", "r308", "r309", "r310", "r311" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net gain (loss) resulting from sales and other disposals of real estate owned for investment purposes.", "label": "Gains (Losses) on Sales of Investment Real Estate", "negatedTerseLabel": "Loss on sale of real estate", "terseLabel": "Loss on sale of real estate", "verboseLabel": "Gain (loss) on sale of real estate" } } }, "localname": "GainsLossesOnSalesOfInvestmentRealEstate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements", "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r46" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r185", "r188" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r62" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r62" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts and other receivables, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Change in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r62" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets, net" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "stringItemType" }, "us-gaap_InterestAndFeeIncomeLoansCommercialRealEstate": { "auth_ref": [ "r290" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest and fee income generated from loans secured by commercial properties. Examples of properties commonly securing commercial real estate loans may include office buildings, apartment buildings, shopping centers, industrial property, and hotels.", "label": "Interest and Fee Income, Loans, Commercial, Real Estate", "terseLabel": "Interest income" } } }, "localname": "InterestAndFeeIncomeLoansCommercialRealEstate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestAndOtherIncome": { "auth_ref": [], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements": { "order": 3.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).", "label": "Interest and Other Income", "terseLabel": "Interest and other income" } } }, "localname": "InterestAndOtherIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r37", "r115", "r250", "r253", "r291" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest Income, Other", "terseLabel": "Interest income related to preferred equity investments" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r56", "r60", "r66" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentBuildingAndBuildingImprovements": { "auth_ref": [ "r304" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails": { "order": 2.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate of the carrying amounts as of the balance sheet date of investments in building and building improvements.", "label": "Investment Building and Building Improvements", "terseLabel": "Buildings and improvements" } } }, "localname": "InvestmentBuildingAndBuildingImprovements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Land": { "auth_ref": [ "r6", "r22" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails": { "order": 1.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land", "terseLabel": "Land" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]", "terseLabel": "Lease Contractual Term [Axis]" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement.", "label": "Lease Contractual Term [Domain]", "terseLabel": "Lease Contractual Term [Domain]" } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LessorLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessor, Lease, Description [Line Items]", "terseLabel": "Lessor, Lease, Description [Line Items]" } } }, "localname": "LessorLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LessorLeaseDescriptionTable": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessor's leases.", "label": "Lessor, Lease, Description [Table]", "terseLabel": "Lessor, Lease, Description [Table]" } } }, "localname": "LessorLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessor, Operating Lease, Payments, Fiscal Year Maturity [Abstract]", "terseLabel": "Future Contractual Minimum Rental Income" } } }, "localname": "LessorOperatingLeasePaymentsFiscalYearMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "auth_ref": [ "r258" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payments to be received by lessor for operating lease.", "label": "Lessor, Operating Lease, Payments to be Received", "totalLabel": "Total" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceived", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": { "auth_ref": [ "r258" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails": { "order": 6.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Five", "terseLabel": "2026" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": { "auth_ref": [ "r258" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails": { "order": 5.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Four", "terseLabel": "2025" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.", "label": "Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Schedule of Total Future Contractual Minimum Rental Income" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": { "auth_ref": [ "r258" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year One", "terseLabel": "2022" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear": { "auth_ref": [ "r258" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year", "terseLabel": "2021 (nine months)" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter": { "auth_ref": [ "r258" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails": { "order": 7.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThereafter", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": { "auth_ref": [ "r258" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails": { "order": 4.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Three", "terseLabel": "2024" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "auth_ref": [ "r258" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails": { "order": 3.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Two", "terseLabel": "2023" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeaseRenewalTerm": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Term of lessor's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessor, Operating Lease, Renewal Term", "terseLabel": "Lease renewal term (in years)" } } }, "localname": "LessorOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LessorOperatingLeaseTermOfContract": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessor, Operating Lease, Term of Contract", "terseLabel": "Initial lease term (in years)", "verboseLabel": "Amended lease term (in years)" } } }, "localname": "LessorOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r26", "r73", "r122", "r138", "r221", "r222", "r223", "r241" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r18", "r73", "r138", "r241", "r284", "r300" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Equity:" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r9", "r283", "r295" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Unsecured revolving credit facility" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Facility fee on revolving commitment fees (percent)" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r24" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Credit facility borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r24", "r75" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Unsecured revolving credit facility", "verboseLabel": "Revolving Facility" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LoansReceivableBasisSpreadOnVariableRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage points (also referred to as 'margin') added to the reference rate as stated in the loan agreement and used to compute the variable rate on the loans receivable. For instance, the loan agreement might state that the interest rate the borrower is obligated to pay is the London Interbank Offered Rate (LIBOR) plus three quarters (3/4) of a percentage point adjusted quarterly (each three months). LIBOR in this example is the index or reference rate, 3/4 percentage point is the margin, the reference rate plus the margin is the fully indexed rate. This element would be used to report separately the margin.", "label": "Loans Receivable, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate for loan (percent)" } } }, "localname": "LoansReceivableBasisSpreadOnVariableRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LoansReceivableFairValueDisclosure": { "auth_ref": [ "r135" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of loan receivable, including, but not limited to, mortgage loans held for investment, finance receivables held for investment, policy loans on insurance contracts.", "label": "Loans Receivable, Fair Value Disclosure", "verboseLabel": "Mezzanine loan receivable" } } }, "localname": "LoansReceivableFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An amount of money or property, or a portion thereof, leant to a borrower (debtor) in exchange for a promise to repay the amount borrowed plus interest at a date certain in the future.", "label": "Loans Receivable [Member]", "terseLabel": "Other loans receivable" } } }, "localname": "LoansReceivableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "LIBOR" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r9", "r157", "r283", "r299" ], "calculation": { "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Outstanding borrowings", "totalLabel": "Carrying Value" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermLoansPayable": { "auth_ref": [ "r28" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Loans Payable, Noncurrent", "terseLabel": "Senior unsecured term loan, net" } } }, "localname": "LongTermLoansPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r28", "r155" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MortgageReceivablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amounts due the Company for loans secured by the collateral of specified real estate property and which loan the borrower (debtor) is obligated to repay in accordance with a predetermined set of payments.", "label": "Mortgage Receivable [Member]", "terseLabel": "Mortgage loan receivable" } } }, "localname": "MortgageReceivablesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r58" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r58" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r58", "r61", "r64" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r3", "r35", "r36", "r40", "r64", "r73", "r80", "r82", "r83", "r84", "r85", "r88", "r89", "r93", "r117", "r120", "r123", "r126", "r128", "r138", "r241", "r288", "r306" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails": { "order": 1.0, "parentTag": "ctre_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss)", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements", "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity", "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1": { "auth_ref": [ "r67", "r68", "r69" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction.", "label": "Noncash or Part Noncash Divestiture, Amount of Consideration Received", "terseLabel": "Sale of real estate settled with note receivable" } } }, "localname": "NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other loss:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayableFairValueDisclosure": { "auth_ref": [ "r25" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of notes payable.", "label": "Notes Payable, Fair Value Disclosure", "terseLabel": "Senior unsecured notes payable" } } }, "localname": "NotesPayableFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableGross": { "auth_ref": [ "r141", "r142", "r143" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of financing receivable.", "label": "Financing Receivable, before Allowance for Credit Loss", "terseLabel": "Mortgage loan receivable" } } }, "localname": "NotesReceivableGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableNet": { "auth_ref": [ "r14", "r133", "r141" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.", "label": "Financing Receivable, after Allowance for Credit Loss", "terseLabel": "Loan receivable" } } }, "localname": "NotesReceivableNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfRealEstateProperties": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of real estate properties owned as of the balance sheet date.", "label": "Number of Real Estate Properties", "terseLabel": "Number of facilities" } } }, "localname": "NumberOfRealEstateProperties", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails", "http://www.caretrustreit.com/role/OrganizationDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfStatesInWhichEntityOperates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of states the entity operates in as of the balance sheet date.", "label": "Number of States in which Entity Operates", "terseLabel": "Number of states with properties" } } }, "localname": "NumberOfStatesInWhichEntityOperates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/OrganizationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLeaseIncome": { "auth_ref": [ "r103", "r257", "r262" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 }, "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable.", "label": "Operating Lease, Lease Income", "terseLabel": "Rental income", "totalLabel": "Total rental income" } } }, "localname": "OperatingLeaseLeaseIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLeaseIncomeLeasePayments": { "auth_ref": [ "r103", "r261" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLeaseIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.", "label": "Operating Lease, Lease Income, Lease Payments", "terseLabel": "Contractual rent due" } } }, "localname": "OperatingLeaseLeaseIncomeLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": { "auth_ref": [ "r103", "r262" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of components of income from operating lease.", "label": "Operating Lease, Lease Income [Table Text Block]", "terseLabel": "Schedule of Rental Income" } } }, "localname": "OperatingLeaseLeaseIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r4", "r224" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.", "label": "Other Commitment", "terseLabel": "Funding commitment" } } }, "localname": "OtherCommitment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of other commitment.", "label": "Other Commitments [Axis]", "terseLabel": "Other Commitments [Axis]" } } }, "localname": "OtherCommitmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other future obligation.", "label": "Other Commitments [Domain]", "terseLabel": "Other Commitments [Domain]" } } }, "localname": "OtherCommitmentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCommitmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Commitments [Line Items]", "terseLabel": "Other Commitments [Line Items]" } } }, "localname": "OtherCommitmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about obligations resulting from other commitments.", "label": "Other Commitments [Table]", "terseLabel": "Other Commitments [Table]" } } }, "localname": "OtherCommitmentsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsForDepositsOnRealEstateAcquisitions": { "auth_ref": [ "r51" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow related to amounts given in advance to show or confirm an intention to complete an acquisition of land, buildings, other structures, or any item classified as real estate.", "label": "Payments for Deposits on Real Estate Acquisitions", "negatedTerseLabel": "Escrow deposits for potential acquisitions of real estate" } } }, "localname": "PaymentsForDepositsOnRealEstateAcquisitions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r54" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends paid on common stock" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r55" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedTerseLabel": "Proceeds from (costs paid for) the issuance of common stock, net", "terseLabel": "Commissions paid on stock issuance" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r54" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Net-settle adjustment on restricted stock" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireCommercialRealEstate": { "auth_ref": [ "r51" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from the acquisition of property as primarily intended to generate income for its owner.", "label": "Payments to Acquire Commercial Real Estate", "negatedTerseLabel": "Acquisitions of real estate, net of deposits applied", "terseLabel": "Payment to acquire facility" } } }, "localname": "PaymentsToAcquireCommercialRealEstate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireLoansReceivable": { "auth_ref": [ "r50" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the purchase of loan receivable arising from the financing of goods and services.", "label": "Payments to Acquire Loans Receivable", "negatedTerseLabel": "Investment in real estate mortgage and other loans receivable" } } }, "localname": "PaymentsToAcquireLoansReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance stock award" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails", "http://www.caretrustreit.com/role/StockBasedCompensationValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in usd per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized (shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, issued (shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, outstanding (shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r12" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.01 par value; 100,000,000 shares authorized, no shares issued and outstanding as of March 31, 2021 and December 31, 2020" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssets": { "auth_ref": [], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.", "label": "Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other assets, net" } } }, "localname": "PrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrimeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.", "label": "Prime Rate [Member]", "terseLabel": "Prime Rate" } } }, "localname": "PrimeRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromCollectionOfLoansReceivable": { "auth_ref": [ "r47" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the collection, including prepayments, of loans receivable issued for financing of goods and services.", "label": "Proceeds from Collection of Loans Receivable", "terseLabel": "Principal payments received on real estate mortgage and other loans receivable" } } }, "localname": "ProceedsFromCollectionOfLoansReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "auth_ref": [ "r53" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.", "label": "Proceeds from Debt, Net of Issuance Costs", "terseLabel": "Net proceeds from issuance of senior notes" } } }, "localname": "ProceedsFromDebtNetOfIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": { "auth_ref": [ "r48", "r57" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.", "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital", "terseLabel": "Repayment of other real estate investment", "verboseLabel": "Return of initial investment" } } }, "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r52" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Gross proceeds", "verboseLabel": "Proceeds from (costs paid for) the issuance of common stock, net" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfUnsecuredDebt": { "auth_ref": [ "r53" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt.", "label": "Proceeds from Issuance of Unsecured Debt", "verboseLabel": "Gross proceeds from issuance of senior notes" } } }, "localname": "ProceedsFromIssuanceOfUnsecuredDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLoans": { "auth_ref": [ "r59" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from principal payments made on loans related to operating activities.", "label": "Proceeds from Loans", "terseLabel": "Proceeds from settlement of loan" } } }, "localname": "ProceedsFromLoans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "auth_ref": [ "r53" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Proceeds from Long-term Lines of Credit", "terseLabel": "Borrowings under unsecured revolving credit facility" } } }, "localname": "ProceedsFromLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfRealEstateHeldforinvestment": { "auth_ref": [ "r49" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from the sale of real estate that is held for investment, that is, it is part of an investing activity during the period.", "label": "Proceeds from Sale of Real Estate Held-for-investment", "terseLabel": "Net proceeds from sales of real estate", "verboseLabel": "Proceeds from sale" } } }, "localname": "ProceedsFromSaleOfRealEstateHeldforinvestment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Real Estate [Abstract]", "terseLabel": "Real Estate [Abstract]" } } }, "localname": "RealEstateAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RealEstateDisclosureTextBlock": { "auth_ref": [ "r328", "r329", "r330", "r331", "r332" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for certain real estate investment financial statements, real estate investment trust operating support agreements, real estate owned, retail land sales, time share transactions, as well as other real estate related disclosures.", "label": "Real Estate Disclosure [Text Block]", "terseLabel": "Real Estate Investments, Net" } } }, "localname": "RealEstateDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_RealEstateInvestmentPropertyAccumulatedDepreciation": { "auth_ref": [ "r303" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails": { "order": 2.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of depreciation for real estate property held for investment purposes.", "label": "Real Estate Investment Property, Accumulated Depreciation", "negatedLabel": "Accumulated depreciation and amortization" } } }, "localname": "RealEstateInvestmentPropertyAccumulatedDepreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyAtCost": { "auth_ref": [ "r304" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails": { "order": 1.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of real estate investment property which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments.", "label": "Real Estate Investment Property, at Cost", "totalLabel": "Real estate investments" } } }, "localname": "RealEstateInvestmentPropertyAtCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyNet": { "auth_ref": [ "r304" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of real estate investment property, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments.", "label": "Real Estate Investment Property, Net", "terseLabel": "Real estate investments, net", "totalLabel": "Real estate investments, net" } } }, "localname": "RealEstateInvestmentPropertyNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetInvestmentinOwnedPropertiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentsJointVentures": { "auth_ref": [ "r304" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The book value of investments in real estate joint ventures including direct and indirect investments.", "label": "Real Estate Investments, Joint Ventures", "terseLabel": "Other real estate investments, net" } } }, "localname": "RealEstateInvestmentsJointVentures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets", "http://www.caretrustreit.com/role/OrganizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Real Estate [Line Items]", "terseLabel": "Real Estate [Line Items]" } } }, "localname": "RealEstateLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RealEstatePropertiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Real Estate Properties [Line Items]", "terseLabel": "Real Estate Properties [Line Items]" } } }, "localname": "RealEstatePropertiesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/OrganizationDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RealEstateTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about real estate investment companies including, but not limited to, real estate investment trusts, real estate owned, retail land sales, and time share transactions.", "label": "Real Estate [Table]", "terseLabel": "Real Estate [Table]" } } }, "localname": "RealEstateTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RealEstateTaxExpense": { "auth_ref": [ "r215" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A tax based on the assessed value of real estate by the local government. The tax is usually based on the value of property (including the land).", "label": "Real Estate Tax Expense", "terseLabel": "Property taxes" } } }, "localname": "RealEstateTaxExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivableTypeDomain": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.", "label": "Receivable [Domain]", "terseLabel": "Receivable [Domain]" } } }, "localname": "ReceivableTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesFairValueDisclosure": { "auth_ref": [ "r19", "r33", "r285", "r301" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of receivables, including, but not limited to, trade account receivables, note receivables, and loan receivables.", "label": "Receivables, Fair Value Disclosure", "terseLabel": "Loan receivable" } } }, "localname": "ReceivablesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetAssetSalesandAssetsHeldforSaleNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r97" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted stock award" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings", "terseLabel": "Vesting of restricted common stock, net of shares withheld for employee taxes (in shares)" } } }, "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings", "terseLabel": "Vesting of restricted common stock, net of shares withheld for employee taxes" } } }, "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r113", "r114", "r119", "r124", "r125", "r129", "r130", "r131", "r172", "r173", "r278" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Independent living facilities" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": { "auth_ref": [ "r174" ], "lang": { "en-us": { "role": { "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.", "label": "Revenue from Contract with Customer, Product and Service [Extensible List]", "terseLabel": "Independent living facilities, revenue services" } } }, "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "extensibleListItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r38", "r73", "r113", "r114", "r119", "r124", "r125", "r129", "r130", "r131", "r138", "r241", "r292" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Total revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving credit facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]", "terseLabel": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails", "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r109", "r131" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Rental income, exclusive of operating expense reimbursements" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r218", "r219" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r28", "r75", "r164", "r167", "r168", "r169", "r251", "r252", "r254", "r294" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Debt Instruments" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Reconciliation of Weighted-Average Common Shares Outstanding Used in Calculation of Basic EPS to Diluted EPS" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/EarningsPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r192", "r203", "r211" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFinancingReceivablesPastDueTable": { "auth_ref": [ "r140", "r143" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about aging analysis for financing receivable.", "label": "Financing Receivable, Past Due [Table]", "terseLabel": "Financing Receivable, Past Due [Table]" } } }, "localname": "ScheduleOfFinancingReceivablesPastDueTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRealEstatePropertiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning real estate properties and units within those properties by ownership of the property.", "label": "Schedule of Real Estate Properties [Table]", "terseLabel": "Schedule of Real Estate Properties [Table]" } } }, "localname": "ScheduleOfRealEstatePropertiesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/OrganizationDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of real estate properties and units in those properties that are included in the discussion of the nature of an entity's operations.", "label": "Schedule of Real Estate Properties [Table Text Block]", "terseLabel": "Summary of Investment in Owned Properties" } } }, "localname": "ScheduleOfRealEstatePropertiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r193", "r206" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails", "http://www.caretrustreit.com/role/StockBasedCompensationValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r30", "r71", "r105", "r106", "r159", "r161", "r162", "r164", "r165", "r166", "r167", "r168", "r169", "r170" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails", "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTextBlock": { "auth_ref": [ "r11", "r12", "r13", "r160", "r161", "r162", "r164", "r165", "r166", "r167", "r168", "r169", "r170" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.", "label": "Schedule of Stock by Class [Table Text Block]", "terseLabel": "Summary of the At-The-Market Offering Program" } } }, "localname": "ScheduleOfStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior unsecured notes payable" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r194" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r196" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "terseLabel": "Shares forfeited (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Number of awards granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Award grant date fair value (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r197" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "terseLabel": "Unvested stock awards outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "terseLabel": "Valuation Assumptions" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r201" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield (assuming full reinvestment)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected stock price volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails", "http://www.caretrustreit.com/role/StockBasedCompensationValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r191", "r195" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails", "http://www.caretrustreit.com/role/StockBasedCompensationValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r199", "r210" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected service period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationValuationAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r31", "r77", "r78", "r79", "r81", "r87", "r89", "r104", "r139", "r163", "r170", "r207", "r208", "r209", "r216", "r217", "r243", "r244", "r245", "r246", "r247", "r248", "r315", "r316", "r317" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r77", "r78", "r79", "r104", "r278" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r12", "r13", "r163", "r170" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock, net, (in shares)", "verboseLabel": "Number of shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity", "http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails", "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r12", "r13", "r163", "r170" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock, net" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Share repurchase program authorization" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r13", "r16", "r17", "r73", "r134", "r138", "r241" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets", "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r72", "r170", "r171" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StraightLineRent": { "auth_ref": [ "r62" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLeaseIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between actual rental income due and rental income recognized on a straight-line basis.", "label": "Straight Line Rent", "negatedTerseLabel": "Straight-line rental income", "terseLabel": "Straight-line rent" } } }, "localname": "StraightLineRent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r249", "r265" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r249", "r265" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r249", "r265" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r249", "r265" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]", "terseLabel": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r264", "r267" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails", "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r13", "r163", "r170" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Shares repurchased (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TypeOfCostGoodOrServiceExtensibleList": { "auth_ref": [ "r174" ], "lang": { "en-us": { "role": { "documentation": "Indicates type of cost from product sold and service rendered.", "label": "Cost, Product and Service [Extensible List]", "terseLabel": "Independent living facilities, cost of services" } } }, "localname": "TypeOfCostGoodOrServiceExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements" ], "xbrltype": "extensibleListItemType" }, "us-gaap_UnsecuredLongTermDebt": { "auth_ref": [ "r28" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of uncollateralized debt obligation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Unsecured Long-term Debt, Noncurrent", "terseLabel": "Senior unsecured notes payable, net" } } }, "localname": "UnsecuredLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r91", "r96" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "verboseLabel": "Weighted-average diluted common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements", "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Denominator:", "verboseLabel": "Weighted-average number of common shares:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements", "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r90", "r96" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted-average basic common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedIncomeStatements", "http://www.caretrustreit.com/role/EarningsPerCommonShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 13 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r102": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=SL77927221-108306" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r112": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r135": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/subtopic&trid=2196772" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "79", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82922352-210448" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "80", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82922355-210448" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=121558832&loc=d3e400-110220" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r151": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r154": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r158": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r171": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r214": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6419918&loc=d3e35301-107843" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r224": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20,22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "40", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121604053&loc=SL77918607-209975" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121561866&loc=SL77919311-209978" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919396-209981" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919359-209981" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919359-209981" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919372-209981" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919372-209981" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r267": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(7))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(14)(d))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.1)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "360", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117337397&loc=d3e23415-158514" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "360", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117337397&loc=d3e23439-158514" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117337411&loc=d3e23528-158515" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=d3e9120-115832" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r328": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "970", "URI": "http://asc.fasb.org/topic&trid=2156125" }, "r329": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "972", "URI": "http://asc.fasb.org/topic&trid=2134617" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13728-122682" }, "r330": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "974", "URI": "http://asc.fasb.org/topic&trid=2156429" }, "r331": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "976", "URI": "http://asc.fasb.org/topic&trid=2134846" }, "r332": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "978", "URI": "http://asc.fasb.org/topic&trid=2134977" }, "r333": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r334": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r335": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r336": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r337": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r338": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r4": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=SL94080555-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r76": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" } }, "version": "2.1" } ZIP 70 0001628280-21-009294-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-21-009294-xbrl.zip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�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